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Preface
The Research Analysis and Utilization System (RAUS) is designed to
serve four functions:
Collect and systematically classify the findings of all
intramural and extramural research supported by the
National Institute on Drug Abuse (NIDA);
Evaluate the findings in selected areas of particular
interest and formulate a state-of-the-art review by a panel
or scientific peers;
Disseminate findings to researchers in the field and to
administrators, planners, instructors, and other interested
persons;
Provide a feedback mechanism to NIDA staff and planners so
that the administration and monitoring of the NIDA research
program reflect the very latest knowledge gleaned from
research in the field.
Since there is a limit to the number of research findings that can he
intensively reviewed annually, four subject areas are chosen each
year to undergo a thorough examination. Distinguished scientists in
the selected field are provided with copies of reports from
NIDA-funded research and invited to add any information derived from
the literature and from their own research in order to formulate a
comprehensive view of the field. Each reviewer is charged with
writing a state-of-the-art paper in his or her particular subject
area These papers, together with a summary of the discussions and
recommendations which take place at the review meeting, make up a
RAUS Review Report in the NIDA Research Monograph series.
v
“Drug Abuse Treatment Evaluation: Strategies, Progress, and
Prospects” was chosen as a subject for one of these comprehensive
RAUS reviews in FY 1983 because a body of knowledge had evolved,
including several large treatment evaluation systems. Reports are
included on the DARP program of the seventies and on the more
recent TOPS system, both designed for treatment evaluation.
The results of these reviews and discussions are presented in this
monograph. Dr. Frank M. Tims served as a chairman of the meeting
and editor of the resulting monograph. Dr. Jerome H. Jaffe served
as the other chairman. Dr. Jaffe has subsequently accepted the
position of Director of the NIDA Addiction Research Center in
Baltimore. Ms. Jacqueline P. Ludford, coeditor of the monograph,
is coordinator of NIDA’s RAUS system.
Contents
Preface v
Executive Summary
Jacqueline P. Ludford 1
Introduction
Frank M. Tims 9
Evaluating Drug Abuse Treatment: A Comment on the State of
the Art
Jerome H. Jaffe 13
National Treatment System Evaluation Based on the Drug Abuse
Reporting Program (DARP) Followup Research
D. Dwayne Simpson 29
Treatment Outcome Prospective Study (TOPS): Client Character-
istics and Behaviors Before, During, and After Treatment
Robert L. Hubbard, J. Valley Rachal,
S. Gail Craddock, and Elizabeth R. Cavanaugh . . . . . . . 42
Program-Based Evaluation Research in Therapeutic Communities
George De Leon . . . . . . . . . . . . . . . . . . . . . . . 69
Clinical Trials in Drug Treatment: Methodology
Sharon M. Hall . . . . . . . . . . . . . . . . . . . . . . . 88
Outcome of Narcotic Addict Treatment in California
M. Douglas Anglin and William H. McGlothlin . . . . . . . . . 106
Psychotherapeutic Approaches in the Treatment of Drug Abuse
Charles P. O'Brien, George E. Woody,
and A. Thomas McLellan . . . . . . . . . . . . . . . . . . . 129
Clinical Implications of Drug Abuse Treatment Outcome Research
Edward C. Senay . . . . . . . . . . . . . . . . . . . . . . 139
The State Perspective
Douglas S. Lipton and Philip Appel . . . . . . . . . . . . 151
A Treatment Evaluation Agenda:
Discussion and Recommendations
Frank M. Tims and Sherry Holland . . . . . . . . . . . . 167
List of NIDA Research Monographs . . . . . . . . . . . . . . . . 175
vii
Executive Summary
Jacqueline P. Ludford, M.S.
A considerable body of evaluative research on the treatment of drug
abuse has been generated in recent years, by clinical experience and
project research and from large evaluative studies such as the Drug
Abuse Reporting Program (DARP) of the 1970s and the more recent
Treatment Outcome Prospective Study (TOPS). Clearly, the field was
ready for a state-of-the-art review of the results of these efforts
and of what we have learned about the effectiveness of different
treatment modalities, methods, and techniques.
The RAUS review addressed not only the obvious questions regarding
treatment components and effectiveness but also such ouestions as:
To what extent should we invest in large-scale studies of
process and effectiveness vs. smaller, program-based
research?
What are the needs from the viewpoint of the providers?
From the viewpoint of the researchers?
To address these questions and the current state of the art, a RAUS
meeting was convened on May 25-26, 1983. The presentations included:
Evaluation of Drug Dr. Jerome Jaffe
Abuse Treatment: A V.A. Medical Center
Comment on the State Newington, Conn.
of the Art
National Treatment System Dr. D. Dwayne Simpson
Evaluation: Drug Abuse Texas A & M University
Reporting Program (DARP)
National Treatment System Mr. J. Valley Rachal
Evaluation: Treatment Dr. Robert Hubbard
Outcome Prospective Study Research Triangle Inst.
(TOPS) North Carolina
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Program-Based Evaluation
Studies
Clinical Trials in
Drug Treatment
Outcome of Narcotics Addict
Treatment in California
Evaluation of Psychotherapeutic
Approaches to Drug Treatment
Clinical Implications of
Treatment Outcome Studies
Treatment Evaluation: The
State Perspective
Dr. George De Leon
Phoenix House
New York City
Dr. Sharon Hall
University of California
San Francisco
Dr. M. Douglas Anglin
University of California
Los Angeles
Dr. Charles O'Brien
VA Hospital
Philadelphia
Dr. Edward Senay
University of Chicago
Dr. Douglas Lipton
New York State Division
of Substance Abuse
Services
Dr. Jerome Jaffe, of the Veterans Administration Medical Center,
Newington, Connecticut, and Dr. Frank Tims, of the Division of
Clinical Research, NIDA, served as cochairmen for the meeting and
led the discussions.
Dr. Simpson discussed the results of the Drug Abuse Reporting
Porgram (DARP), established in 1969 to collect data on community-
based treatment services. Eventually it collected standardized data
on 44,000 clients in 52 treatment agencies. Because of a lack of
accepted criteria regarding treatment definition, classification,
and outcome, the first task under DARP was to define and document
terminology and standards to be commonly accepted. DARP then
measured treatment outcome on the basis of amount and kind of drug
use, productive activity, alcohol use, and criminality. Data on
male opioid addicts, the best represented subsample, indicate most
favorable outcomes were associated with methadone maintenance,
therapeutic communities, and outpatient drug-free treatment; the
outcome differences between the three types of treatment were not
significant. There were differences in the types of clients served
and in the dropout ratio, however. Dr. Simpson called for research
in smaller, multi-program studies to examine the effects of
differing treatments on different clients and to study process and
procedures within programs, including staff-client interaction.
Mr. Rachal and Dr. Hubbard presented data from the Treatment Outcome
Prospective Study (TOPS) which collected data on approximately
12,000 clients admitted to treatment between 1979-1981. Because the
study is so recent, followup data are necessarily limited. TOPS was
designed to analyze the association between client behavior, client
characteristics, environment, and the treatment process. Its
measures include data on drug use, alcohol consumption, mental
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health, criminal behavior, and economic productivity. One of its
research objectives is to provide testable hypotheses regarding why
and for whom certain types of treatment do or do not work.
The TOPS study design, its advantages and limitations, were
discussed. Pretreatment and intreatment data indicate:
Outpatient drug-free programs had the biggest problem with
retention: 21 percent dropout within a week or less and 36
percent within 4 weeks or less. Methadone clients are
least likely to leave treatment early.
There is a high level of depression among clients seeking
treatment; almost half of all methadone clients reported
having been seriously depressed in the year before intake.
More than 40 percent of all clients reported some predatory
illegal activity (assault, robbery, burglary, etc.) in the
year before treatment; more than 70 percent of these
clients reported cessation of predatory illegal activity
during treatment.
Half of the methadone clients were unemployed when they
entered treatment and most remained unemployed during
treatment.
Outcomes are confounded by many factors other than treatment itself,
as described in the TOPS study (see Hubbard, this volume). Followup
of any drug treatment program is complicated by readmittance to the
same or other treatments and by incarceration which limits
opportunity to use drugs, find jobs, or commit crime. Many of the
methadone clients are still in treatment at followup. Preliminary
measures of outcome, however, indicate:
Clients improve in treatment, regardless of type, and some
of this improvement lasts after treatment. More than
one-third of clients report not using pretreatment primary
drug during followup period.
Between 20 and 30 percent of clients report predatory
illegal acts in the year after treatment, a significant
reduction from pretreatement levels.
After treatment about two-thirds of all clients report no
signs of depression.
The effect of treatment on employment trends is unclear;
data are still being analyzed.
Dr. De Leon, who is Director of Research for Phoenix House, in New
York, discussed program evaluation in a therapeutic community (TC).
The goal of a therapeutic community is to change lifestyle to
reflect abstinence from drugs, to eliminate antisocial activity, and
to develop prosocial attitudes and values. In general, when TCs are
evaluated, it is found that:
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Clients improve significantly over pretreatment status as
measured by drug use, criminality, and prosocial behavior.
Success depends on time in treatment, with improvements for
those who spend several months in program but drop out, and
even more striking improvements for those who complete the
program.
Improvements in psychological adjustment correlate with
improvements in social adjustment and success in the
program.
Individuals who improve psychologically within the first
several months after admission show a greater likelihood of
being retained in treatment. More research is needed on
the subject of retention and its correlates.
Dr. Hall presented an evaluation of clinical trials in drug abuse
treatment. She described the strategies and procedures of various
types of clinical trials, their advantages and disadvantages. In
particular, she noted that:
Drug treatment clients will not accept random assignments
to a treatment modality.
If treatment entry differs between conditions, there tend
to be confounding variables which compromise interpretation
of outcome data.
Different modalities attract different types of clients,
and this fact further complicates comparisons.
Her review concluded that:
Well-controlled, small trials with sample size based on
power analysis yield the clearest outcomes. The best of
these have a treatment manual and well-developed followup
procedures.
Research strategies should involve some degree of
replication.
More standardization is needed in psychosocial areas, e.g.,
standardizing drug use index.
More studies or replication of findings are needed in
psychotherapy, contingency management, skill training, and
family therapy. Since the proportion of women clients
entering treatment is increasing, some emphasis needs to be
placed on treatment services geared to their needs.
Dr. Anglin reported on followup of 1,700 addicts in a study of civil
commitment vs. methadone treatment in California. He pointed out
that successful treatment in substance abuse ameliorates or relieves
the disease but rarely "cures" it in the sense of a medical model.
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Anglin and McGlothlin measured success in terms of narcotic and
other drug use, crime, employment, and family stability.
The results of the evaluation indicate that both civil conitment
and methadone maintenance effectively reduce drug use and crime,
and, to a lesser extent, increase employment and family
responsibility. Differing policies with respect to dose of
methadone and time in treatment produced differing effects. Anglin
considers both types of treatment to involve behavior modification
techniques and offered some possible explanations for differences in
results.
Dr. O'Brien focused on psychotherapeutic approaches in the treatment
of drug abuse, reviewing eight controlled studies of psychotherapy
with opiate addicts. In six of the eight studies, the clients
improved under the psychotherapy condition as compared to controls.
Important factors influencing outcome include:
Diagnosis at entry and improved sophistication in making an
accurate diagnosis;
Taping of therapy sessions and treatment manuals to ensure
adherence to prescribed techniques; rating instruments to
measure patient-therapist interaction;
The number of sociopaths in the study, since psychotherapy
appears to be particularly unsuccessful with sociopaths;
evidence suggests, however, that psychotherapy may be
helpful with addicts when given under certain conditions,
specifically with those addicts on methadone and diagnosed
as having depression.
Dr. Senay presented a paper on the clinical implications of drug
abuse treatment evaluation research. The most important clinical
implication is that treatment for drug abuse works--clients function
more normally, reduce drug use and crime, and generally improve.
But Dr. Senay listed a number of problems and recommendations which
he feels must be addressed:
How can drug abuse treatment be coordinated with standard
mental and health care systems? In the present system
substance abusers tend to get second-class health care. We
need more 'structural" research in this area of integrating
systems rather than operating separate, parallel ones. For
example, CMHCs need to be able to use modern treatment
methods for drug abusers and develop not only knowledge and
skills but also training and tools.
How do different treatment components or phases of
treatment contribute to client outcome? This is a
complicated question, and it may be that structural
research is more likely to pay off than process research.
Substance abusers frequently need services to deal with
psychiatric problems, pregnancy, lack of job skills, and
general health.
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Single State agencies and appropriate professional
organizations should take the lead in licensing,
credentialing, and accreditation of workers in the field.
This would involve a systematic training program for
clinicians and counselors.
Accept the fact that repeated episodes of treatment are
probably necessary for those with serious substance abuse
problems. These do not indicate failure on anyone's part,
but merely reflect the nature of the problem and the
culture.
Provide flexible scheduling, so that addicts can coordinate
treatment with work.
Evaluate from the consumer's point of view. Clients can
frequently provide information regarding the dynamics of
treament and gaps in service.
Undertake collaborative efforts with law enforcement
agencies involving the criminal justice system in
treatment-rehabilitation efforts.
Address the problem of improvement of the addict's overall
general health.
In evaluation, address clinic size (number of patients) as
it relates to success/failure in outcome measures; examine
public vs. private programs.
Reconsider the role of urinalysis in treatment and its
cost/benefit.
Link epidemiological studies with treatment studies and
outreach strategies.
Treatment programs are needed which are geared to cocaine,
marijuana, and multiple drug use. Programs are also needed
to treat females and the geographically mobile.
Dr. Lipton, who is associated with the New York State Division of
Substance Abuse Services, presented a paper on the State's interests
in drug abuse research. In a survey of nine single State agencies,
including such populous states as California, Illinois,
Massachusetts, and New Jersey, Dr. Lipton found:
NIDA materials are used in monitoring, planning, and
evaluation; DAWN, CODAP, high school and household surveys,
monographs and technical reports were mentioned.
Some agencies are making extensive use of DARP reports.
NIDA monographs describing outcome studies were considered
most useful.
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Respondents felt a need for studies on cost-effectiveness
of treatment, "how-to" manuals for treatment evaluations,
bibliographies of treatment studies for program
administrators, formatting of reports for planners and
administrators rather than researchers, and more studies of
nonopiate abusers.
Respondents suggested routine dissemination of a list of
all treatment evaluation research projects and the reports
generated by them, including statements of implications for
treatment programs.
Several suggestions were made for dissemination strategies and
sharing of experience by evaluators, administrators, and
policymakers.
Policymakers note problems with evaluation research, in particular
lack of clear statements of practical application in the field and
the fact that frequently the research answers a somewhat different
auestion than that which the policymakers are asking. Policymakers
tend to adopt uncritically that research which supports their
existing views and to pursue what they perceive to be their
constituents' wishes, regardless of what evaluations show. The
findings of evaluation research cannot reverse popular convictions
which are upheld by policymakers. The more complex an evaluation,
the more "jargon" used, the more scientific caveats, the more the
policymaker is apt to disregard the conclusions.
Lipton proposed seven rules for successful evaluation research:
Establish a dialogue with the policymaker.
Move swiftly to produce.
Accept incremental improvement in staff, data systems, etc.
Make initial rough estimates and then refine.
Produce reports in four parts:
-Executive summary and recommendations
-Body of text with summarizing headlines
-Conclusions in "bullet" form
-All technical material in the appendix
Organize and present results by the applicable political
jurisdiction.
Evaluation should be practical, pecuniary, and political.
A number of suggestions for treatment evaluation studies were
presented.
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Introduction
Frank M. Tims, Ph.D.
The purpose of this review is to assess critically our present state
of knowledge regarding drug abuse treatment evaluation, identify
major research questions which should be the focus of future
efforts, and outline the best strategies for addressing these
questions. The National Institute on Drug Abuse has made
substantial investments in large, longitudinal studies of treated
drug abusers as well as smaller controlled studies. These have
contributed greatly to our understanding of treatment populations,
histories, and outcomes, and have made a convincing case for
treatment effectiveness. It is appropriate now that we begin a
process of consolidation of our knowledge in this area and
definition of future research priorities. Because a recent
monograph edited by Cooper et al. (1983) deals extensively with
methadone detoxification, methadone maintenance, and other
pharmacologically based drug abuse treatments, these will not be of
primary concern in this review, except as they are incidental to
more general questions of treatment evaluation.
Evaluation has been an integral part of the Federal effort to
develop and maintain a national system of community-based drug abuse
treatment programs since it began in the late 1960s. The Drug Abuse
Reporting Program (DARP), established under the auspices of the
National Institute of Mental Health and subsequently supported by
the National Institute on Drug Abuse, began as a management
monitoring system which was designed also to be of value for
treatment research. The DARP strategy has proven to be sound and
useful in describing a treatment population we knew little about in
those early days, in characterizing behavioral patterns and
treatment experiences of those clients, and in evaluating the
effectiveness of those programs and building the foundation for an
extremely productive series of treatment outcome research studies.
The DARP research, described in this volume by Simpson, provided a
substantive and methodological basis for another large-scale
treatment evaluation, the Treatment Outcome Prospective Study (TOPS)
which is described by Hubbard et al., also in this volume. At the
inception of the DARP in 1968, the treatment system was embryonic,
and concerned largely with the treatment of opioid addicts.
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Community-based treatment was controversial, with methadone
maintenance being perhaps the most visible focus of the
controversy. Community-based treatment was unproven, and the basis
for designing the treatment for any individual was usually nothing
more than professional judgment. The TOPS was launched amid a
growing body of empirical evidence regarding the efficacy of
treatment for addiction, but when the system had undergone dramatic
changes. Large numbers of individuals not addicted to opioids, with
various nonopioids classed as their primary drugs of abuse and
perhaps no history of opioid use, began to enter residential
drug-free and outpatient drug-free programs, such that in 1979.
clients reporting opioids as the primary drug of abuse accounted for
less than half the clients in the federally funded treatment system
(NIDA 1982).
The diversity of client populations presented new challenges to the
TOPS researchers, not the least of which was the conceptual
complexity inherent in characterizing the drug dependency of those
whose drug abuse patterns might be widely varied and not explainable
in terms of physical addiction. The TOPS research strategy followed
that which had served the DARP well, a series of admissions cohorts
comprising a client population which could be followed during
treatment and sampled for followup studies after treatment.
Chapters in this volume present data from the DARP over a
considerable posttreatment period and preliminary analyses of the
available TOPS data.
Within the context of treatment outcome studies, a large number of
other studies have been undertaken with NIDA sponsorship, not to
mention the considerable body of work sponsored by other agencies,
most notably the Veterans Administration, which has supported both
large scale followup studies (e.g., Veterans Administration 1979)
and clinical investigations. NIDA-sponsored treatment research has
included a well-designed study of therapeutic community clients (see
De Leon, this volume) with measures of psychological functioning as
well as behavioral outcomes. De Leon's research typifies the
smaller scale, intensive research we have chosen to call "program
based," because it is usually conducted by investigators affiliated
with the program or cluster of programs being studied but does not
necessarily involve rigorous experimental control. Other
investigations which are in the category of controlled studies are
described by Hall in her methodologically oriented chapter, as well
as by O'Brien et al. in their discussion of studies of the efficacy
of psychotherapy in the treatment of addiction.
The work of Anglin and the late Dr. William McGlothlin represents
another of the pioneering approaches to the study of drug abuse
treatment effectiveness. While the DARP, TOPS, and De Leon's
therapeutic community studies considered the outcomes of treatment
generically, Anglin and McGlothlin examined treatment policy in
relation to outcomes. Their ability to impose quasi-experimental
designs on treatment populations affected by given treatment
policies and policy changes, such as compulsory treatment of addicts
in California, sudden changes in methadone maintenance policy
(including discontinuation of publicly funded programs), and local
variations in clinic policy provided opportunities for these
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scientists to study the impact of treatment policy in the natural
environment.
Senay's chapter considers the clinical implications of the emerging
body of knowledge regarding treatment outcomes and examines some
treatment and research issues from his clinical perspective.
Since the Omnibus Reconciliation Act of 1981 dramatically changed
the way in which Federal support is provided to drug abuse
treatment, providing ADM block grants to individual States rather
than having NIDA administer treatment funds, there have necessarily
been changes in the relationship between NIDA and the States. The
States are now more largely responsible for making treatment
allocation decisions, and NIDA's mission is more that of a research
Institute. The changes taking place in the community based
treatment systems are in part a response to the new situation and in
part a continuation of changes which were evolvlng before this
shift. Since the States share many common concerns with NIDA where
treament evaluation research is concerned, it was felt that this
review should also provide a forum for articulation of these
concerns and interests at the State level. Lipton's chapter on "The
State Perspective" presents his impressions based on contacts with
evaluation researchers in a sample of State substance abuse
agencies, as well as his own experience in the New York Single State
Agency.
In the chapters which follow, the authors have attempted systematic
presentation of their individual research areas in a field which is
evolving and diverse in its perspectives. In the opening chapter,
Dr. Jerome Jaffe, who led the Federal treatment effort as Director
of the Special Action Office on Drug Abuse Prevention in the early
197Os, presents a succinct assessment of the state of the art in
treatment evaluation, and sets the stage for this review.
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Evaluating Drug Abuse Treatment:
A Comment on the State of the Art
Jerome H. Jaffe, M.D.
We have been asked to address two fudamental questions at this
review. First, "What do we know about the effectiveness of
treatment of drug abuse?" Second, "Where do we go from here?" We
must keep in mind that drug abuse is a chronic illness and that
evaluating the effectiveness of treatment of chronic illness is
unlike work in biochemistry or certain other fields in natural
science, where the publication of a major finding often marks some
sharp turning point in our understanding. Evaluating the treat-
ment of chronic illness occurs over periods of years.
preliminary analyses are described at meetings, and later more
detailed presentations (and sometimes revisions) eventually are
published. Except where radically new treatments are introduced,
the newly published must be weighed along with all previous
findings. Although the field is still relatively young, there are
now hundreds of papers on the treatment of drug abuse, and it
becomes progressively less likely that any single new study will
radically alter the inferences that have already been drawn from
these observations. It is never quite clear just when we come to
accept a given finding as valid.
Obviously, the discovery of some new medicine or some new inter-
vention technique which represents a dramatic improvement over
previously available procedures might require a major reassess-
ment. Twenty years ago, the evolution of the therapeutic
community and the introduction of methadone maintenance for
treating opioid addicts represented such significant changes. No
comparable dramatic changes in treatment techniques have occurred
in the last 5 years. Indeed, it would be fair to say that the
diverse interventions which we subsume under the very broad
concept of treatment have not changed fundamentally over the past
10 years. What progress we have made in understanding what
current treatment can and cannot do is based on a progressive
evolution in our methods of assessment. This evolution is, in
turn, based on progress in our understanding of the complexities
of the various addictions, of the heterogeneity of the populations
seeking treatment, and on a willingness to subject the data
obtained to ever more sophisticated analyses. Progress is also
based on a farsighted NIDA policy that continues to support
treatment evaluation as a priority rather than an afterthought.
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Having said that there are no dramatic breakthroughs, let me now
make it clear that there have been some very significant advances
in the state of our knowledge. After more than 20 years of
systematic data collection, and after at least 10 years during
which the treatment systems for drug abusers have been relatively
stable, we are able to make some definitive statements about the
long-term effectiveness of various treatments for opioid abuse and
dependence. There are now ample data describing the probable
short-term impact of various generic types of treatment (i.e.,
methadone maintenance, therapeutic communities, short-term de-
toxification, and drug-free programs) on typical urban heroin
users. In general, the prognosis is far better than any one would
have predicted in the early 1970s. We can state with some
reasonable level of predictability how various background
(demographic) characteristics of the patients (or clients) will
influence the outcome at various pints in time over the first
year or two after contact with a treatment program. Not sur-
prisingly, having a more stable family background, an intact
marriage, a job, and a history of minimal criminality predicts a
better outcome in most programs. Those with the highest levels of
criminality prior to seeking treatment continue to represent a
challenge to our capacity to alter behavior. We can make some
general statements about the value of vocational rehabilitation
efforts and other special social interventions. Over the short
run, special programs and supported work do result in more addicts
engaged in gainful activity. Over the long term, however, the
differences between controls and those offered such services
Shrink to levels where the economic value of such programs becomes
questionable, especially during times when so many people are un-
employed. Having employment specialists at clinics appears to
have some positive impact on retention rates, suggesting that such
rates can be modified by changes in program content, but this
apparently has little impact on actual employment rates (see NIDA
1982).
We also have data fran studies which follow patients over long
periods after entry into a treatment system (Simpson, this volume;
Stimson and Oppenheimer 1982; Maddux and Desmond 1980; McGlothlin
and Anglin 1981b; Vaillant 1978). These studies are generally
concordant in presenting the natural history of a syndrome which
is far less incurable and unremitting than was believed as
recently as the 1960s, but is still more than sufficiently
criminogenic and lethal to justify society’s efforts to intervene
and to treat it.
For certain kinds of treatment: such as methadone maintenance, our
statements can be even more refined, and we can make general
statements while patients are in treatment about the relative
impact of varying program parameters, such as urine testing,
dosage, and take home privileges, on retention and outcome.
Additionally, we now recognize that the program and patient
factors which contribute to retention of patients in treatment are
not necessarily those which predict adjustment in the years after
leaving treatment. These general findings, along with the medical
tradeoffs involved in methadone treatment, have been summarized in
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a recent NIDA monograph (Cooper et al. 1983). There now appears to
be a general consensus on the limited value of either outpatient
or inpatient detoxification for those addicted to opioids. For
most types of programs, we can now describe in a general way the
relationship of time spent in treatment to outcome over the next
year. We can even offer some cost benefit analysis of the value
of providing treatment compared to alternative social policies
(McGlothlin and Anglin 1981a,b).
To be able to make such statements is a significant achievement.
Yet, we are dissatisfied. We recognize that the relationships we
have found to date between patient characteristics and outcome,
while reliable, often account for only a small part of the
variance, and that in any given Case it is still not certain just
what treatment, if any, would produce the best outcome for a given
patient (see Rounsaville et al. 1982b; McLellan 1983). Equally
important, we now recognize that a significant proportion of those
seeking treatment do not stay in treatment for more than a few
weeks; that for some individuals, especially those with high
criminality and high psychopathology, treatment generally is of
limited benefit. More recently it has been suggested that some
programs are "toxic" for some patients (see McLellan et al. 1983;
O'Brien et al., this volume).
About 5 to l0 years ago, a number of researchers hypothesized that
a likely reason for our relative inability to predict treatment
outcome was our failure to measure all the relevant variables and
our tendency to analyze the data collected using one background
variable at a time, rather than using more complex, but more
appropriate, multivariate analyses. These shortcomings are being
remdied in more recent evaluations of treatment, and these
improved measures (especially of psychopathology) and more
sophisticated analytical techniques represent the major achieve-
ment of the past 5 years.
Let me offer a few examples. Recent studies have gathered
information on patients seeking treatment that goes far beyond the
demographic and drug use histories that were the major data
elements of earlier efforts. Several groups have done detailed
investigations of psychiatric symptoms and diagnoses among
patients seeking treatment. Kleber, Rounsaville, Weissman, and
their colleagues in New Haven have documented that, in addition to
drug dependence, the majority of opioid addicts seeking treatment
have other psychiatric disorders that met currently accepted
diagnostic criteria. Among the more common diagnostic entities
identified were major depressive disorders, antisocial personal-
ity, and alcoholism (Rounsaville et al. 1982d). McLellan,
O'Brien, Luborsky, Woody and their coworkers in Philadelphia have
found a very similar spectrum of formal diagnoses among veterans
with drug and alcohol problems. They have also reported that the
severity of psychological problems taken as a whole is a powerful
predictor of several outcome criteria, such as illicit drug use,
criminal activity, social productivity, and psychological adjust-
ment, when these are measured 6 months after entry into treatment.
Furthermore, the Philadelphia group finds, as have others, that
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these traditional dimensions of change are relatively independent
and are best predicted by past behavior on that specific dimension
(McLellan et al. 1983). More significant for our concerns about
evaluating treatment are the Philadelphia group's findings using
mulltivariate analyses of relationships among patient character-
istics at intake and outcome at 6 months after entry. The broad
generalization from the early analyses of large-scale multicenter
studies such as Drug Abuse Report Program (DARP), was that
opioid-dependent patients do about equally well (on a composite
measure of overall outsome) whether they enter a therapeutic
community, a methadone maintenance program, or a drug-free out-
patient program. The DARP study did not attempt to assess
severity of psychological problems or psychiatric diagnoses. The
work of McLellan and coworkers suggests that these conclusions
fran the DARP study must now be qualified and that some
opioid-dependent patients, particularly those with severe psycho-
logical problems, do quite poorly when placed in the confronta-
tional milieu of a therapeutic community and do significantly
better in a methadone maintenance program. To what degree the
better outcome is related to the pharmacological effects of
methadone or the less demanding treatment environment is not yet
clear. An additional finding is that those patients with fewest
and least severe psychological problems did quite well in all
treatment programs while those with the most problems did poorly
in all. In the light of this work, it seems likely that the older
findings on the effectiveness of treatment, most of which did not
assess psychopathology or its severity, may have to be reevaluated.
WHY DID IT TAKE SO LONG TO FIND AN EFFECT OF PSYCHOPATHOLOGY ON
OUTCOME OF TREATMENT?
Those not familiar with the evolution of science and medicine may
well wonder why the kind of work just described was not done
sooner. Why was it necessary to spend millions of dollars on the
evaluation of treatment only to find that much of the work now may
need to be redone or, at the least, reassessed? Since policy-
makers may raise this question, we should be prepared to explain
why those studies were appropriate for their time, and why they
remain as important contributions. We should also explain that
even as we move to new levels of sophistication we can already see
the areas where further work will be required.
As the effort to evaluate treatment has evolved, the fundamental
questions have always been the same. What are the relevant
variables about patients, treatments, and environments that we
need to measure, how can they be measured reliably, and what con-
ceptual and analytic frameworks are best suited to understanding
the relationships among the variables?
Even in the 19th century, researchers recognized the heterogeneity
of opiate users and postulated that treatments and outcomes might
be very different depending on who was using the drugs and for
what reasons (see Terry and Pellens 1928). Yet, it seems to have
taken almost 100 years to follow up on these early simple obser-
vations. Before offering some of the reasons why the recent
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findings on the effects of psychopathology did not emerge 10 or 15
years ago, I should note that Kolb (1962) did report considerable
diagnostic heterogeneity among the addicts seen in the 1920s, and
there is an extensive literature on personality testing and psy-
chopathology among addicts that dates back more than 40 years
(Sutker and Archer 1983) . Most of this work was directed toward
understanding the etiology of drug dependence rather than
accounting for differences in response to treatment. Indeed, the
few recent studies which suggested that retention in treatment or
outcome could be predicted from psychological testing or from
typologies derived from cluster analyses of patient character-
istics were largely ignored.
It is fair to say that for a long time it seemed that under-
standing the psychodynamics of an individual in a specific situa-
tion was more important than reaching agreement on what specific
diagnostic category best matched the individual‘s symptoms and
history. Formal diagnosis was not viewed as an overwhelmingly
important issue. American psychiatry emerged fully from that era
only in the early 1970s. It would take us too far from our topic
to review the factors that brought about the deemphasis of
psychoanalytic theory and the reemergence of a descriptive pheno-
menologically oriented nomenclature. Suffice it to say that the
shift in emphasis permitted a revision of the American Psychiatric
Association’s Diagnostic and Statistical Manual (DSM-III) which
provided specific diagnostic criteria for each of the mental dis-
orders. DSM-III was issued in draft form in 1978 and became
official in 1980.
Even prior to the publication of DSM-III, however, there were
research criteria for making diagnoses that could have been used
to attempt to measure psychopathology and psychiatric diagnoses
among drug abusers. Other factors retarded the measurement of
such psychopathology. I will describe a few of these factors as I
perceived them over the decade fran 1968 to 1978.
The therapeutic communities built on the model of Synanon had
developed an anti-medical, if not a broadly anti-intellectual,
attitude from their beginnings. They were pleased when outsiders
lauded their successes, but for the most part they did not look
kindly on detailed analysis of outcome. In general, they kept
minimal records, especially any that might suggest a psychiatric
orientation. It is remotely possible that more attention to a
thorough diagnostic evaluation of drug users seeking treatment
would have led to such programs being redefined as medical
facilities, with all the detailed regulation and malpractice
exposure that such a redefinition might entail. However, I doubt
if such concerns played a role in their early resistance to
evaluation. In fact, some therapeutic community programs began
using psychological testing and psychiatric evaluations more than
a decade ago, but, for a variety of reasons, the findings were
rarely utilized.
Neither were the early methadone programs overly enthusiastic
about systematic psychiatric evaluations. In part, this was
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because sane early proponents emphasized that addicts were
psychologically normal but for their abnormal drug hunger (Dole
and Nyswander 1968). Also contributing to the lack of interest
was the then current psychiatric nomenclature which seemed to be
of little value in predicting who would respond to methadone
maintenance. Lastly, psychiatrically trained personnel were
exceedingly scarce during the rapid expansion phase of these
programs (1966-1974).
Similarly, drug-free programs were often operated by non-
professionals who, if not antagonistic toward medically trained
personnel, often seemed threatened by researchers and evaluators.
It is also possible that many program directors came. to accept as
proven what was originally only a hypothesis: that drug dependence
causes the other problems (social and psychological) commonly
found among drug addicts. If one believes that all problems show
startling improvement when drug-related problems are successfully
controlled, then it is unnecessary to attempt to measure those
other variables, especially if drug use is easier to measure. The
advent of inexpensive urine tests that provided an objective
measure of drug use may have had the effect of devaluing the
"softer" measures of interpersonal and psychological functioning.
In any event, adding detailed psychological assessment to the
other measures would have substantially escalated the costs of
treatment evaluation.
Thus, there were at least five major factors militating against
the incorporation of an additional dimension of formal psycho-
pathology into the assessments of treatment: (1) the lack of
agreed-upon criteria for categorizing and assessing psycho-
pathology (as well as uncertainty about whether instruments
standardized on patients not dependent on drugs were appropriate
for those with drug dependence as a primary problem); (2) in-
difference or hostility of the largest treatment programs to such
detailed assessment; (3) shortages of trained personnel; (4) the
significant additional costs of adding these variables to the
already long list of drug-, work-, and crime-related variables
already deemed essential; and (5) previous work in which
standardized personality tests of addicts in treatment had not led
to the conclusion that such testing had clinical relevance.
Perhaps there was a sixth factor as well. Perhaps those of us
charged with conducting and funding evaluations did not believe
that measures of psychopathology were important enough to be given
priority over the other measures which, at the time, seemed more
likely to predict outcome. It is possible that an overemphasis on
the role of learning in the perpetuation of addiction contributed
to this belief.
It remains for others to provide a weighting for the various
factors that retarded work of this kind. For now it is sufficient
to note that most evaluations of drug abuse treatment, even some
of those recently published, pay scant attention to the possi-
bility that the type and severity of psychopathology that is
associated with drug dependence and abuse may represent a major
variable that interacts with the kind of treatment provided to
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determine long- and short-term outcome.
THE STATE OF THE ART: SOLIDIFYING ADVANCES
It is evident from this long explanation that I believe that the
renewed attention being given to the measurement of psycho-
pathology among drug users in treatment represents a significant
recent advance, but not the only one. Each followup study of the
large multicentered evaluations, such as DARP and Treatment
Outcome Prospective Study (TOPS), has enlarged our appreciation of
the importance of monitoring behavior over time (not months, but
years) and of the need to measure outcome along several dimen-
sions . Other recently published long-term outcome studies from
England provide additional support for this view (see Stimson and
Oppenheimer 1982). We should also count as significant advances
those studies which, without endorsing any specific programs,
meticulously demonstrate that crime rates among opioid addicts are
far higher than the rates estimated fran arrests or rap sheets,
but are substantially reduced when illicit opioid use is con-
trolled (Ball et al. 1983). Such findings, taken together with
those studies of the impact of treatment programs on crime rates,
further underscore the potential benefits to society of more
effective treatment and interventions (Bowden et al. 1978;
McGlothlin and Anglin 1981b; Anglin and McGlothlin, this volume).
We must now turn to the central question: What is the state of
the art? We need to ask ourselves at the outset whether we are
interested in the state of the art of evaluating treatment or the
state of the art of treatment per se. If we are interested in
treatment, then we should not limit ourselves to those papers that
use the latest and most sophisticated evaluation methodologies,
but should use all available information to take the pulse of the
field. My overall impression is that with respect to the treat-
ment of opioid dependence, the phase of expansion and rapid change
is over. Some of the excitement is gone, and some programs seem
more concerned with survival than self-improvement. For the
typical "street addict," we may now be at an ideal time to re-
examine the relationship of treatment to short-term and longer
term outcome. I cannot recall a time when there has been such
stability of program content coupled with such interest and com-
petence in measuring outcome.
The objectives of such a reexamination should include efforts to
resolve apparent inconsistencies in the extensive literature that
has evolved thus far, to learn more about the characteristics of
those who seem to do poorly in all of the available treatments,
and about the nontreatment events that facilitate recovery fran
drug dependence.
We should probably give our highest priority to further verifica-
tion of the findings by several groups of workers that over the
Short term (i.e., 6 to 12 months) the several dimensions of out-
cane (drug use, alcoholism, general health, work, crime, social
and psychological well-being) are relatively independent. Rela-
tive independence of these dimensions implies that programs
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directed primarily at treating drug dependence or drug abuse per
se may not have major influence on other important measures of
adjustment and social functioning. Such relative dependence of
outcome measures has been found among alcoholic and drug-dependent
veterans in Philadelphia by McLellan and coworkers (McLellan et
al. 1983), and among predominantly male nonveteran opioid users in
New Haven by Kleber, Rounsaville, Weissman and their coworkers
(Rounsaville et al., 1982b). More recent data fran the multi-
center DARP program as analyzed by Simpson, Savage, Sells and
their coworkers (Simpson, this volume) are also supportive of this
finding of independence of outcome dimensions, although the
earlier DARP work often used composite scores to represent overall
outcome (Simpson and Sells 1982). Additional data from other
programs bearing on this question may already exist; it may be
unnecessary to conduct new studies. If this relative independence
is generally true for all programs, then the old question of which
programs are best suited to which patients becomes more complex.
It may be necessary to pay more attention to the components of
individual programs to learn which program elements influence
which outcome dimensions for which patients.
The most important implication of these findings may be for our
efforts to communicate with policymakers. They will continue to
ask, "Does treatment work?" They may be annoyed when they are
told that the question can no longer be put in such simple terms.
In our efforts to consolidate our advances, we should give equally
high priority to further independent verification of the clinical
utility of measuring severity of psychopathology among drug users
in treatment, as described by the Philadelphia group (McLellan et
al. 1983). In my view, there is already ample verification of the
high prevalence among drug abusers of psychiatric symptomatology
and diagnosable disorders in addition to drug dependence. It is
the clinical significance of this additional symptomatology that
needs further investigation (see below).
WHERE DO WE GO FROM HERE? - RESOLVING INCOSISTENCIES AND
FILLING GAPS
Given the heterogeneity of the programs and populations studied
and the varied methods, no one should be surprised that different
studies draw somewhat different conclusions from the data. Many
such apparent inconsistencies could be cited, but I would like to
focus on a select few.
In the studies by the Philadelphia group, severity of drug depend-
ence per se, as measured by the Addiction Severity Index (ASI),
did not appear to be a powerful predictor of outcome of treatment
on any of the dimensions studied (McLellan et al. 1983). Although
this finding is consistent with results of a study of addicted
physicians (Morse et al. 1984), it is nevertheless disconcerting
for both theoretical and empirical reasons. From a theoretical
perspective, current views of drug dependence suggest that there
is a core syndrome of impaired control over drug use that varies
in severity along a continuum. One would predict on theoretical
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grounds that the more severe the degree of dependence, the greater
the likelihood of relapse and the smaller the likelihood that the
individual could use the drug of dependence in moderation (see
Edwards et al. 1981). Data from the fields of alcohol and tobacco
dependence support this prediction about the severity of depend-
ence. The DARP study also found evidence that among those who use
opioid drugs, those who were addicted (used every day) responded
quite differently to treatment from those who used less frequently
(i.e., were defined as nonaddicts.) Those not addicted had
better outcomes at followup (Simpson and Sells 1982). Opioid
addicted (i.e., using every day) vs. nonaddicted may be too
coarse adichotomy. One might expect that a finer differentiation
would have been even more revealing, although we must admit that
we do not have any idea of the shape of the theoretical curve of
severity of opioid addiction. In all likelihood, there is sane
level above which the severity curve flattens out and above which
further increases in severity do not affect outcome. We need to
look carefully at how these various studies defined severity. On
theoretical grounds, at least, we should not leave the matter
hanging or expect it to be resolved automatically by some future
megastudy.
One inconsistency may be more apparent than real. Heretofore, a
consistent finding from studies of therapeutic communities (see
DeLeon, this volume) and from the DARP multicenter study (see
Simpson, this volume) has been that time in treatment was reason-
ably well correlated with better outcome. The data from the more
recent TOPS multicenter study do not show pronounced
time-in-treatment effect (see Hubbard et al., this volume). The
differences may be a result of using differing time frames or
criteria for completion of treatment. We should resolve this as
soon as possible. The time-in-treatment effect may be telling us
something important about the dependence process per se.
As I have pointed out, given the consistency of the finding, there
appears to be little need to confirm that drug-dependent patients
seeking treatment have more than their expected share of psychi-
atric symptoms and diagnoses. But what is not clear is how these
findings impact upon participation in and response to treatment.
As I have already noted, the Philadelphia group (McLellan et al.
1978, 1983; O'Brien et al., this volume) found that severity of
psychopathology was a major predictor of outcome on several key
outcome variables. In studies of therapeutic communities,
depressive symptoms seem to predict early dropout which, in turn,
is correlated with poorer outcome on several dimensions (see
DeLeon, this volume). In contrast, Kleber, Rounsaville, Weissman,
and their coworkers in New Haven found that while depressive
symptoms were quite common among opioid addicts, these symptoms
appeared to show considerable spontaneous improvement (Rounsaville
et al. 1982c,d). Further, while those starting treatment during a
major or minor depression showed poorer response in terms of
illicit drug use and psychological symptoms, starting with such
symptoms was unrelated to work, crime, or remaining in treatment.
The New Haven group found that although the prevalence of depres-
sive symptoms was high, the severity of the depression was not.
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Indeed, the depressive mood did not seem to be clearly distinct
from subjects' usual mood. Further, the syndrome appeared to be
self-limiting (Rounsaville et al. 1982c). However, the recent
data from the TOPS project indicate that depressive symptoms among
drug abuse patients can be quite severe if thoughts of suicide are
considered a valid measure of severity (Craddock et al. 1982;
Hubbard et al., this volume). The literature over the past 20
years contains numerous papers suggesting that depression and
suicide are far more common among drug users than in the general
population (see Rounsaville et al. 1982c; Dorus and Senay 1980).
However, in Vaillant's longitudinal study of alcoholics, psycho-
logical symptoms tended to remit when the alcohol use ceased,
leading Vaillant to assert that alcohol use caused depression,
rather than the reverse (Vaillant and Milofsky 1982). It may be
important to do separate analyses according to the class of drugs
being used at entry into treatment. The TOPS data show a
clear-cut trend for those abusing sedatives to have higher levels
of depression than those using opioids only.
These comments on depression among opioid users are meant to be
illustrative of the well-established scientific principle that new
information leads to a few answers but to even more new questions.
Having found that psychopathology is prevalent, we must now find
to what degree it influences other dimensions of treatment out-
come. The work of the Philadelphia group certainly suggests that,
as measured by the ASI, severity of psychological problems is a
major predictor of outcome along all dimensions, at least at the
6 month followup period. That work needs to be independently
confirmed. We also need to find out whether it is composite
severity that is critical, or if there is some significance to
specific diagnostic categories, such as affective disorders or
antisocial personality.
Related to the general topic of psychopathology are the unresolved
questions of whether current psyctrotherapeutic or psychopharmaco-
logical interventions can ameliorate the psychopathology present
and, if the pathology is influenced, whether the overall outcome
of treatment is thereby altered. With respect to depression, the
Philadelphia group appears to have positive findings for both
pharmacological (Woody et al. 1975) and psychological interven-
tions (Woody et al. 1983; O'Brien et al., this volume), while the
group in New Haven finds little incremental benefit from either
(Kleber et al. 1983; Rounsaville et al. 1983). There does appear
to be a consensus that not only do patients who are diagnosed as
having antisocial personality have more psychopathology and a
poorer prognosis, but also that we have little to offer them in
the way of special intervention. To the best of my knowledge,
there are no effective treatments for antisocial personality.
Given the prevalence with which the diagnosis is made and the
negative implications for treatment outcome associated with anti-
social behaviors, the absence of any promising approach represents
a significant gap. In sum, there is consensus that psychopath-
ology is common, but whether we can influence its course or
whether doing so alters either short-term or long-term outcome
22
remains to be determined.
In a similar vein, I find myself puzzled by the inconsistent
findings on prognostic significance of alcohol abuse among
patients treated for drug dependence. Most studies have suggested
that patients who use alcohol excessively while in treatment for
other drug abuse problems have higher degrees of psychopathology,
tend to drop out of treatment, and have a relatively poorer prog-
nosis (Green and Jaffe 1977). However, recent findings from the
group in New Haven show that such patients, despite having fewer
psychological assests and more liabilities, do about as well as
other patients when assessed 6 months after entry into treatment
(see Rounsaville et al. 1982e). Other groups have recently
reached similar conclusions about retention of alcoholics in
treatment (Stimmel et al. 1983). Given the frequency with which
the problem of alcoholism is encountered among opioid users, some
further clarification would be welcome.
I am particularly perplexed by our seeming inability to reach
consensus on the importance of dosage levels in the outcome of
treatment in methadone programs, but since the most recent NIDA
Treatment Research Monograph volume has been devoted to this
question (see Cooper et al. 1983), I will not elaborate further on
this point. For the same reason, I will simply note that I am
similarly perplexed by the finding that, at long-term followup,
those treated in methadone programs in New York do significantly
worse in terms of return to opioid use (see Des Jarlais et al.
1981) than do opioid addicts treated in other parts of the United
States (see Simpson, this volume; Hubbard et al., this volume) or
in England (Stimson and Oppenheimer 1982).
OTHER PERSISTENT GAPS
There are some areas where inconsistent data would be an improve-
ment. Despite the fascinating studies that have emerged over the
past decade suggesting that there may be several genetically
transmitted types of vulnerability for alcoholism, most efforts to
evaluate drug abuse programs do not include detailed family histo-
ries of alcoholism, drug abuse, criminality, or mental illness.
Family studies (i.e., direct interviews of family members) are
rarely linked with treatment evaluation. Some of the work of
Bohman, Cloninger, and coworkers (Bohman et al. 1981, 1982)
suggests that for some forms of genetic vulnerability for alco-
holism (especially that associated with having a father with severe
alcoholism and criminality), the risk of developing alcoholism in
the male offspring is increased about nine-fold, and that adoption
at an early age into a nonalcoholic family does little to lower the
risk. I think it would be useful to study family drug use histo-
ries of patients in treatment to determine whether such familial
factors influence treatment outcome. To gather such information
may not require entirely new studies. Since family history does
not change much over time, ongoing evaluations might fill in such
gaps in the baseline data during followup interviews.
There are additional areas where the tasks of evaluation are in-
complete, and I will mention only a few. Despite such landmark
studies as those of O'Donnell (1969), Stimson and Oppenheimer
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(1982), Vaillant (1978), Nurco et al. (1975), and Maddux and
Desmond (1980), we still need to know more about the long-term
natural history of the opioid dependence syndrome. In the DARP
studies, which followed a relatively recent cohort of opioid users,
each year following treatment the number of opioid addicts indi-
cating illicit opioid use, non-opioid drug use, and arrests seemed
to go down, and the number working seemed to go up. That this was
not a tendency to minimize problems is suggested by the finding
that heavy alcohol use stayed about the same or increased (see
Simpson, this volume; Simpson et al. 1982). A tendency to improve
over time, although not quite so marked in degree, has been seen
among heroin users treated in London (see Stimson and Oppenheimer
1982). What are the pathways out of opioid addiction? Is this
general improvement across groups originally treated in different
programs a reflection of a general tendency for all symptoms to
remit? Is the improvement an artifact due to selective attrition of
those addicts with the poorest prognosis? How significant a factor
is readmission to other programs? Is improvement over the long
term a function of the degree of psychiatric impairment or diag-
nosis, or is it a matter of chance factors? In his work on alco-
holics, Vaillant suggests that finding a caring new spouse, a
better job, Alcoholics Anonymous or renewal of faith are important
events (Vaillant and Milofsky 1982). Maddux and Desmond (1982),
studying opiate addicts in Texas, suggest that moving away from the
area where addiction developed was associated with improvement. If
there is any way our followup studies can contribute to an under-
standing of the process of gradual improvement among contemporary
cohorts of drug users, we should make the effort to gather the data
and conduct the analyses.
The last area I will mention is the relative paucity of information
on the non-opioid drug user. We should acknowledge from the outset
that MDA-supported treatment programs may not be seeing a repre-
sentative cross-section of the individuals dependent on non-opioid
drugs. Historically, in the United States, treatment for depend-
ence on amphetamines, sedatives and alcohol was the responsibility
of State and local governments and of the private sector. Patients
dependent on these drugs were not even eligible for treatment at
the U.S. Public Health Service hospitals at Lexington or Ft. Worth,
but they had little trouble obtaining treatment in State or private
facilites (assuming they could afford the latter.) When NIDA
opened its treatment programs to patients with these problems, the
programs were already characterized as programs for the "street
users" and, for the most part, the more conventional drug-dependent
patients found treatment elsewhere. Allowing for this fact, how-
ever, it is still vexing that we know so little about the natural
history of these patients and of their response to treatment. It
is all the more vexing because the number of patients seeking
treatment for cocaine dependence and marijuana dependence is
growing rapidly, not only in publicly supported programs, but in
the private sector as well.
Brown's review (in press) of the treatment of non-opioid dependence
is a comprehensive summary of the state of our knowledge, but that
knowledge is disturbingly incomplete and has even more inconsis-
tencies than are found in the literature on opioid use. In
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general, Brown's review needs to be amplified with some effort to
determine what proportion of the population with non-opioid drug
problems is seen by the "treatment system." It is my general im-
pression that, to a very considerable degree, most non-opioid drug
users are to be found in the population of patients seen at the
offices of general practitioners, internists, mental hygiene
clinics, and alcoholism programs. Thus, it may be that the group
with whom the "drug abuse evaluation system" has the most experi-
ence is the smallest part of the population with non-opioid
problems. To the degree that certain categories of antecedent
psychopathology (i.e., antisocial personality) are major deter-
minants of both treatment response and longer term outcome, the
prognosis for these "straight" patients may be considerably better
than for those patients for whom non-opioid drug use is but one
element of a more deviant lifestyle.
Related to this issue of non-opioid use are questions of the longer
term biological consequences of drug use and abuse over the years.
There is now a rapidly growing literature indicating that excessive
alcohol consumption may be associated with altered brain structure
and decreased performance on tests of cognitive ability. Some
workers have suggested that such cognitive impairment may adversely
affect the ability to benefit from therapy that requires retention
of verbal material. There is some data suggesting similar deficits
among barbiturate-sedative users, in contrast to the relative lack
of such findings among opioid users (see Rounsaville et al. 1982a).
Alcoholism and non-opioid abuse are problems for a high proportion
of patients in NIDA-supported programs. Eventually we will want to
know to what degree depressive symptomatology so common among drug
abusers, particularly non-opioid drug users, is related to
drug-induced anatomical or functional change, and to what degree
such changes influence participation in and outcome of treatment
and the longer term natural history. I do not underestimate the
costs of such efforts, but I do not believe that large scale
studies are required to study this question.
One last comment seems to be in order. Because NIDA was once the
major source of support for treatment, there may be a tendency to
see as its responsibility the evaluation of the programs or types
of programs it once supported. I would argue, however, that NIDA's
role should be the advancement of knowledge about the treatment
process regardless of the source of support for that treatment.
Every researcher, if asked, can prepare a long list of recommenda-
tions and can extend a wish list of studies that ought to be done
ad infinitum. Given the time and space. available, my list ends here.
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National Treatment System Evalu-
ation Based on the Drug Abuse
Reporting Program (DARP)
Followup Research
D. Dwayne Simpson, Ph.D.
The Drug Abuse Reporting Program (DARP) was established in 1969 as
a nationally oriented data system for the evaluation of community-
based treatment services (Sells 1975; Simpson 1983). It began with
the Federal funding of drug abuse treatment service components
(primarily for heroin addiction) in six community mental health
centers located across the United States, but it soon expanded to
include a wide variety of treatment settings and approaches for
drug abuse. Standardized data collection instruments for admission
and bimonthly during-program progress reports were developed and
later used to describe almost 44,000 clients in 52 different
agencies from 1969 to 1974. Major treatment modalities included
methadone maintenance (MM), therapeutic communities (TC),
outpatient drug-free programs (DF), and detoxification (DT).
During-treatment research, using a multiple cohort design, focused
on classification of treatment types and patient types, development
of outcome criterion scores, treatment retention and performance
evaluations, effects of community context on outcomes, and other
issues. Results of these studies have been reported in a
five-volume series of books (Sells 1974; Sells and Simpson 1976),
in a databook of descriptive tabulations (Simpson et al. 1976), and
in professional journals and NIDA Treatment Research Reports.
In 1974, the DARP posttreatment follow-up research phase began,
again using a multiple cohort design, to study outcomes associated
with various drug abuse treatment strategies and client
characteristics. A total of 6,462 clients in three separate DARP
admission cohorts were selected for follow-up from 34 treatment
agencies. These clients represented the four major treatment
modalities of MM, TC, DF, and outpatient DT; in addition, a
comparison group of intake only (IO) clients was included fran
persons who were formally admitted but who never returned to
receive treatment in the DARP agencies. Sample selection
procedures were stratified to insure adequate representation for
analytic purposes with regard to age, race-ethnicity, sex,
treatment type, length of time spent in treatment, and geographic
location of programs. Altogether, 83% (N=5,340) of this sample
were located; 73% were interviewed after granting informed consent,
5% were deceased, 1% were out of the country (mainly due to
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military service), and 4% used their right to refuse the interview.
The other 17% could not be located. The fieldwork for the
follow-up studies was carried out under the direction of the
National Opinion Research Center.
The major focus of the studies in the 6-year DARP follow-up
research phase has been on treatment outcomes, as summarized in
overview papers by Sells and Simpson (1980) and Simpson and Sells
(1982a,b). These studies have used a variety of multivariate
analytic strategies and independent treatment samples for
replicating research findings, based on the first year, and 3 years
following DARP treatment. In addition, this research series has
also addressed related issues such as client satisfaction with DARP
treatment services, use of other types of community services needed
and received, leisure time activities, alcohol consumption,
covariations of drug use with employment and criminal activities
over a 3-to 4-year time period after DARP, effects of family and
other social relationships on posttreatment outcomes, and
long-range follow-up outcomes. (A bibliography to these papers can
be found in Simpson and Sells 1982.a.)
Currently, the DARP research is being extended to study follow-up
outcomes 12 years after entry into DARP treatment for 697 heroin
addicts who were admitted to treatment from 1969 to 1972 (and who
were also interviewed in the 6-year follow-up study). By the time
of this follow-up interview, at least 14 years will have passed
since most of the respondents first began daily use of opiate
drugs. In addition to the obvious questions about the current
status of these former addicts and the permanence of abstinence
reported in the 6-year follow-up interviews, factors involved in
the initiation, maintenance, and cessation of addiction cycles will
be addressed.
MAJOR RESULTS OF THE DARP RESEARCH PROGRAM
The original purpose of the DARP was to serve the treatment
evaluation needs of a new federally supported service delivery
system. However, the evaluation goals, procedures, and outcome
criteria were unspecified, and there were no standards or
comprehensive models for establishing a large-scale, field-based,
drug abuse treatment evaluation system. Thus, the early years of
the DARP research, reported in Sells (1974) and Sells and Simpson
(1976), dealt with fundamental issues such as criterion development
and measurement, as well as treatment definition and
classification. This work also served to describe a substantial
segment of the national drug abuse treatment clientele during the
early 1970s, and it documented some of the changes in the
treatment clientele over this time. This was an important
conceptual phase for the long-range evaluation goals for the DARP,
but the major results of the DARP research project have been based
on the posttreatment follow-up studies of treatment outcomes.
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Treatment Effectiveness
The results of the various studies of client outcomes after DARP
treatment, are illustrated in Figure 1 (see Sells et al. 1979 and
Simpson et al. 1978a, 1979, 1980). The DARP research has included
opioid as well as nonopioid users, but most of the results
reported in this paper will center on black and white male opioid
addicts. This is the best represented subsample and it can be used
most effectively to illustrate the major treatment outcome
findings.
Since there frequently are differences of opinion on what
constitute reasonable treatment outcome expectations for opioid
addicts, two different outcome standards for the first year
post-DARP are represented in Figure 1: (1) highly favorable
outcomes are defined as no use of illicit drugs (except for
less-than-daily marijuana use) and no arrests-or incarcerations in
any 1 or more months during the year; (2) moderately favorable
outcomes are defined as no daily use of illicit drugs and no major
criminality (i.e., no more than 30 days collectively in jail or
prison, and no arrests for crimes against persons or crimes of
profit). These simplified outcome standards emphasize the major
criteria of drug use and criminal activity, and they accurately
reflect the DARP findings from other studies based on more complex
and sophisticated, empirically determined canposite outcome?
measures (with time-at-risk adjustments) which also take into
account employment, alcohol use, and return to treatment.
Comparable subsamples of black and white males (N=2,099), from all
admission cohorts in the follow-up studies, are included in the
tabulations for Figure 1.
The data demonstrate the consistent DARP research finding that
the most favorable outcomes were associated with the major
treatment modalities of MM, TC, and DF; the DT and IO groups had
significantly poorer outcomes. This same pattern of results was
found using various strategies for statistically controlling and
adjusting outcome measures with respect to client characteristics
(since clients were not randomly assigned to treatments). It was
also found that canposite outcome differences between MM, TC, and
DF treatments were not statistically significant; this finding will
be discussed in more detail later.
Prediction of Individual Client Outcomes
In addition to the between-group comparisons of treatment outcomes,
the DARP research has included studies of variables associated with
individual client outcomes within each treatment. Results based on
stepwise regression analyses have captured the primary thrust of
these findings (Simpson et al. 1978a, 1979, 1980) using client
admission and during-treatment data as predictor variables.
Analyses of individual outcome criteria showed that their
respective preadmission baseline and during-treatment measures were
generally related to posttreatment outcomes: for example. a poor
employment history before and during treatment was predictive of
unemployment after treatment. The most consistent and significant
predictors of composite outcome measures, however, were criminal
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FIGURE 1. Highly favorable and moderately favorable outcomes in
the first year after DARP treatment for black and white male opioid
addicts in each DARP treatment group.
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history and during-treatment performance; higher rates of
preadmission arrests and incarcerations were related to poorer
posttreatment outcomes, and, as expected, higher rates of criminal
activity, drug use, and unemployment during treatment in the DARP
were related to poorer posttreatment outcomes. During-treatment
performance and the length of time spent in treatment were
particularly significant predictors of outcomes. Figure 2
illustrates the relationship of tenure to the highly favorable
outcome standard defined earlier -- that is, no drug use and no
criminality (as indicated by no arrests or incarcerations). In
sane cases, up to about one-third of the variance in composite
outcome scores for individuals in the separate treatment groups was
accounted for by these predictor variables.
The association between treatment tenure and outcomes represents an
important link in the evidence for drug abuse treatment
effectiveness. Not only did the clients who remained longer in
treatment have the most favorable outcomes, but the short-term
(i.e., less than 90 days in treatment) clients in MM, TC, and DF
reported outcomes that were no different fran those of the DT and
IO clients. Furthermore, the relationships between tenure (beyond
90 days) and posttreatment outcomes in the MM, TC, and DF groups
were linear (see Simpson 1981).
These results suggest two things. First, and most obviously,
treatments which last less than about 90 days appear to be of
limited benefit, regardless of the type of treatment involved.
Beyond 90 days, however, treatment outcomes improve in direct
proportion to the length of time spent in treatment. The second
point is methodological in nature. Specifically, the lack of
significant differences between outcomes for short-term clients in
the five DARP treatment groups contraindicates any widespread
sampling bias that would have given preference to any given
treatment group in the client assignment process.
Treatments During the Post-DARP Follow-up Period
Treatments which occurred during the post-DARP follow-up period
have also been found to be associated with significant improvements
in client outcomes, and these outcomes became more favorable as the
length of the treatment contact increased (Simpson 1981, Simpson
and Savage 1980). Thus, some of the major findings associated with
DARP treatment were replicated by those from the post-DARP
treatments.
Detailed inspection and classification of long-term outcomes
throughout the entire follow-up period (i.e., ranging up to 6
years, depending on the time spent in DARP treatment) provided an
alternative method of examining treatment effects in the DARP data
base (Simpson et al. 1982). This study (based on the follow-up
sample for the 1972-73 admission cohort) showed that 61% of black
and white male addicts had achieved abstinence from opioid drugs
for the last 1 or more years before the follow-up interview. Table
1 indicates that 19% became abstinent immediately after DARP
treatment, and another 42% became abstinent later in the follow-up
period. A total of 21% continued opioid addiction throughout the
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FIGURE 2. Highly favorable outcomes (no drug use and no criminality)
in the first year after DARP treatment by length of time spent in MM,
TC and DF treatments for black and white male opioid addicts.
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TABLE 1
Classification of 6-Year Followup Outcomes
of Black and White Male Addicts
Outcome Patterns
Total % of
Number Total
IMMEDIATE OPIOID ABSTINENCE --
a.  Without further treatment
b. With continuous treatment
DELAYED OPIOID ABSTINENCE --
180 18
5 1
c. After further treatment 134 14
d. After jail/prison 54 5
e. After treatment and jail/prison 35 3
f. With continuous treatment 119 12
g. Without treatment or jail/prison 81 8
HEAVY AND SUSTAINED OPIOID USE --
h. Without treatment or jail/prison
i. With long-term treatment
j. With short-term treatment or jail/prison
SPECIAL PROBLEMS --
k. Heavy alcohol use
1. Heavy non-opioid use
m. Continuous jail/prison
n. Periodic opioid use
o. Abstinence to relapse
TOTAL
36
47
115
45
33
51
35
20
990
4
5
12
5
3
5
3
2
100
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follow-up period, while the last 18% had other special problems
(such as alcohol or heavy non-opioid drug use, prolonged
incarceration, or periodic relapse to heavy opioid use). Of the
clients who achieved abstinence, about 75% reportedly terminated
opioid use during DARP or a post-DARP treatment episode (i.e.,
outcome patterns a, b, c, e, and f).
IMPLICATIONS OF RESULTS
There is still an unfortunate but widespread popular belief that
drug abuse treatment is a failure and waste of public funds. The
DARP research project, and other studies reported in this volume,
however, provide convincing evidence for the effectiveness of drug
abuse treatment.
The DARP work reported in this paper has focused on treatment
evaluation, although other issues dealing with drug use, crime,
employment, death rates and causes of death, and so on have also
been studied (see Simpson and Sells 1982a). The DARP has
contributed methodologically in identifying and developing
posttreatment outcome evaluation criteria, as well as in exploring
alternative analytic strategies for dealing with evaluation issues
in applied settings. Seminal work on classification of drug abuse
treatment and patient types has been carried out, and the
posttreatment follow-up phase of the DARP research, which began in
1974, has demonstrated the feasibility of conducting such studies
-- including a sufficiently high canpletion rate in relocating
community-based drug abuse treatment samples (e.g., 83%).
The DARP results on treabnent evaluation suggest that drug abuse
treatment should continue for at least 3 months in order to achieve
positive effects; this is also consistent with studies of
therapeutic commnunity programs reported by De Leon (this volume).
Beyond that, posttreabnent outcomes tend to improve in proportion
to the length of time spent in treatment. This relationship was
also found to be consistent across opioid addict and non-addict
client subsamples, as well as across the major treatment groups,
MM, TC, and DF. Follow-up outcomes for addicts in the DT and IO
samples were significantly poorer than for those in MM, TC, and DF,
but it is important to add that the outcomes of short-term (i.e.,
less than 90 day) MM, TC, and DF treatment clients were not
different fran the DT and IO clients; all of these particular
clients received little or no treatment while in the DARP.
Approximately 60% of the DARP follow-up sample of opioid addicts
re-entered some type of drug abuse treatment within the first 4
years after leaving DARP; readmission rates within the first year
were 32% for TC, 33% for DF, 38% for MM, 40% for DT, and 43% for IO
groups (Simpson and Sells 1982a). Since each treatment readmission
reflects unsolved problems with continued drug use, this can be
considered a negative outcome with respect to DARP treatment. At
the same time, readmission to other treatments after DARP generally
leads to improvements on client behaviors -- which serves to
confound long-term evaluation efforts for DARP treatment. In other
words, effective post-DARP treatments (as well as other positive
relationships and life events) are combined with DARP treatments in
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influencing follow-up outcomes. Indeed, this positive relationship
between treatment readmissions and outcome improvements in the
post-DARP follow-up period is documented by Simpson and Savage
(1980). Its collective influence over time is also illustrated by
a reduction in differences between DARP treatment group outcomes
measured in the last year of the follow-up period, compared to the
first year immediately after treatment (see Bracy and Simpson 1983,
and Simpson et al. 1982). Thus, long follow-up measurement periods
are especially sensitive to these uncontrolled influences, and
posttreatment follow-up studies should adopt measurement strategies
with this in mind.
Although some client characteristics (such as criminal history)
were related to posttreatment outcomes, the relationships were
generally weak, and they provided poorer outcome prediction than
the treatment performance measures (including tenure and
satisfactory completion of treatment). This result was elaborated
in a study designed to investigate categories of similar clients --
defined using sociodemographic as well as criterion-relevant
background and baseline measures -- and their relationship to
treatments (Simpson and Savage 1982). Multiple discriminant and
classification analysis yielded a set of empirically determined
client types, which were then examined with respect to treatment
types (defined on the basis of program goals, policies, and
procedures for treatment, as summarized by Cole and James 1975).
Comparisons of the posttreatment outcome criteria showed that there
was no optimal match between these client types and treatment
types.
Unfortunately, the lack of outcome differences between the MM, TC,
and DF treatment modalities, as well as between the treatment type
classifications within these modalities, provides little guidance
for identifying significant dimensions of the treatment process.
There is considerable variation between treatments, in terms of
goals, service procedures, and client expectations, but each
treatment appears to be effective in improving outcomes of its
clients. Thus, it may be the amount of treatment contact (as
reflected generally by tenure in treatment), and not so much the
type of therapeutic approach, that is important. Retention in
treatment also implies a client "treatability" factor, composed in
part by motivation and determination to change behavior. Another
consideration is the drug abuser's readiness to enter and
participate in treatment, as opposed to involuntary treatment,
usually associated with legal action or other pressures.
Preliminary data now being collected in the DARP 12-year follow-up
of heroin addicts indeed suggests that, in addition to the
prominent role that treatment plays, a personal commitment to
change after "hitting bottom," or becoming "tired of the life,"
marked the majority of recoveries from addiction. The same sort of
personal evaluation and commitment to change has been reported by
Waldorf and Biernacki (1981) in conjunction with recovered heroin
addicts who were never in formal treatment programs.
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The importance of personal commitment to treatment for drug abuse
can hardly be denied. Nevertheless, the objective and reliable
measurement of such commitment has been met with only limited
success, probably because it represents a multidimensional and
dynamic process; a person may resolve either before or during
treatment to terminate drug use, but a personal commitment must
then be sustained, strengthened, and converted to action. Support
and guidance in this process can be seen as a major responsibility
of the treatment program counselor, and Janis (1983) has recently
discussed research on counseling procedures in dealing with such
problem behaviors. However, support for changing drug use and
other problem behaviors does not necessarily reside exclusively
with a treatment counselor; instead, it may come from family,
friends, or other social therapeutic support agents. Thus,
treatment serves as an important setting which is conducive to
client behavioral changes, but it is not necessarily the sole
causal agent.
The DARP data have not discriminated between the major modalities
of MM, TC, and DF in terms of effectiveness based on follow-up
outcomes, but it would be inappropriate to conclude that treatment
approach can be disregarded. Studies on the classification of
treatment types have documented variations in goals, policies,
procedures, etc., and these treatment differences address
differences in client needs. For instance, methadone maintenance
frequently deals with older addicts with longer histories of opioid
use and criminal involvement, and the treatment strategy is
designed to deal with these historically entrenched behavioral
Patterns in separate stages. Theoretically, drug procurement
activities are first removed through chemical maintenance, while
the therapeutic attention is devoted to developing and supporting
client commitment to behavioral change; only later are the
physiological aspects of addiction and withdrawal confronted.
Drug-free therapies (especially in therapeutic communities), on the
other hand, deal simultaneously with drug use withdrawal and
resocialization. To be effective, this form of therapy (especially
when used for opioid addicts) may require a greater initial level
of personal commitment for behavioral change than is necessary in
most methadone maintenance programs. In spite of the evidence that
they generally have limited posttreatment effects, even
detoxification programs can be argued to be beneficial as a stopgap
service that helps address acute drug use problems. At the same
time, the DT treatment group in the DARP research had the highest
percentage of clients who later returned to treatment (usually MM
programs), which suggests that detoxification efforts may help
facilitate later entries into more canplete treatments.
This more demanding requirement for client commitment may also
account in part for the relatively high early drop-out rate for
drug-free therapies. For example, 14% of MM clients left treatment
in the first 90 days, compared to 49% of TC clients (including 17%
in the first 15 days), and 43% of DF clients (Simpson et al. 1978b,
p.48). Similar differences are also reported on more recent
treatment samples in the Client Oriented Data Acquisition process
(CODAP) and the Treatment Outcome Prospective Study (TOPS).
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CONCLUSIONS
The DARP and other treatment evaluation studies have shown that
positive behavioral outcomes are associated with treatment.
However, we still do not know why. It is suggested that three
basic factors are involved, and they should serve as the basis for
further research.
First, it is reasonable to expect that a drug abuse treatment
client should commit to changing his or her life in order to
benefit from the treatment experience. This decision does not
necessarily have to be firmly resolved at the time of entry into
treatment, but a commitment has to be made soon thereafter. In
other words, a medical model that implies that the "medicine will
heal" does not apply -- the client must accept responsibility.
Second, successful treatment requires that counselors establish
rapport with and influence over their clients. The essence of this
relationship is that the client's decision to change is made,
sustained, and translated into action. It requires guidance and
support fran the counselor, as well as a firm stand on what
constitutes acceptable behavior. Different treatment modalities
and programs may vary in the time schedule required for this
sequence of actions, but the basic therapeutic process may in fact
be very similar in all forms of effective treatment. We need to
examine that possibility; indeed, the lack of outcome differences
between the DARP MM, TC, and DF treatment types seems consistent
with this idea.
Third, the client must remain in the therapeutic relationship for a
sufficient period of time in order to benefit from the treatment
experience.
This simple framework for characterizing the therapeutic process
helps to emphasize several familiar evaluation issues. For
instance, we need to know the client's psychological and behavioral
status at intake; this includes background measures such as drug
use and criminal involvement, as well as improved assessments of
ecological considerations, perceived pressures, and motivations for
treatment. The structural and procedural features of service
delivery also need to be more clearly operationalized for treatment
evaluation purposes. We have at least made a start in some of
these areas, but we have to become more insightful and creative in
future work since current treatment variables are able to account
for only a limited amount of variance in outcomes. In addition,
more attention needs to be given to the nature of the interactions
between client and counselor.
Further procedural research should begin with the exploration,
definition, and measurement of the essential dimensions of client
characteristics, treatment structure, and counselor-client
interactions. Then posttreatment follow-up studies are necessary
to judge our success in improving outcome predictions. This sort
of research effort should begin with intensive studies of treatment
procedures within programs, and be expanded later to include
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multiple-program comparisons for outcome evaluations.
Finally, the methodology for treatment evaluation research should
be given attention in order to improve the quality and
comparability of results across studies. Several lessons from
previous research point to the importance of selecting well-defined
treatment and comparison groups. It is also necessary to use a
follow-up time frame (preferably a l-year period) which allows
adequate representation of outcome criteria, with acceptable
statistical and distributional properties for analysis. This
follow-up period for treatment evaluation should begin immediately
after termination of treatment to avoid confounding influences --
such as other treatment episodes -- which accure over longer term
intervals. Studies of outcome status several years after treatment
are essential for our understanding of the long-range implications
of drug abuse, but their purpose and design should not be confused
with the shorter-term goals of treatment evaluation.
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Treatment Outcome Prospective
Study (TOPS): Client Character-
istics and Behaviors Before,
During, and After Treatment
Robert L. Hubbard, Ph.D., J. Valley Rachal, M.S.,
S. Gail Craddock, M.S., and Elizabeth R. Cavanaugh, B.A.
The Treatment Outcome Prospective Study (TOPS) is  a  long
term, large-scale longitudinal investigation of the natural history
of drug abusers before, during, and after receiving services in
publicly funded drug abuse treatment programs. Funded by the
National Institute on Drug Abuse (NIDA), TOPS consists of the
Intreatment Study and the Followup Study. The Intreatment
Study included 11,750 clients in three annual admission cohorts -
1979, 1980, and 1981. To date, posttreatment studies of the 1979
admission cohort (12 and 24 months after termination) and the
1980 admission cohort (3 and 12 months after termination) have
been conducted. A followup study of the 1981 admission cohort
between 12 and 36 months after treatment will be undertaken in
1984. The TOPS research also includes studies of the outcomes
for clients involved with the criminal justice system, particularly
those referred to treatment by the Treatment Alternatives to
Street Crime (TASC) programs. These programs were developed
by the National Institute of Justice (NIJ) to identify drug users
in the criminal justice system and refer them to treatment.
TOPS was designed to provide valid, current, nationally based
information describing drug abuse treatment clients, treatment
programs, and client behavior before, during, and after treat-
ment to help plan, refine, and assess state and local treatment
efforts. An important aspect of the TOPS design and approach
is the identification and analysis of the association of client
behaviors with client characteristics, community environments,
and the treatment process. The TOPS data base provides the
most current information from which reasonable during- and
after-treatment improvement expectations across selected behav-
ioral measures (such as alcohol consumption, drug use, mental
health, criminal behavior, and economic productivity) can be
developed. Improvements (or change) experienced by the TOPS
clients can be viewed as the expected outcome for appropriate
groups of treatment clients. Program managers, policymakers,
and researchers can use the framework provided by TOPS to
design, conduct, and interpret studies and evaluations of indiv-
idual programs, groups of programs, and the general treatment
effort.
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TOPS was intended to expand our knowledge of treatment and its
impact on client behavior. By systematically tracking and moni-
toring individuals  over s ignif icant periods of  t ime,  a  better
understanding of the dynamics of drug treatment and client
behavior is being developed to generate new, better focused
research and to substantiate or reassess the findings of previous
research on a broader scale and enable treatment programs to
better direct their efforts to provide more meaningful, efficient,
and effective treatment. To accomplish this objective, TOPS has
employed the knowledge and useful aspects of methodologies
developed in past efforts. The multi-year cohort, longitudinal
followup design enables a comprehensive and systematic examina-
tion of many of the transitory and persisting changes in partici-
pating treatment programs, community environments, and in the
characteristics and behavior patterns of drug abusers seeking
admission to the treatment programs. One of TOPS’ research
objectives is to provide information that can be used to generate
clear, testable hypotheses about treatment effects and to identify
factors that may help determine why and for whom types of
treatment do or do not work.
The purpose of this chapter is to describe the design of the
TOPS research, summarize some of the key findings from the
Intreatment and Followup Studies, and then present recommenda-
tions for future research. The overall design of TOPS has been
the result of a systematic attempt to develop and implement
state-of -the-art  methodologies  in drug treatment evaluation
research, particularly in sampling, measurement, and analysis.
Many of the key elements of the design can be incorporated into
evaluation studies of different scopes and purposes. The early
results  of  TOPS general ly  support  the f indings of  previous
evaluation research. The overall design, however, will allow re-
searchers and policymakers to increase their understanding of
treatment effects. The recommendations presented suggest ways
to use the TOPS data and other studies to develop this under-
standing.
APPROACH AND METHODOLOGY
A critical element in the successful implementation of TOPS has
been the overall plan which calls for a full-scale longitudinal
study implemented in phases. The recommendations of a group
of experts in the area of drug treatment program research and
evaluation during the initial planning phase of TOPS formed the
basis for the overall plan and design. Many of these recommen-
dations were to build upon and augment the basic design of the
Drug Abuse Reporting Program (DARP) studies conducted from
1969-1973. Work on the initial stages of TOPS began soon after
this planning meeting in 1975 (Williams 1975). After the basic
data collection instruments and field procedures were drafted, a
contract to complete the second and third stages of the TOPS
was awarded to the Research Triangle Institute (RTI) in August
1977. The 18-month intreatment study period was divided into
two phases:  a  comprehensive pretest  data col lect ion last ing
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about 6 months and a pilot study data collection in 1979 lasting
12 months. The second (1980) and third (1981) years of the
Intreatment Study, and Followup Studies for the 1979 and 1980
admission cohorts were subsequently added. A grant to follow
up the 1981 admission cohort was approved and is expected to be
implemented in 1984. Advisory Committees have met several
times during the study to review the project and to recommend
the implementation of subsequent phases of the research plan.
The phased approach to the development and implementation of
TOPS has enabled NIDA and the researchers to (1) determine
the current needs TOPS can fulfill in terms of research and
policy, (2) more precisely focus the TOPS effort to meet specific
objectives, and (3) modify the design and instrumentation to
best meet current and future research and policy needs.
The magnitude of the study and the complex problems inherent
in this research required the careful consideration of a number
of important methodological issues. This section highlights the
key research design, sampling, definition and measurement, and
analysis issues in the overall planning and conduct of the TOPS
research.
Research Design
The TOPS research program is principally a descriptive and
correlational assessment of client behavior. Therefore, a survey
design was selected as the most appropriate approach for the
TOPS data collection. The 1975 Planning Group and other re-
viewers have generally advocated that TOPS be a large-scale,
coordinated longitudinal study rather than a series of individual
studies which might not be integrated and whose results might
not be comparable.
The use of a longitudinal, prospective cohort design has two
major advantages over other feasible designs. First, it permits
the use of measurements collected at one time to predict behav-
iors at a later time. Second, the cohort design can provide an
assessment of the impact of events occurring over time that
might change, including the nature of treatment, the character-
istics and behaviors of clients entering treatment, and the com-
munity environments that may affect program operations and
client behaviors.
TOPS is principally a descriptive study with a prospective cohort
research design. The prospective cohort design is best describ-
ed as a nonequivalent control or comparison group design. The
comparison groups that can be used in TOPS include a contact
only group, clients who stay in treatment for a short time (e.g. ,
3 months), and clients that stay 3 months or longer. In addi-
tion, treatment utilizer groups can be created among clients who
receive more or  less  intensive services .  Cl ients  can also  be
placed in various cohorts based on date of entry into treatment,
date of discharge, chronological age, age of first addiction, or
the occurrence of other significant events. But, as is the case
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for any single quasi-experimental, clinical trial, or correlational
study, TOPS alone cannot provide definitive evidence of causal
relationships. The information available from TOPS, coupled in a
coordinated effort with results from other studies such as DARP,
clinical trials, treatment observations, TOPS substudies, and
other related research will provide the multiple confirmation of
results necessary to confidently attribute overt client behavioral
changes to particular elements of the treatment process.
Study Programs and Client Population
Rather than a random sample of programs or clients, cities and
programs were purposively selected to reflect particular large-
and medium-sized urban areas with certain types of drug prob-
lems and to include programs which were believed to have effec-
t ive approaches to  treatment.  Stable,  establ ished programs
representing major modalities were selected to permit an assess-
ment of treatment process as it might optimally be conducted.
Neither the cities nor the programs represent a national sample.
A listing of the cities and numbers of programs is presented in
table 1.
TABLE 1
Number of TOPS Drug Treatment Programs in Each
City, 1979-1981
Programs
Cities 1979 1980 1981 Total a
Chicago 4 3 3 (4)
Des Moines 4 4 - (4)
Detroit 34 (4)
New Orleans 4 4 3 (4)
New York 5 5 4 (4)
Phoenix 6 5 3 ( 4 )
San Francisco 3 3 (3)
Total Programs 27 32 31 (41)
aTotal indicates the number of unique programs involved in
TOPS from 1979 to 1981. Seventeen programs were involved in
TOPS for all 3 years. The other 24 programs participated for
only one or 2 years. In addition to these, clients entered TOPS
through TASC programs in Chicago, Des Moines, Miami, Phoenix,
and Portland.
Intreatment Study. The first year of the full-scale Intreatment
Study began in January 1979 and involved the voluntary partici-
pation of 3,712 clients at intake to 27 treatment units (outpatient
45
detoxification, methadone maintenance, residential drug free, and
outpatient  drug free)  in s ix  geographical ly  disparate c it ies .
Almost 6,000 additional intreatment interviews were conducted
with these clients. The Miami and San Francisco programs were
added in January, 1980, and the Detroit and Philadelphia pro-
grams were added in January, 1981. Intreatment data collection
was terminated in December, 1981. More than 8,000 clients were
included in the study in 1980 and 1981; the total for the 3 years
was 11,750. The numbers of programs and clients participating
in TOPS are shown in table 2.
TABLE 2
Number of Drug Treatment Programs and Clients in
Each Modality, 1979-1981
1979
Admission Cohort
1980 1981 Totala
Programs
Outpatient Methadone
Residential
Outpatient Drug Free
Outpatient
Detoxification
Total Programs
Clients
Outpatient
Methadone
Residential
Outpatient Drug Free
Outpatient
Detoxification
Otherb
Total Intake
Number of Programs
8 10 10 (12)
9 10 11 (14)
7 10 9 (11)
3 2 1 ( 4 )
27 32 31 41
Number of Intake Interviews
1,135 1,563 1,486
944 929 1,018
906 1,134 874
521 305 367
206 317 4 5
3,712 4,248 3,790
4,184
2,891
2,914
1,193
568
11,750
aTotal indicates the number of unique programs involved in
TOPS from 1979 to 1981. In addition to these, clients entered
TOPS through five TASC programs.
bIncludes TASC clients not assigned to TOPS programs and
clients not eligible for admission to TOPS programs.
The Intreatment Study employed a census rather than a sample
of clients in each participating program except one detoxification
program. A random sampling was used in that program which
had more than 50 intakes per month. A census permits greater
quality control, eliminates sampling error, and permits the obser-
vation of the total scope of the variety of behavior occurring in
a single treatment program. Including all clients in a program
allowed the study resources to be focused more directly and
economically by basing data collection in programs.
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Full-time, program-based data collectors (Program Researchers)
were employed by RTI to interview clients in each participating
program. Their work was integrated with the ongoing operation
of the program. Eighty-two percent of clients were interviewed
at intake.  About 5 percent refused to  partic ipate.  A large
proportion of clients who contacted the program only one time
could not be recontacted for an interview. Ninety percent of
the scheduled intreatment interviews were completed.
Followup Study. The design of the followup study called for 1-
and 2-year posttreatment followups of 1,310 clients entering
TOPS programs in 1979 and 90-day and 1-year posttreatment
followups of 2,300 clients entering TOPS programs in 1980.
Twelve- to 36-month posttreatment followups of 1,380 clients in
the 1981 admission cohort are scheduled to begin in 1984. Data
collection for the 1979 and 1980 followup samples began in May
1980 and was completed in December 1982 with a completion rate
of about 80 percent for each round of interviews.
The population from which the TOPS samples were selected is
composed of all clients who entered TOPS programs and complet-
ed an intake interview in a given year of TOPS, 1979, 1980, and
1981. AU TASC clients who were assigned to one of the outpa-
tient drug free and residential modalities and who completed an
intake interview were selected into the sample because there is
special  analytical  interest  in this  group.  For a comparison
group, samples of TASC clients interviewed at TASC agencies
who were not assigned to one of the TOPS programs were also
selected (1979, n=35; 1980, n=100). Finally, 3 sample cohorts,
one for each year, were selected from the non-TASC individuals
who completed an intake interview. The total sample sizes of
1,345 clients for the 1979, 2,400 clients for the 1980, and 1,380
for the 1981 cohorts were determined by budget constraints with
a goal of achieving acceptable precision (see table 3).
TABLE 3
Followup Sample Design
Number of Clients Selected in each
Admission Cohort
1979 1980 1981
Outpatient Methadone 323
Residential 421 (135)
Outpatient Drug Free 415 (130)
Outpatient Detoxification 151
TASC Clients Not
Enrolling in
841 422
556 ( 4 9 ) 407 ( 4 2 )
714 (186) 451 (138)
189 100
TOPS Treatment 35 ( 35) 100 (100) 0
Total 1,345 (300) 2,400 (335)  1 ,380 (180)
Note. Number of TASC clients in each sample is shown in
parentheses.
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Modalities were treated as primary sample selection strata for the
sample cohorts. Secondary strata for the 1979 cohort sample
were treatment program by time-in-program (short term, long
term) categories. However, the secondary strata for the 1980
and 1381 cohort samples were simply the treatment programs.
Time in program is of interest as an analysis domain for the 1980
and 1981 samples but could not be accurately determined at the
time of sample selection.
For the 3 sample cohorts ,  the object ive of  the al location to
primary strata has been to achieve equal variances (equal preci-
sion) for the 3 primary strata (methadone, residential, and out-
patient drug free) means. A fixed sample size was allocated to
the detoxification modality in each cohort because limited num-
bers of detoxification programs were included in the study, and
the client populations appeared to be more homogeneous than in
the other modalities. The objective of the subsequent allocation
to secondary strata was, then, to minimize the variance (maxi-
mize the precision) of the associated primary stratum means,
subject to the restriction that a sample size of at least 25 would
be chosen for any treatment program with 25 or more eligible
sub je c t s .  Th i s  min imum sample  per  p rogram prov ides  the
opportunity to conduct individual program-based followup analy-
sis.
Definitions
In social program evaluation it is critical to have meaningful and
practical definitions of eligibility for the program and the study,
program enrollment, and termination from the program that not
only apply to all programs but also accommodate individual pro-
gram differences.
An attempt was made to interview all drug abusers when they
first physically contacted the treatment program to gain admis-
sion . Individuals were defined as eligible for an Intake inter-
view if:
they physically visited the program (clinic) seeking
admission or readmission, and
appeared eligible for the drug treatment program, and
initiated the program intake process, and
had not previously participated in TOPS in any pro-
gram, and
h a d  n o t  p r e v i o u s l y  b e e n  c o n t a c t e d  b y  a  P r o g r a m
Researcher (PR) in any program about participating in
TOPS.
Individuals were excluded from the Intreatment Study if they:
were clearly not eligible for the drug treatment pro-
gram, or
had previously participated in TOPS and met TOPS
discharge criteria, or
had previously participated in TOPS in any program
and discontinued treatment interviews for any reason.
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Individuals clearly not eligible for a drug treatment program
were, of course, not interviewed. For example, alcoholics with
no drug problem, individuals with overriding psychiatric prob-
lems, and those not meeting any program eligibility criteria such
as age or drug history were excluded.
In the Intreatment Study, interviews were scheduled for up to
2 years with all clients who were admitted to TOPS programs
and who completed an intake interview. Interviews were con-
ducted until a client:
refused or missed two consecutive intreatment inter-
views, or
refused further participation in TOPS, or
died or was rendered permanently not capable of parti-
cipating in TOPS, or
terminated treatment at the participating program.
Two criteria defined termination from treatment:
a record of discharge and no readmission to the pro-
gram, or
no physical contact with program for 30 days prior to
scheduled Intreatment interview date.
For analyses and sampling purposes, the date of termination from
treatment was defined as the official program record of the date
of the client’s:
last medication or physical appearance at the treatment
center for a counseling session (for detoxification), or
last medication (for methadone maintenance), or
last night in residence (for residential), or
last physical contact for counseling (for outpatient
drug free).
Points of Interview
The longitudinal design of TOPS makes each interview point
critical both technically and operationally. The major technical
concerns in selecting the points of interview include the analytic
and conceptual problems of (1) identifying key points in the
treatment process, (2) identifying points where major changes in
behavior occur, (3) plotting trends in behavior, and (4) estab-
lishing boundaries of time periods by chronological dates or key
events .  The operational  concerns include (1)  scheduling of
intreatment interviews, (2) the respondent’s ability to accurately
recall behavior, (3) the effects of repeated testing and respon-
dent burden, and (4) the timely notification of treatment termina-
tion.
To determine the best points of interview, retention patterns
were examined and discussions were conducted with treatment
administrators and clinicians. The retention patterns of a vari-
ety of programs clearly showed that there is a high dropout rate
in the first month of treatment followed by a leveling off. Also,
discussions with program staff indicated that major behavioral
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changes were most  l ikely  to  occur early  in treatment.  The
points of interview for the Intreatment Study were designed to
best assess behaviors over these time periods.
Past studies indicated that recall of events such as arrests and
employment are reasonably accurate for up to one year. How-
ever, behavior such as drug use, criminal activity, or odd jobs
are often telescoped or forgotten. Interviews at frequent inter-
vals, then, were considered necessary to obtain more accurate
recall of these behaviors and to assess attitudinal and evaluative
data about treatment. Based on both technical and operational
considerations, the interviewing schedule for the TOPS Intreat-
ment Study was:
at initial contact with a program,
one month after treatment admission, and
every 3 months after treatment admission for as long
as 2 years if the client remained in treatment.
In the followup study, attempts were made to interview clients in
the 1979 cohort 3 and 12 months after treatment. For the 1980
cohort, interviews were scheduled 12 and 24 months after ter-
mination from treatment. In the followup of the 1981 cohort,
clients will be asked about the 3 months and 12 months before
the followup interview (usually 12 to 36 months after treatment
termination). The 3-month interview used in the followup of
the 1979 clients provides more detailed information surrounding
termination. The followup after one year corresponds to the
standard followup period used in a variety of evaluation studies.
The longer term followups focus on behavior in the year prior to
the followup interview.
Measurement
TOPS is designed to provide data encompassing broad-based
ecological, social, social-psychological, and socioeconomic per-
spectives. A large set of variables is being examined in the
basic TOPS research approach. The general categories of vari-
ables covered in the TOPS interview are outlined in figure 1.
Whenever possible, standard measures of key variables are used
such as Uniform Crime Report categories of crime and employ-
ment rates as measured and defined by the Current Population
Survey of the Bureau of Labor Statistics. Information on many
types of behavior is collected in three ways: (1) within event-
or time-defined periods, such as age at first daily opiate use,
(2) status at interview or on a particular date such as labor
force participation in the week prior to treatment, and (3) within
chronological time frames such as drug use during the first
month in treatment.
In order to more fully understand the background and context of
client behaviors during and after leaving a drug treatment pro-
gram, information on the treatment received in a program and
the socioeconomic and cultural system outside the program in
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which the client must function is essential. Two TOPS sub-
studies (not reported here) examining treatment process and
community impacts were conducted to complement the basic In-
treatment and Followup phases.
Individual Background
Demographic characteristics
Life style and life changes
Drug and alcohol use and treatment experience
Illegal activities and criminal justice system involve-
ment
Employment history and other socially approved produc-
tive behavior
Treatment
Type of treatment (modality, environment, duration,
orientation)
Client behavior during treatment (drug and alcohol use,
illegal activity, employment, participation in treat-
ment activities)
Treatment services received (counseling, vocational,
medical, legal)
Treatment assessment (opinions about treatment, receipt
of aftercare services, behavior occurring at the time
of last program contact)
Community
Context of drug use problems (indicators of drug avail-
ability, perception of treatment resources, knowledge
of community services)
Social and economic factors affecting individual behav-
ior (labor force participation, treatment availability,
availability of community service)
Social support (support and involvement of family and
others in treatment, family composition changes)
Community involvement (peer group relationships, com-
munity services  received,  involvement in the drug
culture)
Treatment Outcome
Drug and alcohol use
Illegal activity
Employment and other economic or socially approved
productive behavior
Mental health (depression, problems)
Retention in treatment and successful completion of
treatment
FIGURE 1
Types of Data Obtained in TOPS Client Interviews
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Data Analysis Approach
The TOPS data can be used for descriptive, comparative, and
correlational purposes. Examples of specific questions that are
addressed can be organized for each type of data analysis. As
the analyses of the Intreatment and Followup Studies have pro-
gressed, information has become available to help specify ques-
tions in more precise and meaningful ways.
While the primary purpose of TOPS is to describe the charac-
teristics and behaviors during and after treatment of cohorts of
drug abusers contacting the TOPS programs, attempts are being
made to understand differences in behaviors among clients with
different backgrounds, receiving different types of treatment
services, and facing different community environments. Models
of client behavior are being developed which encompass the many
individual and environmental factors that may influence behavior.
Emphasis is being placed on both developing and revising models
that more clearly describe the behavior of treatment clients
during and after treatment, and generating and testing hypoth-
eses  about  the associat ion of  such behaviors  with variables
looked at individually and within various classes.
Framework. Given the large amount of longitudinal, behavioral
data collected, a conceptual framework is necessary to provide
directions to the inquiries and to generate hypotheses that can
be examined with the data set. To better organize the data
analysis, general models are being used to indicate the general
classes of variables and the temporal relationships that should be
examined in the analyses. Four major classifications of variables
are to be investigated in TOPS: client background character-
istics, client behavior, treatment program services, and commu-
nity descriptors. The major analyses focus on behavior indica-
tors in and across the various time periods - before, during and
after treatment (see figure 1).
Specifically, the major analyses are being organized around the
major  individual  outcome variables :  drug use,  employment,
mental health, and criminal behavior. Preliminary attempts were
made to develop composite outcome variables with statistical
combinations and theoretical patterns of outcomes. However,
unlike some previous studies, the major outcome variables in
TOPS did not appear to be related in a clear, systematic way.
Therefore, the use of composite measures could obscure some
important outcome results. Data books showing bivariate associ-
ations between selected predictor and outcome variables were
prepared and examined. These books provided the key informa-
tion for descriptive analyses within cohort and modality. Based
on these analyses, variables are elected for multivariate analysis.
One basic technique used is logistical multiple regression for
categorical data. This approach is most appropriate for highly
skewed, nonnormal distributions common in treatment outcome
research. The models can be developed and the results present-
ed in a form similar to a multivariate contingency table. Inter-
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pretations are probability statements about outcomes for various
combinations of client characteristics,
Time at Risk. In considering the effects of drug abuse treat-
ment on behavior, the opportunity to engage in the behavior of
interest must be considered. A number of drug treatment cli-
ents, especially those entering residential programs, were in
restricted environments such as jails, prisons, hospitals or other
residential treatment centers in the year prior to treatment.
Their opportunities to use illegal drugs, commit crime, or work
were l imited because of  these restrict ions.  In the f irst  year
after treatment 9 percent of methadone, 14 percent of residen-
tial, and 5 percent of outpatient drug free clients spent more
than 9 months in restricted environments. Clearly these differ-
ences in opportunity could affect results.
A number of methods have been proposed to control for time at
risk. The principal approaches include (1) deleting cases with
little time at risk from the sample, (2) adjusting rates of behav-
ior for time at risk, and (3) comparing behavior in time periods
when an individual was at risk with periods when an individual
was not at risk.
Restricted environment, however, does not necessarily result in
elimination of the behavior of interest; rather it more likely
limits involvement in the behavior. For example, illicit drug use
is sometimes reported among individuals in residential drug
treatment programs and inmates in jails and prisons. Other
adjustments for time at risk in effect often impute a consistent
level of high activity in crime or drug use for the period not at
risk (Ball et al. 1982). (The episodic nature of both activities
suggests that levels of behavior may have been reduced even if
the individual had remained at risk.) Thus, adjustments for
time at risk may artificially inflate the level of behavior for some
cases in the analysis. An accurate assessment of time at risk
also requires detailed and time-consuming measurement of episodic
behavior that is extremely difficult to incorporate into large-scale
surveys and data analyses. Even in the most ambitious efforts
to gauge time at risk, only some of the main elements of the
beginning and end points of time at risk episodes and the vari-
ous drug use, crime, and work activities periods could be re-
corded. Problems in recall and data reduction for analysis limit
this approach to an even greater extent.
Both ratio and sample reduction strategies were used to assess
the impact of different strategies for controlling for time at risk
in TOPS. These analyses indicated that time at risk controls
had a major impact on the pretreatment description of residential
clients and a minimal impact on analyses of methadone and out-
patient drug free clients.
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For example, with a sample reduction approach in the residential
modality, the proportion of clients using heroin in the year prior
to  treatment increased by less  than 2 percent as successive
controls for time at risk were introduced; but the actual number
of clients using heroin decreased by half. Even though these
clients were in restricted environments for more than a month, a
significant proportion of them reported weekly heroin use over
the period of a year. Were individuals in restricted environ-
ments removed from the analyses, information on a substantial
number of clients who had a serious drug problem would not be
available. Similar findings hold true for the followup. Of the
almost 200 clients who reported 40 or more weeks not at risk in
the year following treatment, about one-third reported committing
a predatory illegal act during that year. This rate for a “not at
risk” group is higher than that for the TOPS followup sample
which was at risk. These results exemplify the type of trade-
off that is made when time at risk is controlled. Because one of
the major goals of TOPS is to describe the natural history of
drug use among clients before, during, and after treatment, it
seems appropriate to first describe the actual level of behavior
without adjustment for time at risk.
There are a variety of reasons why an individual uses his or her
present  l eve l  o f  d rugs  ( e . g . ,  c o s t  o f  d rugs ,  ava i lab i l i t y  o f
drugs) in addition to time at risk. The early analyses of time at
risk demonstrate that control l ing for  t ime at  r isk is  a  very
complex theoretical and analytic issue. Alternative approaches
should be carefully considered in terms of their overall impact on
the results. Even inclusion of a time at risk control in multi-
variate analysis could result in spurious and misleading findings.
The impact of time at risk is being carefully considered in all
TOPS analysis, but these preliminary results indicate that ad-
justment for time at risk may generate greater bias than a more
straightforward presentation of descriptive data.
OUTCOMES DURING AND AFTER TREATMENT
Changes in criminal behavior, employment and other socially
productive activity, and the use of illicit drugs have repeatedly
been used to evaluate program effectiveness as has program
retention. A number of reviews of studies of treatment (Sells
1979; National Institute on Drug Abuse 1981; Quinones et al.
1979; Simpson et al. 1979; Simpson and Sells 1982) have conclud-
ed that overall there is evidence that a number of treatment
approaches for drug abusers are effective. Although important
changes in client population and treatment have occurred since
these studies were conducted,  results  from TOPS general ly
support these conclusions. In the following sections, outcomes
during and after  treatment for  retention,  drug use,  alcohol
consumption, depression, illegal activity, and employment are
summarized.
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Outcomes During Treatment
The analyses reported below examined behavior during treatment
on a variety of indices for all three TOPS admission cohorts.
The basic measure used was the behavior during first 3 months
in treatment. The use of the 3-month measure provides a large
sample for analysis of changes during treatment and, in general,
behavior over the first 3 months was very similar to behavior
during the first year in treatment.
Retention. Outpatient drug free clients are most likely to leave
treatment in a week or less (21%) and 4 weeks or less (36%).
By 3 months in treatment, more than 60 percent had dropped
out, transferred or completed treatment. Methadone clients are
least likely to leave treatment at any of the early stages, and 3
months after  intake 65 percent remain in treatment.  At  6
months, well over half remain. More than a quarter of residen-
tial clients drop out in the first month of treatment. By the end
of the third month, 56 percent of the clients entering in 1979 or
1980 had dropped out, transferred or completed treatment.
Drug Use. Almost 16 percent of all clients had either not used
drugs or  had only minimally  used drugs in the year before
entering treatment. This ranged from 14 percent of methadone
clients to 19 percent of outpatient drug free clients. Most of
these clients had transferred from other treatment programs or
were in jail or other institutions immediately prior to treatment.
Residential clients were most likely to reduce use of their pri-
mary drug. Ninety-nine percent of those reporting more than
minimal drug use in the year before treatment reported at least
some reduction in the f irst  3  months.  For 95 percent,  this
reduction was “large.” Nine out of 10 methadone clients report-
ing more than minimal use at treatment entrance experienced a
reduction in use. For more than 80 percent this reduction was
“large." Outpatient drug free clients were least successful in
reducing their drug use. About a third of those classified as
more than minimal users at entrance had continued or increased
that use at three months in treatment, though 45 percent of
users reported a large reduction in use.
Alcohol Consumption. A four category quantity-frequency index
of alcohol consumption was constructed. Heavier consumers of
alcohol were defined as those who drank 2 or more ounces of
absolute alcohol one or more times a week. More than a third of
methadone clients were nondrinkers or low level drinkers in both
the year before treatment and the first 3 months in treatment.
Of those who drank, almost a quarter of the methadone clients
increased their alcohol consumption in treatment, but 34 percent
reported at least some reduction in use.
Eighteen percent of outpatient drug free clients were nondrink-
ers or low level drinkers in the year before treatment and the
first 3 months in treatment. Of those who drank, 22 percent
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of  the outpatient  drug free c l ients  increased their  alcohol
consumption in treatment; but 32 percent reported at least some
reduction in use.
Almost 40 percent of residential clients were nondrinkers or low
level drinkers in both the year before treatment and in the first
3 months in treatment. Of those who did drink, only 7 percent
increased their alcohol consumption to the moderate or heavier
levels in treatment and, as would be expected, almost 90 percent
reported some reduction in use.
Depression Indicators. Clients were asked if they experienced
three indicators of  depression:  (1)  being so depressed they
could not get out of bed, (2) suicidal thoughts, and (3) suicide
attempts. Forty-six percent of all methadone clients reported
having been depressed in the year before intake. More than
60 percent of those remaining in treatment at 3 months, how-
ever, reported depression for the pretreatment and/or intreat-
ment periods, indicating that depressed clients tend to stay in
methadone treatment. The same tendency for depressed clients
to remain in treatment holds for the other two modalities. At 3
months in treatment, more than 22 percent of all respondents
show some signs of depression. Outpatient drug free clients are
most likely to be depressed (29%) followed by those in metha-
done (24%) and residential (15%) programs. About 40 percent of
those remaining in treatment at 3 months report having recover-
ed from depression. Outpatient drug free clients are least likely
to  report  recovery (35%) fo l lowed by methadone (39%) and
residential (50%) clients.
Illegal Activity. More than 40 percent of all clients reported
some predatory i l legal  act ivity (assault ,  robbery,  burglary,
larceny,  fraud,  or  stolen property)  in the year before treat-
ment . Residential clients were much more likely to report a
predatory act  (62%).  About a quarter  of  the methadone and
outpatient drug free clients (more than 70% of those who had any
predatory activity before or during treatment) reported cessation
of predatory illegal activity during treatment. The outpatient
drug free programs were less successful at reducing crime among
the clients; about one in four clients who had reported an illegal
act before treatment reported continued illegal involvement. The
reports of residential clients, of course, plummeted. Of residen-
tial clients who had reported activity, 97 percent reported cessa-
tion during treatment.
Full-time Employment (35 or more hours per week). Half the
methadone clients remained unemployed during treatment as did
more than a third of  the outpatient drug free c l ients.  At  3
months in treatment, more than 30 percent of outpatient drug
free clients worked full time or increased their work to that
level ,  a  s l ight  improvement over  intake.  The percentage of
methadone clients working full time in treatment remained about
the same as at intake (24%). Because of the design of most
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residential  programs,  few cl ients work outside the program
during the first 3 months in treatment.
Outcomes After Treatment
How clients function in the first 12 months after terminating
treatment is  a  useful  indicator of  the impact  of  treatment.
Behavior patterns during the first year may also affect longer
term outcomes. Thus, this first year is a major focus of the
TOPS followup analysis.
The data presented in this section are for the merged 1979 and
1980 followup samples. Merging the samples is appropriate for a
general description of outcome. It does not imply that the two
cohorts are equivalent. Differences between the cohorts have
been found that warrant separate analyses in the future. In
this preliminary examination of the data, the followup results
were analyzed by two time-in-treatment groups for each modality:
a short-term group that stayed months 3 or less, and a long-
term group that remained in treatment more than 3 months.
The analyses described in the following sections do not include
controls for a variety of factors, especially three key variables:
cohort, treatment during the followup period, and time at risk.
As described earlier, there are important differences among the
three TOPS cohorts both in terms of the programs included and
the changes that occurred in the programs. We also noted that
results are affected by treatment after TOPS and the opportunity
to engage in various behaviors.
Many clients, especially those in the methadone modality, re-
mained in the TOPS program throughout the followup period;
many other clients left treatment but had then been admitted to
the same or another drug treatment program and were in treat-
ment all or some of the time during the followup period. Other
cl ients were incarcerated or  had l imited opportunity to  use
drugs, commit crimes, or find jobs during the followup period.
Preliminary analyses have revealed that more positive behaviors
are reported by clients who also report more involvement in
treatment during the followup period. A similar analysis for
clients with different amounts of time at risk in the followup
period indicates that opportunity does affect the level of behav-
ior reported but in a more complex way than previously be-
lieved .
The TOPS initial descriptive followup results (see table 4) are
generally consistent with the DARP followup results. There
were major improvements in drug use and criminal activities after
treatment in all modalities, though the rates do not appear to be
as good as those found while the clients were in the treatment
program. Those clients who remained in treatment longer appear
to have more positive outcomes.
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TABLE 4
Comparisons of Behavior One Year Before and One Year After Treatment
for Clients Remaining in Treatment 13 Weeks or Less and More than 13 Weeks
Type of Weekly or
Greater Drug Use
Heroin and Narcotics
Heroin not Narcotics
Narcotics not Heroin
Multiple Nonopioids
Single Nonopiate
Alcohol/Marijuana
Minimal Use
Type of Alcohol User
Nondrinker
Infrequent/Light
Moderate
Heavier
Depression Indicators
None
Depressed
Suicide Thought/Attempts
Predatory Illegal Acts
None
1-10
11 or more
Weeks of Full-Time Work
None
1-39
4052
Sample Size n=386 n=541 n=380 n=340 n=553 n=292
Outpatient Methadone
<13 Weeks >13 Weeks
Before After Before
17.9 10.2 14.5 4.9 12.8 7.0 11 8 4.3 3.5 4.1 4.5 2.4
47.5 23.3 54.8 14.1 18.3 10.9 22.2 7.3 9.1 4.9 8.2 3.4
10.5 10.5 9.0 6.3 18.2 10.4 16.8 6.2 15.1 8.7 10.9 4.9
2.3 1.8 2.1 3.2 11.6 6.3 9.7 3.8 9.5 4.2 6.1 1.8
4.2 7.1 3.4 13 9 14.1 14.7 17.5 9.4 22.5 17.0 24.2 11.4
12.5 29.6 10.6 37.1 15.7 30.1 14.9 36.4 32.6 40.9 36.9 49.7
5.1 17.4 5.6 20.6 9.1 20.5 7.1 32.6 7.7 20.2 9.1 26.4
30.2 34.1 35.3 37.6 31.2 30.9 31.4 32.0 15.7 23.9 17.2 21.9
10.9 8.2 13.8 12.4 7.8 8.0 14.1 10.8 12.0 10.0 13.3 13.9
37.1 39.6 25.8 26.5 15.4 23.2 18.7 27.3 30.8 29.8 36.0 36.7
31.9 28.1 25.1 23.5 45.5 37.9 35 7 30.0 41.5 36.3 33.5 27.5
43 I 68 4 42.5 64.9 36.9 61.6 42.1 71.9 36.8 61.4 34.0 65.5
25.0 17.6 26.8 22.8 20.3 17.8 17.1 12.9 12.2 13.7 19.4 12.3
31 9 14 0 30.7 12.2 42.8 20.5 408 15.1 51.0 24.8 46.6 22.2
58.2 72.8 67.7 80.3 39.7 57.0 39.6 70.5 61.6 74.8 66.2 80.9
27.7 16.3 19.5 13.3 32.6 28.3 29.6 19.8 27.7 18.1 24.4 13.3
14.1 10.9 12.8 6.4 27.7 14.7 30.8 9.7 10.6 7.1 9.4 5.7
44.5 50.4 47.5 59.7 39.2 41.8 38.8 33.3 30.8 32.1 30.8 29.2
29.4 29.7 29.5 21.3 47.3 43.3 48.8 41.9 43.0 40.0 44.0 32.1
26.1 19.9 23.0 19.0 13.5 14.9 12.4 24.8 26.2 27.8 25.2 38.7
After
Residential
<13 Weeks >13 Weeks
Before After Before After
Outpatient Drug Free
<13 Weeks >13 Weeks
Before After Before After
Post-TOPS Drug Treatment. Consistent with DARP findings, a
substantial proportion of TOPS clients were in treatment during
the followup period (see table 5). Forty percent of short-term
and 60 percent of long-term methadone clients were in treatment
during the TOPS followup period. Most of the long-term clients
who reported 40-52 weeks of post-TOPS treatment were metha-
done maintenance clients who remained in the original TOPS
program throughout the followup period. These clients were
interviewed with a Long-term Interview form, and their data
were included in the long-term sample.  The proportions of
clients from residential and outpatient drug free programs re-
turning to treatment were much lower than for methadone cli-
ents. About 30 percent of short-term and 40 percent of long-
term residential clients reported treatment in the followup period.
About one of  4  outpatient drug free c l ients  reported treat-
ment.
TABLE 5
Number of Weeks in Drug Treatment in the Year
After Leaving TOPS Treatment by Modality and
Time in TOPS Treatment
Outpatient Outpatient
Number Methadone Residential Drug Free
of <13 >13 <13 >13 <13 >13
Weeks Weeks Weeks Weeks Weeks Weeks Weeks
None
1-13
14-39
40-52
59.7% 38.9% 71.3% 61.9% 76.2% 78.5%
11.1 6.2 14.5 9.7 12.2 5.9
10.1 8.9 7.5 13.6 6.2 5.1
19.1 45.9a 6.8 14.9a 5.5 10.6a
aCIients who remained in the TOPS treatment program throughout
the followup period are included in the calculation of these
percentages.
Clearly, treatment in the followup period must be considered as
an important covariate of behavior in the followup period. The
preliminary results reveal a nonlinear relationship for methadone
clients. For example, long-term clients who report no treatment
or 40-52 weeks of treatment report less heroin use (32%) and
predatory crime (18%) than clients who report 1-39 weeks of
treatment (60% heroin use and 32% predatory crime). Similar
patterns of predatory crime and treatment were found for long-
term residential and outpatient drug free clients. These curvi-
linear relationships can be taken into account in multivariate
analyses with the use of dummy or categorical indices of post-
TOPS treatment.
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Drug Use. There is a dramatic reduction in the use of the cli-
ent’s primary drug. In all modalities more than one-third of the
clients report not using their pretreatment primary drug during
the followup period.
After methadone treatment, daily or weekly use of heroin and
other narcotics was decreased by 50 percent for short-term cli-
ents ,  and by 70 percent  for  c l ients  remaining in methadone
treatment for  3  to  24 months.  Only one of  10 c l ients  who
remained in methadone treatment throughout the TOPS followup
period reported weekly or greater use of heroin or narcotics.
About 20 percent of all methadone clients reported no weekly use
of alcohol or any other drug in the year after treatment.
Over 20 percent of the short-term residential clients and one-
third of the long-term clients reported no weekly use of any
substance in the year after treatment. Another third of these
former clients reported weekly use of marijuana and/or alcohol
only. These findings are even more impressive considering that
pretreatment multiple use patterns were reported by three of
four residential clients.
For the outpatient drug free modality, one in five short-term
clients reported no weekly use of any substance in this year
after treatment, and 36 percent reported weekly or greater use
of only marijuana or alcohol after treatment. One-fourth of the
long-term clients reported no weekly use of any substance in the
year after treatment, and half reported weekly use of alcohol
and/or marijuana only.
Alcohol Use. Although the proportions of residential and outpa-
tient drug free clients reporting heavier alcohol use after treat-
ment were 5 to 10 percent lower than before treatment, drug
treatment did not appear to have much impact on drinking.
About 3 in 10 clients could still be described as heavier drinkers
after treatment.
I l legal  Activity .  Reports  of  i l legal  act ivity  were much lower
after treatment, especially for clients remaining in treatment
more than three months. Only 20 percent of long-term metha-
done clients, 30 percent of long-term residential clients, and
20 percent of long-term outpatient drug free clients reported
illegal acts in the year after treatment.
The largest changes in predatory illegal activity occurred for
residential clients. Where 60 percent reported at least one act
in the year before TOPS treatment, only about one-third report-
ed activity in the year after treatment. Smaller decreases in
illegal activity were reported for methadone and outpatient drug
free clients. There still appeared to be a group of about 5-10
percent of the clients in all modalities who commit a high number
of predatory crimes. Many appear to be the same clients who
report committing high numbers of predatory criminal acts before
and during treatment.
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Depression Indicators. Clients in all modalities reported a sub-
stantial decrease in indicators of depression. After treatment,
about two-thirds of all clients reported no signs of depression.
Reports of suicidal thoughts or attempts fell from about 30 per-
cent before treatment to 13 percent after treatment for both
long- and short-term methadone clients, from about 40 percent
before to  20 percent after  for  residential  c l ients,  and from
49 percent before to 24 percent after for outpatient drug free
clients. There did not appear to be major differences between
the 2 time-in-treatment groups. Despite the improvements in
repor t s  o f  depress i on  ind i ca tors  a f t e r  t rea tment ,  su i c ida l
thoughts and attempts still appeared to be a significant problem
for 10-25 percent of clients.
Full-time Employment. The results for employment are mixed in
the three modalit ies ,  Fewer methadone c l ients  worked in a
full-time job in the year after treatment than the year before
treatment. A troubling decrease of about 10 percent was also
found in the proportion of clients who reported working full time
40 or more weeks. This result may, in part, be accounted for
by the poorer economic conditions after treatment.
A more positive picture emerges for residential and outpatient
drug free clients who remained in treatment more than three
months. For these clients there was a marked increase in the
proportion who worked full time for 40 or more weeks (12.4%, to
24.8% in residential and 24.7% to 38.7% in outpatient drug free).
We hypothesize that clients who increase their full-time employ-
ment are those who worked full time for at least a few weeks in
the year before treatment. There is little change in the per-
centages of clients who report no full-time work. Many of these
clients may be housewives, the disabled, or students who did
not  seek ful l - t ime work.  Besides employment,  other social ly
productive activities are being considered in analyses to measure
social and economic improvements after treatment.
RECOMMENDATIONS FOR RESEARCH
The conduct  of  the TOPS research,  the nature of  results  to
date, and questions raised about the results by State planners,
as well as researchers, have generated a number of new issues
and questions.
Many new research questions involve moving beyond the basic
question of whether treatment “works." We must focus more on
how treatment influences behavior, what types of clients benefit
most, and how long after treatment and under what conditions
behavioral  changes persist .  Pol icy  questions involving cost-
effectiveness, organization and focus of treatment systems, and
provision of different types of services for different types of
clients need to be continually modified to reflect new knowledge
emerging from studies of treatment effectiveness. Many of the
questions can be addressed with existing data from TOPS or
other studies .  However,  a  number would require  addit ional
further study.
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We have organized our recommendations for future research into
four areas.  The f irst  is  centered on the need for  studies of
three general issues:
characteristics or types of clients,
nature and components of treatment process, and
persisting direct  and indirect  ef fects  of  treatment.
The second area involves the analysis approaches that can be
used to investigate these issues. We stress the need for
clear variable definitions and basic model construction,
utilization of existing data sets, and
replication and generalization of findings.
The third recommendation is the development of a useful, detail-
ed plan for future data collection efforts including:
continuing program-based data collection,
long term followup, and
linkages and integration of clinical trials and individual
program-based studies with a more representative data
base.
A final recommendation is for studies to determine how to best
organize the drug treatment and other health service delivery
systems, including alcohol and mental health systems. Budget
constraints and increasing health service delivery costs must be
included as a parameter in defining how best to organize health
service delivery systems to meet the needs of clients:
who enter drug treatment programs with multiple prob-
lems, including alcohol-related and mental health prob-
lems .
who contact other service delivery agencies such as
alcoholism treatment programs and mental health cen-
ters .
These recommendations have been based on our work in the area
and incorporate many of the suggestions and recommendations of
TOPS review committees. Many of these recommendations reflect
issues raised in discussions with treatment professionals in
alcohol, drug, and mental health treatment programs, and with
state and local decisionmakers. We have integrated our ideas
and others into the following discussions of each area. These
recommendations are presented as a basis for further discussion.
Issues
An awareness and understanding of the diverse types of drug
treatment clients and treatment processes are fundamental to
increasing our knowledge of treatment outcomes, the client, and
the program. Of importance, too, is the more general question
of the persistence of treatment effects first identified in the
recent followup analyses of Simpson and Sells (1982).
Client Typologies. Some important initial work has been done on
client typologies by Sells and Simpson (1976) focusing on demo-
graphic and other client characteristics. We think another key
approach is to classify clients according to drug use patterns.
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Unlike the DARP clients, most clients now entering treatment
present one of a variety of multiple substance abuse patterns.
Anecdotal accounts from treatment personnel and analysis of the
TOPS data indicate clients abusing multiple substances have more
problems and a poorer treatment prognosis .  We think that
analyzing outcomes for users with various characteristics will
generate important findings for clinical and research areas. The
7-category drug use pattern index developed for  TOPS, for
example, could be used for such classification.
Another method is to classify clients according to their problems.
McLellan et al. (1980) have pioneered this effort with the Addic-
tion Severity Index which was constructed for each individual
based on clinical judgment. TOPS uses a similar measure of
drug- and alcohol-related problems based on clients’ attribution
of problems to drug abuse. Further work on the objective and
subjective severity of problems and their attribution to drug use
needs to be conducted. The work of McLellan clearly shows that
treatment outcomes differ for clients with different levels of
severity. We think problem-based typologies should be one of
the key methods of describing clients.
Treatment Process. The complexity of treatment is difficult to
conceptualize and even harder to define and quantify. In TOPS.
important advances have been made in assessing the many levels
and components of  treatment.  Among the components to  be
studied are type of service or methods used and general indica-
tors of treatment such as strength and integrity of treatment
(Sechrest et al. 1979). However, the task of collating and link-
ing components into a comprehensive description of treatment
tied to treatment outcome remains.
Two key aspects  of  treatment process need to  be explored.
First, are services focused on the clients in need of particular
services? Second, given limited treatment resources, is treat-
ment (or are particular treatments) rendered to the clients who
will benefit most from the service? The latter approach can be
assessed in part from a cost-benefit or cost-effectiveness frame-
work.  We think that  a careful  assessment of  the treatment
process and individual  components of  this  process can help
greatly in developing a body of knowledge clarifying how treat-
ment works to provide the practitioner with information on how
treatment might be rendered most effectively and efficiently.
Persistence of Treatment Effects. It is generally acknowledged
that treatment works well while clients remain in a program.
The results of DARP, Phoenix House, and TOPS followups indi-
cate that,  while  treatment ef forts  do persist ,  other factors
become important after the client leaves treatment. The most
recent analysis of the DARP data suggests that 5 years after a
particular treatment, the effects of the treatment experience may
be obscured by intervening events such as a subsequent treat-
ment experience and normal maturation (Simpson et al. 1982).
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The theoretical framework of Moos (1981) incorporates considera-
tion of environmental influences following treatment that may
supplant or override treatment effects.
A fruitful area of research traces the posttreatment behavior
pattern of the client. What are the direct and indirect effects of
treatment on long-term success?  Do some treatment c l ients
move, get jobs, or receive other community services immediately
after leaving treatment that contribute to long-term success?
Are these lifestyle changes a result, in part, of the treatment
experience? To ascertain these effects we need analyses of data
collected soon after treatment which are then linked with longer
term followups. These studies should provide important informa-
tion for the development of reentry and aftercare efforts.
Analysis Approaches
Different approaches to the analysis of treatment outcome data
have been developed. These include simple descriptive tables of
survey data, detailed multivariate statistical analyses, and care-
fully controlled clinical trial designs. We think all approaches
are essential, and more effort needs to be directed toward the
integration and generalization of the findings derived from each
of  these approaches.  We propose three fundamental  ef forts :
development and presentation of clear, meaningful, and useful
concepts and basic models; secondary analysis of existing data;
and concentration on the replication and generalization of results.
Concepts and Models .  We bel ieve that c lear,  direct  results
which can readily be interpreted are essential to advancement of
knowledge and improvement of treatment efficiency. The TOPS
review panels, NIDA representatives, and State, local and indiv-
idual program administrators have urged us to provide data that
can be useful to them. They have consistently cited the monies
spent on previous research and the limited utility of those stu-
dies to treatment programs for clinical, administrative, and other
purposes. An additional objective or concern is the development
of a research base that is useful to the research community and
that will stimulate additional research. For this purpose, the
clear specification of measures, composite variables, and models
is paramount.
Clearly, the techniques for sophisticated multivariate searches
for structure such as factor analysis ,  discriminant function
analysis, and stepwise multiple regression are available. We,
however, propose that these tools be used more as a method to
test  hypotheses and develop theoretical  frameworks than to
create statistically elaborate models which may lack a firm con-
ceptual or theoretical base. Our analysis and model construction
approach for TOPS emphasized, first, the creation of readily
interpretable, conceptually sound measures and, second, the
need to understand how these variables are related to other
variables.
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Only after these first steps are completed do we think it is
efficient to proceed to basic model development. With the basic
data and models, we can then begin to develop more sophisticat-
ed and elaborate models.
Secondary Data Analysis. A vast store of valuable data has
been collected. We strongly recommend that data bases such as
DARP, TOPS, therapeutic community followups, and individual
program studies such as those for Phoenix House and the Phila-
delphia VA Medical Center be mined to their fullest extent.
Researchers should be encouraged to submit grants to conduct
additional analysis for these data sets. For example, a program
could be initiated for secondary analysis of these data, replica-
tions or expansion of the results from these studies, or addi-
tional data collection on supplementary samples of clients.
Such a program should emphasize how analyses of data from a
particular study could complement other existing data bases.
Most of the studies have numerous measures in common. For
example, the TOPS questionnaires include all CODAP items, many
DARP measures, and data that could be used to develop Addic-
tion Severity Index scores. In the reports prepared by RTI,
TOPS aggregate data are compared to DARP and CODAP results.
The analyses conducted under this program could compare re-
sults from other data sets with findings from the CODAP, TOPS,
and DARP data bases and vice versa.
Replication and Generalizability. The data now available for
secondary analysis lead us to stress the need for replication of
results. We have previously pointed out that DARP and TOPS
cohorts of drug treatment clients differ in many ways. Treat-
ment programs and systems evolve. Therefore, it is essential
that findings be carefully replicated in different client popula-
tions, programs, and points in time to determine the limits to the
generalizability of results of individual studies. We now have
two general data bases, TOPS and DARP, that offer the opportu-
nity for such replication and generalization. We think research-
ers should be encouraged to submit grants designed to replicate
to the extent possible their results in the TOPS and DARP data
bases. Research findings that can be replicated and generalized
provide the firmest foundation for the orderly progress in the
development of knowledge and the design of effective treatment.
Need for Additional Data Collection
Data collection of sufficient scope to effect research advances
and practical improvements in treatment are costly in terms of
time, money, and effort. Therefore, any future data collection
efforts should be carefully considered in terms of their potential
utility. We think that the three types of data collection efforts
discussed below deserve such careful consideration.
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Long-Term Followup Studies. The long-term followup studies
such as those initiated in the DARP research should be contin-
ued and others encouraged. They provide important information
on the development and maturation of addicts and drug abusers.
Five-  and 10-year fol lowup studies  could be conducted with
carefully selected samples from existing data sets. In a long
term followup study, the focus should be more on a natural
history of addict careers rather than on the impact of a particu-
lar treatment episode. In the followup studies, the focus should
be on issues such as episodic and persisting changes in behav-
ior, the history of treatment since the initial treatment episode,
and the changes in the relationships among various conditions,
treatments and behaviors, and mental health and psychological
status.
Multipurpose Treatment-Based Research Program. The past,
current, and potential utilization of the DARP and TOPS data
bases, and to a more limited extent CODAP, shows that a treat-
ment-based research program can serve a variety of purposes
for NIDA researchers and the drug treatment community. Unfor-
tunately, for the first time in the past 15 years, no such data
base exists. We have fragmented information on what has hap-
pened in treatment since 1981 and what kinds of clients are
entering treatment. The reestablishment of a treatment data
base can:
provide updated descriptions of drug abuse patterns
and service needs of clients seeking drug abuse treat-
ment,
identify administrative and treatment-related changes
in the treatment system and individual program organi-
za t i ons ,  s e rv i ces  r endered ,  and  e f f e c t s  on  c l i en t
outcomes,
continue the important aspects of the CODAP epidemio-
logical data base and augment the National Drug Abuse
Treatment Utilization Survey (NDATUS) treatment
management information system,
provide samples for followup, and
develop information about treatment/clinical and admin-
istrative/ management issues for knowledge transfer to
State and local agencies.
More specifically, four major needs that a treatment-based re-
search such as TOPS or DARP can fulfill are:
monitor changes in the population of drug abusers
seeking entry to drug abuse treatment,
develop in-depth information on the nature and extent
of treatment received, especially under the block grant
funding mechanism,
collect followup data after treatment termination, and
provide a population base for clinical trials, individual
program studies,  special  studies,  or  special  issues
analyses.
6 6
Linkage with Clinical Trials, Special Studies, and Program-Based
Studies. The need for more generalizable research findings can
be fulfilled by linking various types of data collection efforts
with similar instruments and samples. During TOPS, a number
of programs, researchers, and doctoral students supplemented
the TOPS data collection with special studies and used TOPS
data for secondary data analysis. TOPS data collection forms
were used by Daytop in their mini-university followup and in a
community mental health center study of appropriate diagnoses of
drug use by physicians and mental health practitioners. The
emphasis on linkages would promote assessment of how individual
study results can be integrated into the existing body of knowl-
edge.
Studies of the Drug Treatment System Organization
Perhaps the major change which has taken place in drug abuse,
alcohol, and mental health treatment systems recently has been
the switch to State-directed block grant funding. Clearly, there
is a need to develop knowledge about the types of organizations
and treatment services which may be efficient and effective
under this system. It is likely that in many States and localities
at least some drug abuse treatment services will become more
closely associated with alcohol and mental health services, and it
is  important to  assess the outcome of  these changes from a
clinical or treatment effectiveness point of view, particularly for
clients with multiple problems.
FOOTNOTE
1It should be noted that TOPS defines termination as the last
physical contact with the OPDF program for counseling. Official
records used for reporting to NIDA’s Client Oriented Data Ac-
quisition Process (CODAP) management information system could
show a discharge date up to 30 days after the last contact.
Therefore, compared to CODAP, TOPS data would indicate short-
er retention.
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Program-Based Evaluation
Research in Therapeutic
Communit ies
George De Leon, Ph.D.
There are four major treatment modalities addressing the problem of
substance abuse: detoxification, methadone maintenance, drug-free
outpatient settings, and therapeutic communities (TCs). Each modality
has its view of drug abuse; each impacts the abuser in different ways:
and the effectiveness of each must be evaluated in terms of its own
principal aims.
The primary aims of therapeutic communities are to achieve the
following: a global change in lifestyle reflecting abstinence from
illicit substances, elimination of antisocial activity, increased
employability, and prosocial attitudes and values. A critical assumption
in TCs is that stable recovery depends upon a successful integration of
these social and psychological goals. The rehabilitative approach,
therefore, requires multi-dimensional influences and training that, for
most clients, can occur after an extended period of living in a 24-hour
residential setting.
The effectiveness of therapeutic communities has been evaluated pri-
marily through followup studies. Many of these have been executed by
investigating teams engaged in large scale modality comparisons that
include therapeutic communities. Others have been conducted on and
by individual TCs. This chapter selectively reviews these program-
based studies to assess the effectiveness of the TC. The emphasis of
this research has been on treatment outcome, although there has been
some investigation of retention and treatment process. Illustrative
findings and conclusions from these studies are summarized briefly.
The literature is not surveyed exhaustively, nor is it reviewed
critically. Three criteria guided the selection of research to be
reviewed. First, studies involved therapeutic communities whose
planned duration of treatment exceeded 12 months in residency.
Studies of hospital-based and shorter term TCs were excluded on the
assumption that these constituted departures from the traditional TC
model either in treatment goals or in the procedures. Although
evaluation of these modified TCs is important, their findings would not
fairly reflect the effectiveness of the traditional approach. Second,
the studies were conducted by research teams that were affiliated
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with, or based in, therapeutic community settings. Third, the studies
have been published, were in press, or were technical reports of
completed projects. Finally, findings from externally based research
(multimodality) are also cited to highlight corroboration or disagreement
with the conclusions drawn from the program-based evaluations.
TREATMENT OUTCOME
The program-based followup studies surveyed varied with respect to
sample size, length of followup period, number of variables observed
and complexity of data analysis. However, all observed at least one of
three separate outcome variables: illicit drug use; criminality and
unemployment; and several constructed composite measures of individual
social adjustment (success or favorable outcome status). Most of the
studies utilized self-report which was considered reliable, although
several also contain corroborating information from outside agencies.
Separate Outcome Variables
All of the studies revealed that immediate and long-term outcome
status of the clients followed improved significantly over pretreatment
status. Drug use and criminality declined while measures of prosocial
behavior (employment and/or school involvement) increased (Aron et al.
1976; Barr and Antes 1981; Brook and Whitehead 1980; De Leon 1984;
De Leon et al. 1979; Holland 1978, 1983; Pin et al. 1976; Pompi et al.
1979; Romond et al. 1975; Wilson 1978; Wilson and Mandelbrote 1978).
Studies which examined differences between clients who complete
(graduate) and those who drop out of treatment indicated that the
graduates were significantly better than dropouts on all measures of
outcome. The investigations that analyzed time-in-program reported a
positive relationship between favorable outcome and length of stay in
treatment among dropouts (Barr and Antes 1981; Coombs 1981; De Leon
1984; De Leon et al. 1979; Holland 1978, 1982; Wilson and Mandelbrote
1978). None of the recent studies yielded contrary results, although
the magnitude of the changes varied, and several with positive findings
failed to obtain time-in-program differences (Brook and Whitehead
1980).
Success Rates
A few studies utilized a composite index of outcome, based upon self-
reported employment, opiate use or primary drug use, and criminal
activity. In these studies, maximally or moderately favorable outcome
occurs in approximately half of the clients followed (De Leon 1984).
Figure 1 illustrates the stability of therapeutic community success
rates in relation to length of stay. Two cohorts of male opioid
abusers, drawn from different admissions populations, were compared at
followup. Success rates by time-in-program for both cohorts were
virtually indistinguishable, ranging from zero percent for those who
remained under one month to approximately 50 percent among dropouts
beyond a year in treatment (De Leon et al. 1982).
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FIGURE I
Success & Improvement Rates
Comparisons between the 1970-71 and 1974 cohorts through 2 years of
followup for male opioid abusers. Success (group 4) and improvement
rates by time-in-program (TIP) are shown by the 1974 TIP
classifications. There are no significant cohort differences at any
point on the curve, revealing a striking replication of the time-in-
program function.
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These social adjustment findings have been obtained in large-scale
multimodality efforts that included therapeutic communities. For
example, in the Drug Abuse Reporting Program (DARP) samples of
therapeutic community dropouts and completed clients, the direction
and magnitude of results obtained on outcome variables and composite
indices vary little from those obtained in the program-based eval-
uations. Moreover, the DARP studies also substantiated the significant
relationship between time-in-program and outcome (Simpson and Sells
1982). In general, other multimodality evaluations report similar
findings for the traditional TCs studied (Bale et al. 1980; Sheffet et
al. 1980), although one investigation didn’t obtain length-of-stay
differences (Burt et al. 1979).
Psychological Adjustment
Although a primary goal of therapeutic communities is psychological
adjustment, this domain appears in few outcome studies (Brook and
Whitehead 1980; De Leon 1984; De Leon and Jainchill 1981; Kennard
and Wilson 1979). In these, psychological scores or profiles
significantly improved at followup-a finding obtained in all of the
investigations reviewed, including those outside of the U.S.A. The
Phoenix House studies have demonstrated a direct correlation between
social adjustment (success rate) and psychological adjustment at two-
year followup (De Leon 1984; De Leon and Jainchill 1981).
Factors Associated with Successful Outcome
Does success or improvement relate to treatment or to client factors?
This question still requires research answers. Added to these factors
are the apparent influences of maturation and intercurrent life events
upon long-term, posttreatment status.
Only a few studies, program-based or otherwise, have systematically
examined factors that are associated with successful outcome.
Primarily, these studies have focused upon predicting outcome status
from client and background characteristics, pretreatment variables, and
treatments after discharge from TCs (De Leon 1984; Holland 1978;
Simpson and Sells 1982).
Significant correlations have been obtained between demography,
primary drug, and successful outcome; although these findings were not
stable and tended to vary across studies. For example, in the Phoenix
research, females and opioid abusers showed higher success rates, and
females revealed significantly better psychological adjustment than did
males at followup (De Leon and Jainchill 1981). Although the dif-
ference in psychological outcome by sex was impressive, it remains to
be replicated in other programs.
Regression studies have identified several predictors of the separate
outcome measures, e.g., lifetime criminality, pretreatment educational
level, opioid drug use, and reentry into treatment within the first post-
discharge year (De Leon 1983a; Simpson and Sells 1982). Though
significant, these associations were small when compared with the
effects of time in program. Moreover, they failed to predict
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successful status when measured with the composite index (De Leon
1983b).
Finally, program-based studies have assessed nontreatment hypotheses in
explaining positive outcome. In these, behavioral cycle, statistical
regression, social climate factors, maturation, and other influences have
been rejected as valid alternatives to treatment effectiveness (De Leon
et al. 1982; De Leon 1984; Holland 1984).
In summary, the findings from the program-based followup research
provide convincing evidence for the effectiveness of the TC approach
for drug abuse. Significant improvements occurred on the separate
outcome measures of social adjustment (drug use, criminality, and
employment), and on composite indices for measuring individual status.
With few exceptions, followup studies reported a positive relationship
between time-in-program and posttreatment outcome status. Generally,
these findings were obtained in larger scale, externally based followup
studies that included therapeutic communities.
In the few program-based studies that investigated psychological
outcome, results uniformly showed significant improvement at followup.
Recent Phoenix House studies have demonstrated a direct relationship
between success status and psychological adjustment at followup.
Univariate and multivariate investigations revealed relatively few
significant predictors of successful outcome other than length of stay
in treatment. Finally, several program-based studies have advanced
persuasive arguments and data that reject various nontreatment
hypotheses offered as alternatives to treatment effectiveness.
RETENTION
The most consistent predictor of successful outcome has been length of
stay in treatment. This finding stresses the importance of under-
standing retention as a phenomenon in its own right. Notwithstanding
the importance of this issue, research has not systematically
investigated the three main retention questions: What are the re-
tention rates? Who are the dropouts? And, why do they leave treat-
ment?
Reviews of retention studies have been published (Baekland and
Lundwall 1975; Brook and Whitehead 1980; Cole et al. 1981). The
main findings and conclusions from the few program-based investi-
gations on retention can be summarized briefly.
Correlates of Retention
Most of the dropout studies, program-based or otherwise, have focused
upon client characteristics and selected pretreatment variables that
correlate with retention. In these studies, typical client profiles in
relation to retention have not been delineated. While some variables
have consistently correlated with length of stay, their predictive power
has not been corroborated in replicational study designs.
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The variables studied in relation to retention may be grouped into
several categories which assess demography, client background
characteristics, or client status prior to entry into treatment: (1)
Demography and primary drug: these variables have not consistently
related to retention, although Hispanics and non-opioid abusers have
revealed significantly shorter length of stay (De Leon 1983a); (2)
Previous treatment history: the number and type of previous treatment
experiences have not related to retention in TCs, although a few
studies report somewhat longer retention in those with more previous
treatment admissions. Specifically, among readmissions to the same
programs, the number of days before initial dropout has been found to
be a significant predictor of long-term retention in subsequent
admissions (De Leon 1983b; De Leon and Schwartz 1984); (3)
Background (lifetime characteristics): family background, criminal
history and social relations generally have not related to retention in
treatment, although those with longer and more severe lifetime criminal
histories reveal shorter durations of stay in therapeutic communities
(De Leon 1983a); (4) Current status (pretreatment): variables
describing the client’s status in the days or months prior to entry into
treatment generally do not relate to retention. However, younger
clients with legal pressure, admissions with prior attempts at ceasing
drug use, clients who are less defensive about their problems, or those
who desire to change their deviancy remain somewhat longer in TCs
(De Leon 1983a; Holland 1982); and (5) Psychological adjustment:
several investigations indicate that early dropouts reveal higher levels
of psychological dysfunction measured with standard paper and pencil
instruments (Sacks and Levy 1979; Wexler and De Leon 1977).
Although significant, the magnitude of the correlations between
psychological scores at admission and length of stay is moderate, indi-
cating their relatively low predictive power. One impressive finding,
however, obtained in a recent investigation involving a consortium of
therapeutic communities, revealed a striking relationship between
psychological change during treatment and overall retention. Indi-
viduals who improved psychologically within the first several months
after admission showed a significantly greater likelihood of continuing
their stay in treatment (De Leon 1980). This finding has obvious impli-
cations for clarifying the relationship between client progress and re-
tention.
Retention Rates
Retention rates in therapeutic communities have received some
attention in the program-based literature (Brook and Whitehead 1980;
De Leon and Schwartz 1984; Glaser 1974; Sansone 1980). Generally,
these studies agree in revealing a rather high dropout rate in
therapeutic communities, although interpretation of these rate studies
is clouded by the method of analyzing and reporting retention data.
For example, a summary statistic is usually provided of either the
percentage of those who failed to complete treatment or 12 month
retention rates. These single values ignore differences in residential
programs such as planned treatment duration. The units of analysis
vary (days, weeks, months, quarters) as do the methods of calculating
rates (i.e., based upon all admissions, dropouts, surviving admissions).
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Moreover, the temporal pattern, or critical points of dropout, have not
been well described.
Several of these difficulties have been overcome in a recently
completed, program-based, research project in which retention rates
and the temporal pattern of dropout were compared among drug-free
residential programs in several data sets (De Leon and Schwartz 1984).
The main results show: (a) across seven traditional therapeutic
community programs, the 12-month retention rate ranged from 9% to
15%; and (b) based upon rates adjusted for those who left treatment
(“survivor rates”), estimates indicated that the likelihood of continued
retention increased significantly with longer stay in treatment. Figure
2 shows, for example, that almost 70 percent of clients remaining in
treatment 180 days continue through 9 months’ residency.
Analysis of other data sets revealed that attrition is the rule in all
drug treatment modalities. For example, among 1979 admissions to all
federally funded treatment programs in the CODAP system, 12-month
75
retention rates averaged 22% in methadone maintenance, 9% in drug-
free ambulatory programs, and 7% in drug-free residential programs (De
Leon and Schwartz 1984). Yearly analyses have reliably documented a
decline in annual retention rates across all modalities from 1964
through 1980 (Bayer and Koenigsberg 1981; Simpson and Joe 1976).
Some recent evidence, however, suggests a reversal of this trend in a
number of traditional TCs.
Finally, the temporal pattern of dropout is remarkably stable. Figure
3, for example, presents retention curves for the residential drug-free
modality in several data systems. Though not shown, this pattern of
dropout is the same for nonresidential settings, methadone, and
outpatient drug-free programs. While the absolute levels of dropout
may vary (higher retention for methadone maintenance), the shape of
the retention curve is the same as that depicted in Figure 3.
FIGURE 3
Retention in Several Data Systems (DARP admissions, 1969-71; TCA,
1979; CODAP, 1979; Phoenix House, 1979)
Reasons for Dropout
Why clients drop out of treatment is a question that has not been
investigated adequately, although several research teams are currently
exploring this aspect of retention (De Leon 1983a). Hypotheses con-
cerning client reasons for dropout have been offered mainly from
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clinical impressions, with some preliminary research, and remain to be
empirically tested (Baekland and Lundwall 1975; De Leon 1980; De
Leon and Rosenthal 1979; Heit and Pompi 1977; Sansone 1980).
In summary, program-based research on retention reveals only sporadic
and weak correlates of dropout with demographic factors, primary drug,
background characteristics, pretreatment status, and psychological ad-
justment. No client profile has emerged that predicts length of stay in
treatment. This conclusion is confirmed in multimodality investi-
gations of client predictors of dropouts (Burt et al. 1979; Sheffet et
al. 1980; Simpson and Joe 1976). For example, the DARP studies con-
clude that patient characteristics are not strong predictors of retention
in any treatment modality (Joe 1976).
Research on some quantitative aspects of retention, however, has
yielded lawful and predictable patterns of retention in long-term
therapeutic communities. Dropout is highest within the first 15 days
of admission and declines sharply thereafter in such a way that the
likelihood of dropout decreases with length of stay itself. Although
overall retention rates differ across programs and modalities, the shape
of their retention remains uniform. Thus, attrition is the rule in drug
treatments, substantiating the observation that retention is a lawful
phenomenon. Finally, little is known of the client’s reasons for leaving
or remaining in treatment.
TREATMENT PROCESS
Treatment process has been the least investigated problem in drug
abuse treatment research. Ironically, the first process studies in TCs
appeared more than a decade ago, but their importance receded in
favor of the need to establish firm information concerning treatment
effectiveness and cost effectiveness.
To facilitate review, the relatively few process related studies in the
literature were classified into three categories: studies of treatment
change, direct investigations of treatment process elements, and client
attribution of treatment influences. A departure from the previous
sections is that published studies in the last 12 years were included
along with data from several unpublished efforts.
Treatment  Change
These studies examined psychological measures of client change during
their stay in programs without assessment of treatment components.
They are reviewed as process studies since many of the psychological
scores measured change as reflecting program goals, e.g., attitudes, ego
strength, emotional control, responsibility, self-esteem, etc. Together
with behavioral changes in drug use and antisocial behavior,
psychological change during residency strengthens inferences concerning
the specific influences of treatment elements.
The program-based studies employed standardized psychological
inventories such as the Minnesota Multiphasic Personality Inventory
(MMPI), the Tennessee Self Concept (TSC), as well as specific scales
assessing I.Q., moods, or psychological symptoms. The studies vary
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with respect to design, number of variables measured, and the number
of observations during the treatment (Brook and Whitehead 1980; De
Leon 1974, 1976, 1980, 1984; De Leon et al. 1971, 1973, 1984; Kennard
and Wilson 1979; Sacks and Levy 1979; Zuckerman et al. 1975).
The results are quite uniform in showing significant improvement on
most psychological scales during treatment. Most apparent is the fact
that the entry profile or pattern of psychological scores is also similar
across programs and even cultures. For example, the signs of
character disorder, personality inadequacy, mood disorder, poor self-
esteem and dull-normal intellectual level are prominent. At second
testing, overall psychological status improves significantly across most
measures but generally does not attain normative or healthy levels.
Larger improvements occur in self-esteem, ego strength, socialization,
and depression. Relatively small changes occur in the more enduring
personality features, e.g., the character disorder elements. Thus, drug
abusers in the TC show significant improvement in most psychological
domains, although long-standing character traits are more resistant to
change.
Several studies contained multiple measurement points of psychological
change during treatment and at followup (Brook and Whitehead 1980;
De Leon 1984). The results are fairly uniform in showing that
psychological improvement posttreatment generally exceeded the gains
made during treatment, although one study obtained no further gains at
four year followup beyond those obtained in the first posttreatment
year (Brook and Whitehead 1980).
The studies completed at Phoenix House further correlated social
adjustment (success status) with psychological improvement during
treatment and at followup. Clients with an unfavorable success index
at followup showed little psychological change during treatment or at
followup. In contrast, clients who obtained a favorable success index
revealed significant psychological improvement during treatment and
continued psychological gains at followup. This important finding
offered indirect, but positive, evidence for the influence of treatment
factors in the change process (De Leon 1984).
Studies of Process Elements
These studies addressed the relationship between specific treatment
elements and client change during residential treatment. Two early
studies at Phoenix House evaluated the immediate effects of the
encounter group experience upon emotional and physiological changes in
group participants. When compared with baseline measures, results
showed significant reductions in self-rated emotionality (depression,
hostility, anxiety) and in physiological “upset” (systolic blood pressure)
immediately following participation in encounter therapy sessions (Biase
and De Leon 1969; De Leon and Biase 19751.
Research in progress at Daytop Village therapeutic community has
experimentally evaluated the effects of a specific educational
intervention (college credit courses) upon clients in a therapeutic
community during the primary treatment stage of their residency.
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Eligible clients were matched on a number of variables and were
randomly assigned to one group, those who received college courses in
addition to their usual treatment, or to a second group, those who only
received the usual TC treatment. Significant longitudinal changes in
self-concept occurred for both groups, but gains were larger in the
college clients. These findings support the TC assumptions concerning
process and role changes. The student role significantly enhanced self-
esteem over that expected from treatment effects alone in the TC
(Biase 1981).
The design of the above studies evaluated clients under various
controlled or comparative conditions (e.g., no college, discussion groups,
work activities). This design strengthens conclusions concerning the
effects of the specific treatment interventions (e.g., encounter group
or college). Thus, though limited, these investigations affirm the
feasibility of studying treatment process with acceptable methodology.
Treatment process has also been examined in several program-based
studies which measured client and staff perception of the therapeutic
community environmental elements, using an instrument based upon
empirically derived dimensions which assess aspects of social and health
environments such as prisons, hospitals, and community oriented
programs. The respondents completed two forms of the instrument,
expressing their opinions concerning the actual state of the
environment and the way the respondent would like to see the
environment if it were the best possible treatment program.
Despite the preliminary investigative status of this area, the research
has provided a considerable amount of information from several pro-
grams, with apparent consistent results. First, all TC programs in the
research revealed environmental profiles that were similar and positive
compared with profiles obtained from prisons and hospitals. Thus, the
assumption that common philosophy and practices underlie the
traditional TCs, which generate a unique treatment environment, is not
contradicted by the staff’s and residents’ perceptual data provided in
the studies. Second, client perceptions of the environment were in
accord with expectations concerning the treatment process associated
with length of stay (De Leon et al. 1980).
Attribution
These studies have investigated client perceptions of their experiences
in TCs (Browne 1980; Simpson and Lloyd 1979; Wexler and De Leon
1983; Winick 1980). Generally, on measures of satisfaction, clients
reported a favorable experience in the therapeutic community and
would recommend their particular residential program to others. Other
analyses have yielded findings clarifying the specific relationship
between program components and client status during and after
treatment. One study of in-treatment change obtained a positive
association between time-in-program, client insight, and participation in
encounter groups (Browne 1980).
A large scale, program-based study assessed the relationship between
clients’ status at followup and their retrospective perceptions of the
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treatment experience (Wexler and De Leon 1983). Successful status
and length of stay in treatment were directly related to client ratings
of their satisfaction with treatment, the relevance of specific program
components to their status, and their weighting of the relative
importance of treatment and nontreatment influences upon their
lifestyles since leaving Phoenix House. Although clear, these findings
must be interpreted cautiously, given their retrospective nature.
Possible halo effects, or dissonance factors, might have influenced
client perception of treatment experience and their own followup
status. Nevertheless, the results firmly support hypotheses concerning
the relationships between treatment experience, treatment elements,
and outcome status.
In summary, there is relatively little published research on the
treatment process in therapeutic communities. The small program-based
literature has, for the most part, indirectly examined process through
longitudinal studies of treatment change, and clients’ retrospective
perceptions of their treatment experience. Only a handful of studies
directly investigated the relationship between program components and
client change.
In general, the findings from all these studies support inferences
concerning the process of client change, although the process itself
remains to be studied directly. This conclusion is not contradicted by
the findings of the few multimodality studies which contain measures
of clients’ perceptions of the treatment experience.
SOME IMPLICATIONS FOR FUTURE RESEARCH
The treatment research reviewed, both program and externally based,
appears to have converged upon several conclusions, issues of
interpretation, and implications for future research directions. These
are discussed in relation to the three main areas of inquiry reviewed.
Treatment Outcome
A substantial followup literature indicates that drug treatments are
effective when evaluated in terms of their principal aims. Program-
based followup studies, for example, have firmly established the
effectiveness of the TC approach in terms of its principal aim of
modifying both social and psychological adjustment.
Nevertheless, conclusions concerning treatment effectiveness remain
tentative in light of familiar methodological considerations, the most
serious of which is the lack of control groups. The followup samples
studied may be self-selected to seek, remain in and benefit from the
TC; or, perhaps, to improve without any treatment. Thus far,
however, solutions to these selection problems have eluded research
design strategies. Assembling untreated matched controls or
comparative treatment groups through random assignment has not been
feasible. There are ethical problems in withholding treatment; and
random assignment to modalities has resulted in high and differential
attrition rates, presumably arising from client-treatment mismatch. (As
80
noted below, however, random assignment within treatment programs
can be implemented).
These difficulties stress the need for a revised perspective on the
interpretation of treatment outcome research that would reflect the
multivariate complexity of individual change. One such perspective has
been outlined for therapeutic communities in other writings (De Leon
et al. 1982). Briefly, successful outcome emerges from an interaction
of client, treatment, and nontreatment influences. The specific impact
of the treatment experience is most apparent during and immediately
following residency; thereafter, though less recognizable, treatment
effects may integrate with (or perhaps alter) the contribution of other
experiences in maintaining successful status.
This perspective emphasizes several assumptions that are relevant for
the design of outcome studies. First, drug abusers can be classified
according to differences actually observed in relation to their
treatment involvement. This suggests that the universe of drug abusers
can be quadrisected by definition: Those who come to treatment and
those who do not, and within each, those who make positive changes
and those who do not.
The differential outcomes among the four groups reflect each group’s
unique membership. For example, those untreated drug abusers who
mature out of their addiction lifestyle are simply different people from
those who enter treatment and change. This assumption avoids the
dead end criticism of the no-treatment control since the four groups
do not serve as controls for each other, although they can be usefully
compared.
Second, among those who enter treatment, change reflects an
interaction between the individual and the treatment. This implies a
mutual, bidirectional exchange between the person and the treatment
environment. Thus, treatment influences, as unique measurable events,
are not readily extractable. Furthermore, the treatment experience
itself is an episode, one of many experiences in the individual’s
continually changing status. Thus, “proving” a treatment influence is
less relevant than identifying its contribution to a continuing process
of individual change.
From this perspective, treatment effectiveness should be assessed for
those clients who seek, or perhaps remain in, treatment settings.
Comparisons among the clients in the other quadrants, however, could
reveal much about individual differences and the many influences that
contribute to the change process.
Finally, the primary source of information about this process is the
client’s own view of the relevant influences. External corroboration of
client change through records or other evidence validates the fact of
change, but does not reveal the reason for change. In the last
analysis, it is the client who evaluates the relevant influences in his
or her life.
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Retention
Dropout is the rule across all drug treatment modalities. The program-
based retention findings reviewed contain several implications for
directing research on this problem. First, although factors have been
shown to correlate with retention, the consistency and magnitude of
their predictive power has been relatively low. This finding was sub-
stantiated in the externally based studies of the number of programs,
modalities, or variables surveyed.
The fact that retention is difficult to predict from client char-
acteristics suggests that the populations studied (drug abusers seeking
treatment) are, not unexpectedly, more similar than different. Hence,
measures of their characteristics tend to show relatively low vari-
ability, evident in the generally small to moderate multiple correlations
obtained in regression analyses predicting time in program.
Nevertheless, even those who seek treatment could be diverse in ways
that have not yet been fully explored. These presumed differences
reflect not who clients are, in terms of fixed background character-
istics, but how they perceive themselves, their circumstances, and their
life options at the time of treatment contact.
Assessment of these differences could focus upon at least four domains
of client perception variables which alone, or in combination. affect
dropout:
(1) Motivation (intrinsic pressures): This refers to the severity of the
problem and the need for personal change;
(2) Circumstances (extrinsic pressures): These refer to influences from
family, personal relationships, health and legal conditions, employment,
educational, and fiscal matters;
(3) Readiness: This refers to the perceived need for any treatment to
assist in personal change, compared with alternative options such as
self-change or other offerings; and
(4) Suitability: This refers to the client’s understanding and
acceptance of particular treatment approaches.
The specific variables within each domain remain to be elaborated, and
their relevance to the orderly retention curve must be investigated
empirically.
Second, the pattern of retention is lawful and quantitatively
predictable, but the phenomenon itself remains to be explained. Not
unlike the perspective on outcome, however, retention can be viewed
as a complex interaction of client diversity and treatment influences.
Shifts in the relative contribution of each component may be reflected
in the different segments of the retention curve. Within this
interactional context, however, a constant proportion of dropout is
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expected when homogeneous procedures (e.g., treatment) are imposed
upon a diversity of clients.
Nevertheless, the stable temporal characteristics of retention can be
utilized by researchers and program managers in several ways. For
example, these permit analyses of factors that may alter expected
dropout rates. The critical points of termination are particularly
relevant for treatment planning and for enhancing retention. Finally,
the relatively invariant temporal pattern provides a reliable dependent
variable in evaluating efforts to reduce dropout.
Treatment Process and Program-Based Research
The importance of treatment process studies is evident to most
investigators. To a large extent, the conclusions concerning treatment
retention and effectiveness highlight the need to clarify the treatment
process. Although impressive, the relationship between length of stay
and treatment outcome only indirectly implies the influence of
treatment elements upon client status. Process studies can render
explicit the correlation between actual events in treatment and change
in client status. It is this interplay between treatment elements and
client change which defines process.
The study of drug treatment can best be advanced by a comple-
mentarity between externally- and program-based research efforts.
Much has been learned from program-based research as to the
implementation of studies in treatment settings (see, for example, De
Leon 1979, 1980). An important lesson from these efforts is that
treatment process is perhaps the one investigative area that is uniquely
suitable for program-based or affiliated research teams. This is
evident in the following points.
First, as noted earlier, some of the treatment process studies of
therapeutic communities employed rather rigorous research designs
involving control conditions or random assignment procedures. The
implementation of these designs is possible only in treatment settings
that involve the complete cooperation of staff and clients. The
likelihood of obtaining this cooperation of staff and clients is greater
with program-based research personnel.
Second, the successful completion of process studies will vary directly
with the degree to which programs view their utility. Clinical and
management personnel appreciate outcome studies since these are
relevant to issues of funding, program marketability, and staff morale.
Moreover, these studies exert relatively little demand on program
activities. Treatment process research, however, imposes heavy strains
upon program activities, and it is understandably resisted by staff
unless they can see its benefits. Thus, acceptance and utilization of
treatment process research is more likely to be facilitated by program-
based research teams who serve in educative roles.
More generally, treatment process studies should be designed to solve
problems rather than test theories. Human services programs
experience practical, everyday problems concerning staff turnover and
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training, client dropout, and inconsistent treatment outcomes. Thus,
treatment process studies present the strongest challenge to
researchers, program-based or otherwise, to provide relevant answers
for pressing clinical and administrative questions.
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Clinical Trials in Drug Treatment:
Methodology
Sharon M. Hall, Ph.D.
The most common form of clinical trial is the between-group
comparison study. Subjects are randomly assigned to one or more
innovative treatment conditions or to a control condition. Variants of
between-group designs are the most powerful tools available for
determining the effects of treatment. An optimally designed, between-
group, clinical trial can control for time in treatment, therapist
attention and qualifications, client and therapist expectations, and
client characteristics. Multiple examples of this design are in the drug
treatment literature (for example, Hall et al. 1981a, 1981b; Stanton et
al. 1980).
The within-subject design is less common. Here, different treatment
conditions are sequentially presented to the same subject or to a small
group of subjects. Comparisons are then made across different
treatment conditions for the same subject(s). The best example of the
within-subject design in drug treatment is the systematic work of
Stitzer and her colleagues on contingency contracting (Stitzer et al.
1980).
No matter which design is used, two groups of factors are important in
evaluating a controlled trial: Experimental design and treatment
design.
EXPERIMENTAL  DESIGN
Experimental design includes factors which are central in determining
the internal validity of the study. Internal validity refers to the
degree to which the results of a study can be interpreted unambig-
uously (Campbell and Stanley 1963).
Design survival is a necessary, but not sufficient, criterion for a
controlled trial’s usefulness. This term refers to whether the
treatment design survived the study so that the outcome can be
interpreted as an experiment. A second factor is outcome
measurement. Since drug abuse affects many aspects of a client’s life,
multifocal measures are usually preferable to single-focus measures.
As in any research endeavor, measures should be reliable and valid.
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The issue in evaluating sample size is usually whether the experiment
includes enough subjects to detect significant differences in the
population. Occasionally, however, the rationale for unusually large
sample sizes is not clear. Attrition is related to sample size; high
attrition rates can reduce an originally acceptable sample size to a
final sample that is too small to detect differences. It can also result
in inadvertently testing only the most highly motivated subjects.
Differential attrition can produce treatment conditions which become
confounded on crucial variables. Finally, in the ideal experimental
design, nonspecific factors can be ruled out, and any outcomes can be
attributed to the specific aspects of the treatment. That is,
differences between conditions cannot be attributed simply to different
amounts of time in treatment, or different amounts of attention from
therapists. Similarly, treatments can be presented so that client
expectations of success differ. This can occur independently of actual
treatment efficacy. Expectations of success and actual success are
probably related; thus, in the ideal designs, subjects in all conditions
enter treatment with identical expectations of success.
TREATMENT DESIGN
Treatment design refers to the adequacy of the experiment as a test
of a particular treatment; that is, whether the findings can be
generalized and applied to actual clinical practice.
Credibility and representativeness of change agents are part of
treatment design. For example, a psychiatrist and a drug counselor
are perceived differently as health providers. While it is difficult to
say which class of provider is most effective (LoScuito et al. 1979),
clear cut differences between them may well confound provider
differences with treatment differences. Also, atypical change agents
may produce non-replicable findings, and subject representativeness
must be a factor when considering the treatment population for which
results can be generalized. This is particularly crucial in drug
treatment, since client characteristics vary widely across and within
modalities. Both the number and representativeness of different
settings must also be considered in generalizing results. Studies
replicated in multiple facilities are less likely to be confounded by
characteristics unique to a single facility than studies completed in one
facility.
Some followup is usually necessary for results to be clinically useful.
The standard length for followups is 6-12 months, since relapse usually
happens immediately after treatment termination (Hunt et al. 1971).
Protocol adherence is another aspect of treatment design; treatments
can change subtly as therapists gain experience or lose enthusiasm.
Therefore, studies which use a treatment manual or some other method
of formally standardizing treatment are more likely to produce
treatments which are consistent over time. Thus, what is being
evaluated is clearer.
Factors in this review were addressed only if they affected the
interpretation of the study.
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STRATEGY AND CLINICAL TRIALS
The value of a clinical trial rests not only on its individual
characteristics, but also on the research strategy in which it is
embedded. Three strategies have been used in evaluating drug
treatments: single trials; multiple-site, partial replications; and series
of partial replications.
Single Trials
Most controlled studies are single trials completed in isolation from
other research. An example is the large-scale, family therapy trial
completed by Stanton et al. (1980). The advantages of single trials
center around the great degree of possible control; because single
trials are executed by a single investigator or investigative team on
one subject sample, confounding variables can be tightly controlled or
eliminated. Also, the protocol can be explicitly developed. On the
other hand, single trials have no built-in replication mechanism, as do
the other research strategies. Single trials do not provide estimates of
the parameters of conditions under which a particular treatment is
effective. Further, they do not allow convergent validation; that is,
they do not indicate whether conceptually similar therapies applied in
slightly different ways produce a given result. Single trials are
potentially the most dangerous in terms of risk/benefit ratios; there is
always the risk that, despite considerable effort, a controlled trial will
collapse and fail to yield useful information.
Multiple Site, Partial Replications
In partial replications at different sites, studies are completed at more
than one site by different investigative teams. This category does not
include studies completed at different treatment facilities by the same
team, where the goal is to use exactly the same procedures at each
facility. In that case, treatment facility is simply an independent
variable in a single trial. For partial replications at multiple sites,
independent and dependent variables may be drawn from the same
universe but need not be used in exactly the same fashion. This
strategy gives a broad picture of the efficacy of a particular
intervention and is especially informative if general outcomes are
replicated, since the strategy provides information about the conditions
under which treatments are useful, as well as the convergent validity
of a particular treatment. Also, differences in outcome between sites
help develop preliminary hypotheses. The risk of not having useful
information is lower, since failure at one site does not prevent useful
information being obtained from another site.
The multiple-site study is logistically more difficult to control. Also,
if outcomes at different sites are the same, the case for validity is
established. If they vary, however, the source of differences is hard
to detect, although hypotheses may be generated.
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Series of Partial Replications
The final strategy in this type of drug treatment research uses a
series of partial replications. The replicates are partial because some
aspects of the procedure vary, but the general questions asked and
major aspects of the procedures overlap. This strategy usually involves
a series of studies completed at the same site. Examples in drug
treatment include the series of three Job Seekers’ Workshop studies
(Hall et al. 1977; Hall et al. 1981a, 1981b), and the series of
contingency management studies completed by Maxine Stitzer and her
associates at Baltimore City Hospital (Stitzer et al. 1977; Stitzer and
Bigelow 1978; Stitzer et al. 1979a, 1979b, 1980). When properly
designed, such studies have all the advantages of a single trial. They
may also allow a more precise definition of the range of factors that
determine effectiveness. These studies are less risky than the single,
large-scale trial, because, even if one study is defective, others in the
series may yield useful information. Series of partial replications are
generally completed over a considerable time period. Thus, failures to
replicate can be the result of weak and variable effects, or the result
of changes that occur because of the passage of time. An example of
the latter is changes in characteristics of clients attracted to a
particular treatment.
For this review, controlled trials are broken down into three classes:
1) major drug treatment modalities; 2) psychotherapeutic interventions,
including contingency contracting, relaxation training, and biofeedback;
and 3) vocational rehabilitation interventions. Because of the scope of
the literature, studies were eliminated which, even if they had been
executed perfectly, would not have yielded clinically useful
information. These generally had one or more of the following
characteristics: 1) They did not include followups (under conditions
when followups were necessary for results to be clinically meaningful);
2) They had a sample size too small to allow any conclusions; or 3)
They were so incompletely reported that they could not be evaluated.
Also, one or two well-controlled studies (for example, Havassy and Hall
1981) were omitted, primarily because they addressed areas without
sufficient research to draw any useful conclusions.
COMPARISONS OF MAJOR DRUG TREATMENT MODALITIES
An early, ambitious comparison of methadone maintenance and
therapeutic communities was reported recently by Bale et al. (1980).
Five hundred and eighty-five male veterans were randomly assigned
either to methadone maintenance or to one of three therapeutic
communities. Subjects were interviewed, at 6, 12, and 24 weeks
following treatment assignment. A cross check of interview and urine
data indicated fairly good validity. Data was collected on drug use,
criminal behavior, and work and school attendance. However, only 108
of the subjects accepted the random assignment, and spent as long as
1 week in their assigned program. Most subjects dropped out early in
treatment, especially in the therapeutic community condition.
Because of this high dropout rate, and despite an exemplary followup
rate and sophisticated data analyses, the outcome was virtually
uninterpretable.
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The only other comparison of major treatment modalities which was not
solely a drug trial was the Heroin Antagonist and Learning Therapy
(HALT) project, which began as a trial of behavior therapy, naltrexone,
and naltrexone and behavior therapy combined. This study had a
unique recruiting procedure: Subjects had to “earn” their way into
treatment by completing phone calls to the treatment facility, avoiding
drug use, and performing other prosocial behaviors. The most recent
report (Callahan et al. 1980) presented only data from the naltrexone
condition and the combined condition. Of the 104 potential male
subjects in this condition, 40% earned their way into the naltrexone
therapy condition, and 34% into the combined condition. Dependent
variables were days on naltrexone, time in program, illicit drug taking,
and reported side effects. These variables were assessed during three
7-month periods. The combined group showed more days on naltrexone,
greater time in treatment, and reported fewer side effects during the
initial assessment period. However, these differences disappeared
during the second and third assessment periods.
An earlier report (Rawson et al. 1979) revealed the fate of the
behavioral treatment condition. Of the 71 subjects assigned to this
condition, only 15 (21%) completed the requirements necessary for
entering treatment. Even the behavioral subjects who entered
treatment had worse outcomes, including treatment completion,
completion of therapeutic assignments, and illicit drug use than did the
other groups.
Perhaps the behavioral treatment was so unattractive that only the
most highly motivated clients persisted if they were assigned to that
condition and the behavioral condition greatly worsened their outcome.
Or perhaps only the least functional clients persisted and the
behavioral treatment was potentially as effective, but the subjects
enrolled in it were so impaired that the treatment could not bring
them to the level of the rest of the sample. The latter possibility is
less likely. However, as these considerations illustrate, the cause of
any differences between conditions cannot be attributed to treatments
since subjects may have differed prior to treatment entry.
Summary: Comparison of Major Drug Treatment Modalities
These early studies were basic, and I believe sophistication in design
has increased greatly since their execution. Still, we can learn at
least three lessons from them. First, drug treatment clients will not
accept assignments to widely varying treatments, especially if they
have a stake in one treatment or another.
Second, designs in which treatment entry differs between conditions
are risky and will probably confound variables obtained later in the
study. Both entrance and exit from treatment are clinically interesting
variables, but they should not be studied through random assignment;
any differences between conditions will compromise the interpretation
of the remaining outcome data.
Finally, different drug modalities may attract different client groups.
Therefore, comparisons between modalities are probably not possible
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since no two modalities approach equal attractiveness for any one
subject pool.
EVALUATIONS OF PSYCHOTHERAPIES
Psychotherapy
Perhaps the best controlled, single study of a psychotherapeutic
intervention was the family therapy study completed by Stanton and his
associates (1980). To be eligible for this Veterans Administration (VA)
study, male applicants for methadone maintenance had to meet a
restrictive set of criteria, including regular contact with parents or
surrogates, and both parents living together in the same household.
Over 25% of the clients screened met these criteria. Eligible subjects
were assigned to family treatment if an opening existed. Otherwise,
they were assigned to a standard treatment control. Family treatment
subjects were randomly assigned to either paid family therapy, unpaid
family therapy, or a paid family movie therapy condition. In the latter
condition, families were paid for attendance at movies and for drug-
free urines produced by the subjects. This condition controlled for
time in treatment and for payment. Interview data obtained for two 6-
month blocks following family treatment indicated different patterns of
outcome. In the initial 6 months, both paid and unpaid family
conditions had more drug-free days than the movie group or the
nonfamily group. Differences were stronger for the paid than for the
unpaid group; no differences in alcohol use or in days spent working in
school were found. In the second 6 months, differences between the
conditions were less.
This study was characterized by moderate rates for both pretreatment
drop out (30%) and refusal to participate among family therapy
assignees (21%). Analyses of the data did not indicate that the
legitimacy of the comparisons was compromised by pre-existing
differences between treatment conditions. Also, the nonrandom
assignment probably introduced some unknown bias. However, if this
bias existed, it was not evident. Attrition at followup was moderate
and was not differentially distributed across treatments (11% at 6
months; 17% at 1 year).
This study is strong. The design, subject sample, length of followup,
and verifiability of drug measures all provide reasonable conclusions
about treatment efficacy. The paid family movie condition is an
interesting innovation. However, it does not appear equal in credibility
or expectations of success to the family treatment conditions. Also,
since the treatment was conducted by a drug counselor, therapist
status and expectations about change may have helped determine
outcome. Thus, while the paid family movie condition controls for
amount of contact and for use of contingencies without other
therapeutic intervention, therapist variables are confounded with
treatment variables. Also, the effects of differences in therapeutic
attention and client expectations are unknown. Finally, this study
should be replicated with women, for whom family dynamics may be
quite different.
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Apparently, the only studies in this category using multiple-site, partial
replication in drug treatment were the psychotherapy studies in New
Haven and Philadelphia. The impetus for these studies grew out of a
series of conferences sponsored by The National Institute on Drug
Abuse (NIDA) which considered the issue of psychotherapy-particularly
psychoanalytic therapy-in drug treatment (Woody 1977).
The Philadelphia study indicated that psychotherapy might help addicts
(Woody et al. 1983). On entrance into treatment, male methadone VA
clients were randomly assigned to one of three conditions: 1) sup-
portive expressive therapy, a psychodynamic therapy; 2) cognitive
behavioral therapy; or 3) drug counseling. In the first two conditions,
subjects received psychotherapy from a paraprofessional counselor in
addition to drug counseling. In the third condition, only drug
counseling was provided. AU conditions were conducted according to
detailed treatment manuals. Subjects could continue treatment with
their therapists for up to 6 months. Clients were assessed on a
battery of psychological tests, including the Addiction Severity Index
(ASI) (McLellan et al. 19801, a multi-scale index which taps medical,
legal, drug and alcohol abuse, employment, family and psychiatric
problem severity; on the Schedule for Affective Disorders and
Schizophrenia-Lifetime and -Change versions (SADS-L and SADS-C); and
on urine test results, methadone dose, and licit prescription drug use.
According to study criteria, 60% of the clients were eligible for
treatment. About 60% of these clients entered treatment and
completed three sessions. From the beginning of the study to the
7-month followup, subjects who received psychotherapy in addition to
drug counseling made more and larger gains than those who received
counseling alone. They also were maintained on lower doses of
methadone and ancillary medications, without increases in illicit drug
use.
This study is sound. The experimental manipulations were successfully
completed. The study provides data which indicate that the addition
of psychotherapy to drug counseling may be valuable, especially for
patients in some diagnostic classes (Woody, personal communication,
May 1983).
The primary criticism of this study is that the treatment conditions
differ on time in treatment. The investigators acknowledge this, and
note that their aim was to study efficacy of adding psychotherapy to
drug counseling, not replacing drug counseling with psychotherapy.
Another factor is the possibility (unmeasured) that the conditions
differed in treatment expectations, especially since the therapists
differed in status.
The companion study in New Haven did not find a treatment effect
(Rounsaville et al. 1983). This study evaluated short-term,
interpersonal psychotherapy-a brief psychodynamic therapy for
methadone clients with apparent psychiatric disorders. Subjects were
72 clients diagnosed as having current psychiatric disorders, such as
anxiety or depression. Clients doing poorly in treatment or having
significant psychopathology were especially encouraged to attend. In
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the psychotherapy condition, subjects received 1 hour per week of
individual therapy with a professional therapist. The control condition
did not receive individual psychotherapy, but met with a psychiatrist
once per month for 20 minutes. Treatment manuals were used as
guides. Both conditions received access to all clinical services and the
standard 90-minute group therapy provided all clients. Treatment was
available for 6 months. The multiple outcome measures included
treatment attrition, number of urines positive for illegal drugs, number
of arrests, psychiatric symptomatology, personal and social functioning,
and attainment of individual goals. Attrition was high in both
conditions; only 38% of the subjects completed the psychotherapy
condition, and 54% completed the control condition. The results
indicated few differences between the two groups.
The authors discussed several factors which might have obscured
differences between conditions. They included the large amount of
counseling provided for all subjects, the selection of only
psychopathological subjects, and the restriction that subjects be
recruited into the study only after spending 6 weeks in methadone
treatment (when motivation to change may be less than earlier in
treatment). Two other factors warrant consideration. First, the 90-
minute group sessions and the individual sessions may have provided
conflicting therapeutic directives. Second, by encouraging clients who
were not doing well in methadone treatment to enter psychotherapy,
the most noncompliant clients may have been included in the study.
This could explain the extremely high dropout rates.
These two studies of psychotherapy, taken individually, are clearly
among the strongest in the drug treatment literature. They provide
comparisons of standardized treatments, use treatment manuals, and use
reliable and valid measures with clinically appropriate populations and
therapists. The Philadelphia study controlled attrition sufficiently for
interpretation of results. However, neither study addressed nonspecific
effects or exceptional factors.
These two trials imply that further research is needed on
psychotherapy. They also suggest two methodologies for such research.
One, the measures used may provide the basis for assessing drug
treatment. Both used standardized measures which were sensitive to
therapeutic change in drug treatment clients. Two, the contrast
between outcomes of the two studies suggests that the recruiting and
implementation strategies of Woody et al. (1983) should be considered
in designing additional treatment trials. These strategies include
induction of a broad range of clients early in treatment, as well as
the close integration of drug treatment and psychotherapy staff.
Despite the costs, these two studies illustrate the potential benefits of
multiple-site studies. First, the studies alone are of value. Second,
comparisons between them on the limited set of variables on which
they differ provide some clear hypotheses for further study. Finally,
had the brief analytic therapy been effective in both sites (as it might
in possible future trials), the therapy would be established as a
generally useful tool.
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Contingency Contracting
Contingency management is a behavior change intervention in which
reinforcers and punishers are provided depending on adaptive behavior.
Drug treatment clinics-especially methadone clinics-have control over
several reinforcers which could be used, including methadone dose and
take-home privileges.
A series of partial replications on contingency management were
completed by Maxine Stitzer and her colleagues at Baltimore City
Hospital. Stitzer and Bigelow (1978) demonstrated that take-home
doses can be used on chronic nonattenders to increase attendance at
counseling sessions. Weekend take-home doses, which were either
contingent on or independent of session attendance, were given to 16
subjects during five successive 2-month periods. During contingent
delivery periods, attendance increased significantly above levels
observed during noncontingent periods, when attendence rates did not
return to the same low level observed during the baseline phase.
Stitzer et al. (1980) assessed the effects of a limited contingency
“menu” on heroin use The participants were seven male clients who.
consistently produced morphine-positive urines during a baseline period.
Reinforcement was available during randomly selected weeks for clients
with morphine-free urines. Reinforcers were a choice between $15,
two methadone take-home privileges, or two opportunities to self-
regulate dose. During contingent reinforcement, the rate of morphine-
positive urines declined significantly. However, the morphine-positive
rate also declined during study periods when no reinforcement was
available.
Two other studies from this group addressed the use of illicit
benzodiazepines among methadone maintenance clients. In the first
study, eight chronic benzodiazepine abusers were given prescriptions
for 20 mg diazepam daily. If they refused their dose, they were given
the opportunity for one take-home dose, or self-regulation of their
methadone dose for a day. During baseline, 95.6% of available
diazepam was requested. Only 11.2% of diazepam was requested when
refusal resulted in take-home doses, and 69.7% when refusal resulted in
methadone dose self-regulation opportunities. Unlike counseling session
attendance and heroin use, requests for the diazepam prescription
rapidly returned to baseline levels when reinforcers were terminated.
This methodology was extended in a subsequent study (Stitzer et al.
1982) to out-of-clinic benzodiazepene self-administration. The ten
subjects were selected on the basis of a history of benzodiazepine
abuse. Benzodiazepine-free urines were reinforced by a choice of two
methadone take-home doses, $15 cash, or two single-day opportunities
to self-regulate dose. The efficacy of the contingencies was evaluated
in an A-B-A (baseline-treatment-baseline) design. Clear effects were
evident in five of the ten subjects; benzodiazepine use decreased
during treatment, and returned to baseline levels during the second
baseline. During the intervention period, three other clients showed
runs of five to eight consecutive clean urines which were not present
during the baseline period.
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The small-scale, well-controlled studies of Stitzer’s group suggest that
contingencies can control problem behaviors in methadone maintenance
clients. However, these behaviors are sometimes found not to return
to baseline levels when a repeat baseline is included as the final phase
of the study. Since some therapeutic effects occur during
noncontingent periods, nonspecific effects may result from participation
in an experiment.
Similar positive results were reported by Hall et al. (1979) in a study
completed in 21-day outpatient detoxification. Unfortunately, the
methodology of this study did not control for attention-related effects.
The 81 subjects were randomly assigned to receive either standard
treatment, or contingent payment and information feedback for opiate
free urines and treatment completion. A single experimenter
administered both contingent and noncontingent conditions. Contingent
payment increased the rate of drug-free urines on days when subjects
were paid (but not on unpaid days) and did not affect treatment
completion.
Any treatment effect in 21-day outpatient detoxification is important
since this modality may have little therapeutic impact (Sheffet et al.
1976; Wilson et al. 1975). However, this short-term treatment effect
could result from payment, feedback, increased attention, or other
nonspecific factors regulated by this design.
The only negative results from contingency management were those
reported by Havassy et al. (1979) and Havassy and Hargreaves (1981).
The 116 subjects from two methadone maintenance clinics were
randomly assigned to either dose self-regulation, self-regulation with
take-home incentives for dose reduction, or to a standard treatment
control for 48 weeks. No reinforcement effect was found in this
study, even among the subset of clients on voluntary detoxification.
This study may have failed to find a positive outcome because of
factors unique to the setting. Shortly after the initiation of the
study, the clinics became involved in long-term political and
administrative turmoil which lasted throughout the study. Although the
delivery of treatment was monitored by research staff, such chaos may
have swamped experimental effects.
Relaxation Training and Biofeedback
Three controlled studies of relaxation response are notable, primarily
because of the convergence of their findings and the disagreement of
these findings with uncontrolled clinical reports. After completing a
small (n=20) pilot study which showed weak positive results, Khatami et
al. (1982) assigned 37 male, VA methadone clients to either a
biofeedback condition or to a noncontingent, “pseudobiofeedback”
control. Pseudobiofeedback control subjects received feedback matched
to an experimental subject, independent of their own response.
Subjects were assessed on patient self-report, including measures of
depression, anxiety, withdrawal symptoms, drug references, and
psychiatrist rated depression. Information was also obtained from
patients and their counselors on job or school status, social adjustment,
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and illegal activity. Subjects were evaluated at the end of the
treatment and at 1-month followup. Data were only obtained for the
subjects who completed 15 sessions (n=19).
The two groups had no meaningful differences. The control condition
in this study is particularly noteworthy; it controlled for all attention-
and expectation-related factors which might be correlated with
biofeedback. However, the sample sizes were sufficiently small
-especially after attrition--that even clinically interesting differences
were statistically insignificant, and therefore overlooked. For example,
the experimental group showed positive changes in several self-report
measures, and showed less opiate relapses. But the sample size was so
small that differences did not reach traditional levels of statistical
significance.
However, negative findings were also reported in a larger scale study
of relaxation training--a therapy considered by many practitioners to
be similar to biofeedback. Our group completed a study of relaxation
training as an adjunct to methadone detoxification (Hall et al. 1983).
The 53 subjects recruited from seven methadone maintenance clinics
were randomly assigned to either a relaxation information condition or
to a standard treatment control. Treatment followed a manual
(Kushner et al. 1981). Two therapists each led half the treatment
groups. Clients were assessed at weeks 0, 5, 12, 24, and 52.
Assessments included measures of general and detoxification-specific
anxiety, mood state, withdrawal symptomatology, and self-reported
alcohol and drug use. Methadone dose and urine test results were
collected throughout the 1-year followup period. Seventeen of the 27
experimental clients completed treatment.
The data indicated little difference over the year between the
experimental and control subjects in methadone dose reduction or
complete detoxification. Experimental subjects reported less alcohol
use and fewer withdrawal symptoms immediately following treatment,
but these differences were not evident at later followup periods. No
differences in other psychometric measures were found. This study did
not control for therapist expectations or attention. Further, the
attrition in the experimental group was great enough that it could
have prevented a fair treatment assessment.
Summary: Psychotherapy, Contingency Management, and Relaxation
Training
The conclusion is that random assignment studies are feasible if the
subjects are all drawn from the same drug treatment modality. The
success of these trials at methadone maintenance clinics suggests the
importance of embedding psychosocial interventions in other modalities
with “bonds” to reduce attrition. Informative trials have been
completed. Many of these studies are characterized by clear
descriptions of the treatments delivered, or, even better, by use of a
treatment manual. In most instances, the only conclusion which can be
drawn, however, is that a specific treatment is better than a standard
treatment. Such designs are appropriate in a new field. However,
designs which control for therapist- and attention-related factors are
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the next step. Also, the studies provide little, if any, information
about treatment processes; that is, what factors in the treatment are
correlated with change. Contingency contracting and psychotherapy
show some promise; relaxation therapy and biofeedback do not.
VOCATIONAL REHABILITATION
Three large- scale, random- assignment, controlled studies were
completed on vocational rehabilitation in drug treatment. The earliest
of these was the Wildcat Demonstration Program (Friedman 1978) which
evaluated the effects of supported work on 604 drug treatment clients,
80% of whom were from methadone programs. The intervention was
compared with a standard treatment control condition. Criteria for
acceptance into the study varied across time. The exact intervention
also varied; some subjects were placed with work crews, others were
not. At the end of the supported work period, efforts were made to
place participants in nonsupported jobs. These efforts also varied.
Clients were interviewed at intake and during the following 3 years.
Interview information was verified against other data sources. About
one-third of the original sample was lost. Included in this one-third
were 30 experimental clients who failed to take the job assigned to
them. Differences in employment, use of public assistance, and stable
relationships occurred during the year of supported work, but mostly
disappeared during followups. No differences were found in drug
abuse.
Any interpretation of the results is weak with such a large proportion
of the sample lost-particularly since 30 of the experimental subjects
lost had removed themselves from the sample by never appearing for
work. These were the least motivated clients, and their exclusion
artificially increased the differences between the two groups. Also,
even if the differences between the groups are “real,” the
interventions are so diffuse and poorly spelled out that it is difficult
to describe the experimental conditions which may have caused the
differences.
TREAT (Training, Rehabilitation, and Employment for Addicts in
Treatment; Bass and Woodward 1978) recruited subjects from a single,
large, multimodality drug treatment program, and randomly assigned
them to either Comprehensive Employment and Training Act (CETA)
training or to a control condition. Experimental clients were more
likely to decrease drug use (as indicated by urine analysis) and to show
better outcome on a multicomponent measure of treatment outcome,
but showed no differences in treatment retention or criminal behavior.
Experimental subjects worked full time more often and earned higher
salaries than controls, but showed no differences in the number of
weeks worked.
Again, confidence in these results is diminished by the procedure used
for experimental dropouts; results were reported for the entire control
condition. But, in the experimental condition, early dropouts were
replaced and not included in the data, thus biasing the data in favor
of the experimental condition. Later dropouts were not replaced.
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Also, perhaps differences between the conditions existed prior to the
intervention; 21% of the experimental subjects and 35% of the controls
had not worked in the 2 years prior to the study. Other research
(Hall et al. 1981b) showed that lack of recent employment history is a
powerful predictor of failure in job seeking.
In the random assignment, supported work project of the Manpower
Demonstration Research Corporation, approximately 1,200 (12%) of the
10,043 participants were ex-addicts (Board of Directors, Manpower
Demonstration Research Corporation 1980). Over half the ex-addict
sample (54.5%) was drawn from methadone maintenance clinics; the
remainder were primarily from drug free treatments. Subjects in three
cohorts were followed for 1, 2, and 3 years, respectively. At the end
of the 12-month, supported work period, clients were assisted in
finding employment. All subjects who completed random assignment
and who could be located were included in the final data analyses.
One-year followups-which were completed for all available
subjects-provided data on only 974 subjects. However, differential
attrition between conditions was not evident.
During the supported work period, experimental subjects worked more
hours than controls and had higher employment rates. Interpretation of
the followup data was difficult because of differences between cohorts
entering the program at different time periods. In general, differences
were only significant for early entrants, primarily because of lower
employment rates among early controls. Supported work did not
influence drug and alcohol use. However, arrest rates for the
conditions differed, especially during the period immediately following
supported work. Methadone clients benefited more from the program
than did other drug treatment clients.
Why such large sample sizes were needed is unclear. Monitoring
experimental procedures to prevent significant deviations over time and
across sites is difficult with a large sample; deviations increase
variance and could attenuate the findings. A second problem concerns
precise specifications of the interventions themselves, especially in
staff contact and peer group support. This problem mostly affected
multisite studies that had significant variations across time and from
site to site. Also, the handling of dropouts and missing subjects was
often vague enough that legitimate conclusions could not be drawn.
An investigation of change mechanisms and a better link between
actual intervention content and outcome are needed. Differences in
outcome as a function of intervention leaders have rarely been
addressed, and no studies comparing different treatments or attention
controls exist.
We have completed a series of small-scale studies to test the
usefulness of a job-finding intervention for drug treatment clients.
The Job Seekers’ Workshop (Hall et al. 1977, 1981a, 1981b) is a
behaviorally based, skill training program designed to help ex-heroin
addicts increase job interviewing and job skills. Treatments were
based on a manual. In the initial study, 49 methadone maintenance
clients (recruited from several clinics) seeking either jobs or placement
in a competitive skill training program were randomly assigned to the
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workshop or to a minimal treatment control. At the end of the
workshop, an interviewer who was “blind” to experimental conditions
rated subjects on employability/acceptability as trainees. Three months
after the interview, subjects were contacted and asked whether they
had found a job. Of the experimental subjects, 50% had been placed;
only 14% of the controls had found employment or placement in a
training program. Also, Job Seekers’ Workshop clients were rated more
favorably than the controls on both interview skills and completed
application forms.
In a second study, 60 job seeking, methadone maintenance clients were
assigned to either the workshop or the minimal contact (information
only) control. The program, which was streamlined from the initial
effort, was presented in 11 hours over 4 days. At treatment
termination, subjects were assessed by two "blind" interviewers on a
multi-item scale tapping specific interview behaviors. Experimental
subjects were rated more positively than controls, particularly in
general interview competence and manner of presentation. By the end
of 3 months, 52% of the experimental subjects were employed, as
compared with 30% of the controls.
In a final study, 55 probationers and parolees with heroin abuse
histories were randomly assigned to the workshop or to the control
condition. The workshop content and format were modified to suit the
needs of this population. Measures were identical to the previous
study. The two groups differed on scales measuring interview skills
and rate of employment. By 3-months posttreatment, approximately
86% of experimental subjects had found employment, as compared to
54% of controls.
Considerable similarity in outcome exists between the two methadone
maintenance studies. In both, employment rates at the end of 3
months were approximately 50%. Some variation in control group data
existed between the two studies (14% vs. 30%), but, in fact, when
subjects seeking placement in training programs were removed from the
data of the first study, these differences lessened. Further, the data
indicated a sharp difference between methadone maintenance and
criminal justice subject pools. Interventions were essentially identical
among the three studies. The methadone maintenance samples had
similar overall employment rates; both groups had considerably lower
overall employment rates than the criminal justice sample.
The studies did not control for time in treatment or for expectations.
Leader differences were noted in the only study which evaluated
them-the second methadone maintenance study; but characteristics
which described successful and unsuccessful leaders could not be
determined.
Summary: Vocational Rehabilitation Interventions
In many ways, the research strategy for vocational rehabilitation
interventions has been less rigorous than that of psychotherapy studies.
The treatment protocols are vague, changing with time and varying
from site to site. In some instances, dropout rates may have
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compromised the random assignment. Despite these many faults, a
surprising convergence emerges from the data: in effect, supported
work projects, independent of their precise content, decrease
dependence on public assistance and increase employment. These work
projects may not have much long-term effect, and they do not directly
affect drug abuse.
Even though these studies were not designed for replication, they
accomplished that purpose better than might be expected. However,
small-scale, well-controlled studies have been successfully conducted in
this area, and seem to yield more conclusive results. These results
indicate that skill training is a promising modality for enhancing
vocational effectiveness. However, further research on nonspecific
factors in skill training is desirable.
CONCLUSIONS AND RECOMMENDATIONS
1. Well-controlled, small trials with sample size based on power
analyses have been the most successful in yielding clear outcomes and
comprehensible data. The best of these trials are characterized by use
of a treatment manual or a standardized treatment, and by well-
developed procedures for tracking patients over a long time span.
Further research of this kind should be completed and is preferable to
large, national attempts at controlled outcome trials where variations
are so great, and the size of the projects so large, that findings are
difficult to interpret.
2. Research strategies which are planned with some degree of repli-
cation are preferable to isolated single trials for several reasons.
First, if such trials are relatively small scale, the risk associated with
one trial is less because several studies can be built into the research
plan. Second, replication quickly provides clear hypotheses for further
study. Finally, such strategies determine the situations and parameters
under which an intervention is effective.
3. Developing a basis for measuring drug use might help in evaluating
treatments. The core of such measures lies in drug screens from
urines and in treatment attendance data. However, more
standardization in psychosocial areas would be useful. The ASI could
provide part of this battery. Again, this standardization would
facilitate replications and comparisons between studies.
4. Promising strategies have emerged from controlled research.
Clearly, more studies are needed on psychotherapy, contingency
management, and skill training. In psychotherapy, the findings of
Woody et al. (1983) need replication in a different site. Also, the
positive results of family therapy warrant more research, especially
since, next to medical service, psychological and family services are
among the most frequently offered treatments. The proportion of
women clients in treatment seems to be increasing, so the inclusion of
women seems even more crucial-especially in family therapy studies.
Two directions are important in contingency management. One is
controlled studies which partial out any placebo factors from specific
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treatment effects. The other is larger scale studies which evaluate
the effectiveness of contingencies in one or more “typical” drug
treatment clinics. This point is important, because the best work to
date has been completed at one site in a small research clinic. Skill
training appears to be valuable, and is appropriate and acceptable to
the drug treatment clients. Studies evaluating its use outside the
vocational area seem warranted.
5. Many valid studies have demonstrated differences between in-
novative treatments and standard treatment controls. Refinements in
intervention design are needed. Factors such as time in treatment,
placebo, and expectational effects have been neglected. Often these
factors can be controlled or measured without sacrificing clinical
generalizability.
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Outcome of Narcotic Addict
Treatment in California
M. Douglas Anglin, Ph.D., and
William H. McGlothlin, Ph.D.
INTRODUCTION
Society has attempted for many years and in many ways to control and
rehabilitate the narcotic addict. Where all methods of social
intervention have achieved less than desired results, methods which
incorporate some concept of treatment have generally been more
effective than those that have not. In particular, solely criminal
sanctions have proven relatively ineffective. The theory underlying the
preceding statements is based partially upon interviews with more than
400 heroin addicts of both sexes, diverse ethnic backgrounds, and
heterogeneous personality types. These interviews were conducted in
the course of several treatment followup studies of some 1,700 narcotic
addicts in which their entire addiction careers (from 12 months prior
to their first use of a narcotic up to the time of interview) were
chronologically recorded. The data collection procedures allowed a
determination of quantifiable changes over time in addiction related
patterns of behavior. The analyses of the addict career histories
further substantiate this theory. These results are presented in detail
elsewhere (Anglin 1980; Anglin et al. 1983; McGlothlin and Anglin
1981a; McGlothlin and Anglin 1981b; McGlothlin et al. 1977). Some
highlights of this research and their implication in assessing the overall
efficacy of drug abuse treatment will be presented here.
Our research group at UCLA has conducted a number of followup
studies of narcotic addicts in two types of long term treatment: civil
commitment and methadone maintenance. Civil commitment was
virtually the only major publicly supported program for addicts during
the 1960s. Methadone maintenance became a major treatment
modality for the State beginning in 1970.
Some comments about the use (or misuse) of the word "treatment"
when applied to narcotic addicts are in order. The word is borrowed
directly from medicine, where it is applied to any course of action
designed to cure, ameliorate, retard, or provide symptomatic relief
from a physical disease or condition. Generally, desirable results are
obtained from a medical course of treatment. Thus, the term has most
often become associated with its highest level application: cure.
Although the use of the term in the area of drug abuse is appropriate,
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the level to which it can be applied is typically much lower:
amelioration, retardation, temporary relief, or no effect. A rational
evaluation of treatment efficacy in drug abuse has to deal with the
general public’s expectation of treatment as a cure. Given the
multiple determinants of a complex physio-psycho-social behavior such
as addiction, the generally poor premorbid characteristics of those who
become addicted, and the lengthy time course of the addiction, it is
not surprising that cures, in the usual sense of the word, are relatively
rare. They should not even necessarily be expected.
Three considerations are important in evaluating treatment outcomes.
The first is a clear description of the characteristics of the target
population to be treated. Addicts are a very heterogeneous group and
the etiology of addiction is complex. This renders the goal held by
public health administrations of providing a comprehensive system of
services much more difficult to implement. Second, the proportion of
patients meeting the various treatment outcome levels mentioned above
must be considered. What proportion are “cured” of their addiction?
What proportion experience amelioration vis-a-vis society and
themselves? For what proportion is the treatment ineffective at that
time? It should be expected that those proportions would not
favorably compare to those resulting from treatments for most physical
diseases. Finally, the consideration of treatment effects over time is
an important one. Unlike the physical diseases, most character
disorders can be expected to be chronic. Since long term-addiction
may often have more psychological components associated with it that
physiological ones, it should be expected to be a chronic condition in
the majority of cases.
The general question then becomes a probabilistic one: “What is the
time-related probability that the outcome of treatment will be
desirable for a group of addicts with defined characteristics?” Time-
related means the proportion of addicts showing the desired outcomes
at stated intervals (in years, probably) during or after treatment.
Desirable would mean some demonstrated amelioration for society or
for the individual in the expected nontreated course of the addiction.
The phrase “defined characteristics” emphasizes the understanding that
premorbid characteristics of the individual addict are important in
determining outcome of treatment.
Having these distinctions made explicit leads to very different
evaluation questions from those typically asked in the drug abuse field.
The stereotypical question has been: “How many patients become
completely drug free (cured) after treatment?” It is more appropriate
to ask, “How has the course of the behavior been changed for the
betterment of society and the individual from what it probably would
have been had treatment not been available?” A corollary question is,
“What is the overall benefit of the treatment compared to the cost to
society for providing it?” This question is not as unhumanitarian as it
seems; it is a necessary consideration in any society with limited
resources. Cost benefit analysis, usually determined by the traditional
economic weightings of reduced criminal costs and increased treatment
costs, can be appropriately augmented by humanitarian considerations
such as the quality of life improvement envisioned for the addict.
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Presented below is an overview of the results our research group
obtained from evaluations of the California Civil Addict Program (a
civil commitment program hereafter abbreviated as CAP) and of several
methadone maintenance programs in the Southern California area
(hereafter abbreviated as MM). Full descriptions of these studies may
be found in McGlothlin et al. (1977), Anglin (1980), McGlothlin and
Anglin (1981a), McGlothlin and Anglin (1981b), and Anglin et al. (1983).
Background
Since 1973, we have conducted research on heroin addiction and
treatment in California. The greater part of our research has been
directed toward evaluating the effectiveness of civil commitment
and/or methadone maintenance for chronic heroin addicts. Measures
used were narcotic and other drug use. incidence of crime and/or drug
trafficking, employment, and family stability. Evaluations included
assessments of the cost/benefits of these programs. During the past 10
years, we have conducted four major studies involving ten chronic
addict samples (primarily male) for a combined sample size of 1784
(McGlothlin et al. 1977; Anglin et al. 1981; McGlothlin and Anglin
1981a; Anglin et al. 1983). Each sample was drawn from a different
program or from multiple programs. Thus, we have sampled a
reasonable number of long term California treatment programs
(including some of the largest) from various geographical areas, serving
different client populations, and, with Federal and State guidelines,
having diverse administrative policies. We have been able to address
questions concerning what effect treatment entry and treatment
termination had on addict behavior, and what specific subgroups of
addicts responded differently to treatment efforts. Our followup
interview was designed to take retrospective longitudinal data covering
the entire addiction history, from 12 months prior to first narcotics
use to the time of interview. This approach allows for time series
analyses of behaviors for extended periods before and after entry into
treatment. The self-report data obtained from the interview are
supplemented by the official arrest and incarceration history as
detailed in the California Criminal Investigation and Identification
record (CII or “rapt’ sheet) and by urinalysis results from a voluntarily
obtained specimen requested, without prior notification, from a
volunteer at the time of interview.
Samples
The research data were obtained from samples of heroin addicts
identified from three general sources: 1) admission records of the
California Civil Addict Program (CAP), a compulsory treatment
approach operated by the Department of Corrections and the major
treatment program available during the 1960s; 2) admission records of
various Southern California county methadone programs; and 3) active
client lists of Southern California county methadone programs. In
some instances the samples were representative of the populations of
their respective programs; other samples were matched to these
representative samples for comparison purposes and are themselves not
necessarily representative.
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Table 1 summarizes the geographical and chronological characteristics
of the ten samples. Sample sizes of interviewed subjects are
reasonably large and represent from 83% to 97% of the originally
selected samples. The median dates of the first daily use for the 10
samples range from August, 1958, to February, 1970. Median interview
dates range from January, 1975, to March, 1979. For those entering
methadone maintenance, the post-methadone entry followup periods
range from 20 months to 82 months, The samples are generally
representative of addicts from many areas in the State. The time
periods for which data were obtained cover two decades, the 1960s
and the 1970s.
Interview Procedures
The interview was adapted in part from a schedule developed by Nurco
and colleagues (1975), and has been described in detail in an earlier
monograph (McGlothlin et al. 1977). Briefly, a schematic time sheet is
prepared prior to the interview showing all known arrests and intervals
of incarceration, legal supervision, and methadone treatment. The
interviewer establishes the date of first narcotic use on the time
chart, then proceeds chronologically to the point where narcotic use
changes from less than daily use to daily use, or vice versa, or the
respondent’s legal status changes. Data is then collected on narcotic
use, employment, criminal behavior, and certain other variables for that
interval. The interviewer then proceeds to the next interval, and so
on until the interview date. Each interval is uniform in terms of
narcotic use, legal status, and drug treatment enrollment. This method
of segmenting the interview into intervals which are meaningful to the
respondent has proven quite successful in collecting retrospective data.
Typically, the respondents appear to have little difficulty recalling, for
the specific period, whether they were employed, how frequently they
were using narcotics, their costs, and how they were obtaining funds
for drug purchase. The procedure requires the interviewer to work
closely with the respondent to structure the period of concern.
Extensive interviewer training is necessary. The authors participated
as interviewers for all samples and were responsible for training and
supervising the interviewing staff. Graduate students in psychology,
sociology, and education served as interviewers.
RESEARCH RESULTS
The accumulated data base collected for the 10 samples provides
sufficient information to answer questions concerning many aspects of
civil commitment and methadone maintenance treatment. Immediate
and long-term outcomes of these two treatment approaches are
summarized below.
Perhaps the best evidence for the efficacy of both civil commitment
and methadone maintenance treatment comes from evaluation of the
California Civil Addict Program (McGlothlin et al. 1977). For this
study we were able to construct a pre/post time series design with a
matched comparison group. The treatment groups came from two
different time periods: early admissions to the program, in the years
1962-1964, and later admissions, from the year 1970. The size of the
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1964 admissions sample was 225, and the 1970 sample size was 251.
The comparison sample came from a group of 1962-1963 program
admissions who were released after nominal exposure to the inpatient
phase of the program because of technical errors committed by the
courts. A sample of 214 was chosen from this group to match the
characteristics of the treatment groups.
TABLE 1
Characteristics of UCLA Folowup Samples of Heroin Addicts
Entering Treatment
The Effects of Civil Commitment
Figure 1 is a time series presentation of the effects of the civil
addict program on the daily narcotic use of the two treatment samples
and the comparison sample. The percentage of precommitment and
postcommitment nonincarcerated time during which the respondents
reported that they were using narcotics daily is represented. During
the precommitment period, the comparison sample (minimally exposed to
the CAP) shows a somewhat higher percentage of daily use than that
for the early treatment (maximally exposed to the CAP) sample. The
rate of daily use is relatively low for the late treatment sample during
the early precommitment years, perhaps as a result of more polydrug
use and less commitment to the opiates. An interesting aspect of the
precommitment graphs is the sharp rise in daily usage which occurs
during the two years prior to admission for all three samples. This
rise in usage is undoubtedly closely related to the initiation of the
commitment proceedings. A similar rise in usage very likely occurs
during the period preceding volunteering for, or being coerced into,
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treatment programs generally. Thus, followup evaluations which utilize
relatively short pretreatment baseline periods are likely to ensure a
spurious improvement in the postadmission behavior by virtue of this
self-selection phenomenon.
The postcommitment graphs of daily narcotic use show a marked
improvement in behavior for the early treatment sample over the
comparison sample for the first four years, and a moderate
improvement during the remaining time until the interview. The
percentage of postcommitment daily narcotic use for the late treatment
sample begins substantially above the early treatment sample level, but
then falls below the latter curve by the time of the interview. As
will be discussed later, a considerable portion of the sharp drop in the
late treatment sample graph is attributable to the increasing
percentage enrolled in methadone maintenance programs. Another
reason for the drop in daily use in this sample is the higher rate of
exclusions from the CAP and their subsequent prison sentences.
The comparison and early treatment sample graphs both show a gradual
decline in daily use over time. This decline is in accord with the
“maturing out” hypothesis (Winick 1962), but part of the decline in the
later years is also due to increasing enrollment in methadone
FIGURE 1
Percent of Nonincarcerated Time
Reported as Daily Narcotic Use: CAP Admission
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programs. It should be kept in mind that the postadmission period for
which methadone treatment was available varies for the different
samples in figure 1. Methadone treatment became available about year
9 for the comparison sample, about year 7 for the early treatment
sample, and year 1 for the late treatment sample. This may account
for some of the difference between the rate of daily narcotic use for
the comparison and early treatment samples during the years
immediately prior to the interview.
Figure 2 presents the precommitment and postcommitment level of self-
reported criminal activity. With the exception of the late treatment
sample, the precommitment level is relatively stable until the rise in
the last two years preceding the commitment (the period corresponding
to a sharp increase in daily narcotic use). There are no notable
differences between the precommitment levels of criminal activity
reported by the comparison and early treatment samples. During the
postcommitment period, the pattern is quite similar to that for the
percentage of daily narcotic use for all three samples (figure 1).
Figure 3 shows the combined full- and part-time-employment levels for
the precommitment and postcommitment periods. During the
precommitment period, employment  generally declines over the time
corresponding to the heavier involvement in daily narcotic use. The
precommitment employment level for the comparison sample is more
uniform than that for early treatment group. In the
postcommitment period, the comparison and early treatment graphs
show a mirrow image of the daily narcotic usage pattern (figure 1);
For example, the figure shows much higher employment for the early
treatment sample for the first four years, declining to only slightly
FIGURE 2
Percent of Nonincarcerated Time Involved
in Crime Other than Drug Offenses: CAP Admissions
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higher employment thereafter. The postcommitment employment level
for the late treatment sample is substantially lower than that for the
early treatment sample, and shows a rise over time corresponding to
the drop in daily narcotic use.
Successive Effects of Civil Commitment and Methadone Maintenance
A second analysis allows an examination of the successive effects of
the Civil Addict Program and methadone maintenance. Of the 439
combined comparison and early treatment samples used to evaluate the
CAP, 118 (29%) subsequently entered methadone treatment when it
became available in California in the early 1970s. By this time, nearly
all the sample had completed the commitment period and were no
longer under the supervision of the CAP. Thus, they were essentially
“free agents” and could maintain their rehabilitated status (if it had
been achieved), continue in an addicted life style, or enter a different
type of treatment (methadone maintenance) for another try at
controlling their drug use. The data showed that all three outcomes
occurred for this combined sample.
Two populations could be differentiated from those who did not enter
methadone treatment. One type, inactive addicts, consisted of
individuals who, in the initial years of methadone maintenance
availability in California, showed minimal drug use, and whose lifestyle
gave little indication of a return to daily involvement with narcotics.
This group may be considered, in Winick’s terms, to have “matured out”
of addiction (Winick 1962). The second type, active addicts, were
individuals who, like methadone entrants, showed continued daily use of
narcotics, but who had not chosen or had not been coerced into
entering methadone treatment. This is the more appropriate reference
group. It is composed of active addicts who supposedly would benefit
from treatment, while inactive individuals have no need for methadone
maintenance.
FIGURE 3
Percent of Nonincarcerated Time Employed: CAP Admissions
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An examination of the overall personality and behavioral patterns of
those who entered methadone maintenance revealed that they had not
responded well to any effort by society to control their addiction and
had not themselves been able to achieve the control shown by a
certain proportion of the addict population (the inactive subsample)
(Anglin 1980). Generally they showed less antisocial behavior than the
other chronic users, who did not enter maintenance (the active
subsample).
Time series data were constructed to demonstrate the effects of the
CAP and methadone maintenance on a comparative basis for the three
subsamples. Figures 4, 5, and 6 present the data for daily drug use,
criminal involvement, and employment for periods before CAP
admission, during the CAP, after the CAP, as well as before and after
methadone maintenance. In examining the implications of figures 4, 5,
and 6, it is important to recall that two major social interventions
have occurred for the sample: CAP commitment and methadone
treatment entry. For this combined sample, the two events were well
separated in time. These two interventions show clear effects in the
time series graphs-both for the variables presented, and for other
variables affected by addiction (Anglin and McGlothlin, in press).
During the pre-CAP period, the inactive subsample shows more
employment and somewhat less incarceration, daily drug use, and crime
involvement than the active subsample. The methadone subsample is
FIGURE 4
Percent of Nonincarcerated Time Reported as Daily Narcotic Use:
CAP Inactive, Active and Methadone Subsamples
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FIGURE 5
Percent of Nonincarcerated Time in Crime:
CAP Inactive, Active, and Methadone Subsample
FIGURE 6
Percent of Nonincarcerated Time Employed:
CAP Inactive, Active, and Methadone Samples
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intermediate, although a few fluctuations do occur in which values for
the methadone sample exceed those of the active or inactive
subsamples.
CAP commitment at premethadone entry, year 8, produces an
immediate effect in all three subsamples, and this continues for the
duration of commitment (years 8 through 14). The inactive group
shows the greatest amount of improvement for the three behaviors
(daily drug use, crime involvement, and employment) while the active
group shows the least improvement. Except for criminal involvement,
where their behavior resembles that of the active group, the
methadone subsample is again intermediate.
The postcommitment, premethadone period (years 1 through 3) shows a
continuation of these gains for the inactive subsample, illustrating
moderate further improvement in behavior. The active and methadone
subsamples exhibit marked increased in daily drug use and crime
involvement, and a sharp drop in employment for the period. Part of
this increase can be attributed to the termination of CAP supervision
and a resulting “bounce back” effect. However, at this same time
(1968-1971), heroin addiction was at epidemic levels in the United
States (NIDA 1981). The increased availability of heroin appears to
have resulted in higher levels of use by both the methadone and active
groups. The inactive group had achieved enough control to not be
affected.
Figure 4 compares the postmethadone period to the premethadone
period. The active and inactive subsample data maintain nondisjunctive
patterns. Note, however, the sharp decline in daily drug use for the
active subsample, which corresponds to the end of the heroin epidemic
period. In strong contrast, the methadone subsample data demonstrate
marked and immediate reductions in daily drug use and crime
involvement. A moderate increase in employment is also evident. The
variables remain relatively constant for the three year followup period.
Data presented in this section confirm that, for considerable number of
narcotics addicts, civil commitment and methadone maintenance produce
substantial reductions in antisocial behavior and moderate improvement
in prosocial activities (employment).
EARLY METHADONE MAINTENANCE ADMISSIONS
Another series of followup studies provides compelling evidence for the
efficacy of MM alone in producing desirable outcomes in chronic
addicts. In the first of these, a sample of 347 was drawn from the
male first admissions in three multiple clinic county methadone
programs in Southern California during the years 1971-1973 (McGlothlin
& Anglin 1981b). The number of addicts selected from the Los
Angeles, San Bernardino, and Orange County programs were 138, 99,
and 110, respectively. The samples were selected to study the impact
of civil commitment parole status on methadone patient behavior, and
they are not necessarily representative of the overall methadone
admissions to the programs (Anglin et al. 1981). Figures 7-10 are time
series presentations which plot percent time in methadone maintenance,
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daily narcotic use, crime involvement, and employment. The graphs
show the immediate beneficial outcomes of treatment on these
behaviors. Comparing the performance of clients from the three
programs also shows distinct interprogram differences in level of
desirable outcomes achieved. A brief synopsis of the policies of the
three programs will provide a context for interpreting the results.
The Los Angeles program was initiated in October 1970, and generally
employed a high-dose blockade policy. There was about an 18-month
waiting list throughout the time period sampled, and preference was
given to persons with a long history of addiction-hence the greater
mean age at admission. There was no firm date at which clients were
expected to detoxify, and, except for cases involving violence,
involuntary terminations for program violations were employed only as
a last resort after a series of probations and appeals. In April 1973,
the State mandated a maximum dose of 80 mg per day unless State
permission for an increase was received on a case-by-case basis. This
resulted in some drop in dose levels.
The San Bernardino program began in September 1971, and the original
protocol listed the stabilization dose at 80-160 mg. One year later,
the dose was lowered to a maximum of 100 mg. This was further
FIGURE 7
Percent Time on Methadone Following Entry
for Los Angeles, San Bernardino and Orange
County Methadone Admissions
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reduced in April 1973 under the new State regulations. There was an
initial waiting list of about 6 months, and admission was on a first
come, first served basis. San Bernardino was also flexible with respect
to involuntary terminations, and there was no firm expectation for a
maximum time in the program.
The Orange County program differed considerably in policy from the
other two. This program began in September, 1969, and initially
employed stabilization doses of 80-120 mg. However, in October 1971,
the maximum dose for incoming patients was set at 50 mg. Thus, a
low-dose policy prevailed during most of the period in which patients
were selected for this study. In May 1972, there was a two-year
waiting period for admissions, but this had been reduced by 1974. In
addition to the low-dose regimen adopted in 1971, the program imposed
a fairly strict policy of termination for program violations, as well as
an expectation of treatment graduation after two years on
maintenance.
Effects of Treatment Entry
Of the three programs, Los Angeles and San Bernardino counties fit
the MM-A (adaptive) type, and Orange County fits the MM-CO (change-
oriented) type described by Gorsuch and associates (1976). While
Gorsuch and associates’ evaluation of the Drug Abuse Reporting
Program (DARP) sample indicated similar improvements for clients in
both types of maintenance programs, our data show considerable
differences. Figures 7-10 are time series graphs for the three program
FIGURE 8
Percent of Nonincarcerated Time Reported as Daily Narcotic Use: Los
Angeles, San Bernardino, and Orange County Methadone Admissions
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FIGURE 9
Percent of Nonincarcerated Time Involved
in Crime: Los Angeles, San Bernardino, and Orange
County Methadone Admissions
FIGURE 10
Percent of Nonincarcerated Time Employed
Los Angeles, San Bernardino, and Orange County
Methadone Admissions
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samples beginning 8 years prior to admission and extending 6 years
after admission. Variables plotted are: daily narcotics use, crime
involvement, and employment. Two features are noted. First, there is
a distinct postmethadone entry improvement for these variables for all
three programs. Second, while there are no consistent patterns of
premethadone differences among the three programs, the postmethadone
results tend to correspond to the proportions of time on methadone,
which are strongly related to the policies of the three programs.
Except for employment, Los Angeles county shows the greatest
improvement, San Bernardino is next, and Orange County shows the
least improvement. In general, Orange County measures are roughly
equivalent to those of the other two programs in the premethadone
period, but are substantially lower in the postmethadone entry period.
These results remain after controlling for race and age. Also, a
similar pattern is found for other variables not shown here:
incarceration, arrest rate (particularly for property and drug-related
crimes), and employment (McGlothlin and Anglin 1981b).
The Southern California findings provide substantial support for
arguments that methadone maintenance programs are not as effective
as they might be because of excessive regulation and a misplaced
emphasis on minimizing dosage levels for moral or political reasons,
rather than choosing a dosage appropriate to the legitimate needs of
the client (Anglin and McGlothlin, in press).
CROSS-SECTION SAMPLES
Of the ten major samples described in table 1, the last four to be
discussed differ from the first six in that they represent not
admissions, but cross-section samples of their respective clinic
populations. In addition, these four samples were not utilized to
determine the effects of treatment entry, but to demonstrate the
effects of the termination of entire treatment programs. One sample
was from the only methadone program in Bakersfield, California, which
closed in September 1976. For the purposes of the followup, all 99
(60 males and 39 females) who were enrolled in the clinic as of June
30, 1976, were included. The second sample, chosen to be comparable
to the Bakersfield sample, was obtained from the Tulare clinic. The
Tulare sampling population was defined as those enrolling after January
1, 1971, and still in the program as of June 30, 1976. A stratified
sample of 59 males was selected, controlling for age and race so that
these characteristics would match the Bakersfield male sample. Since
there were only 29 females in the Tulare program who met the
sampling criteria, the total population was included.
The third and fourth samples were drawn to assess the effects of the
closure of the San Diego County methadone maintenance program (in
December 1978) on client’s drug use, and criminal and social behavior.
The research was also designed to allow an evaluation of the overall
costs and benefits of the substitution of fee-for-service methadone
programs for those supported by public funds. A detailed report of
the findings of this study is available elsewhere (Anglin et al. 1983).
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The San Diego sample was drawn from the 561 enrolled in the County
program as of September 30, 1978. The 50 Veterans Administration
and 11 pregnant female clients who enrolled in the private programs,
but whose fees were paid from public funds, were excluded. A random
sample of 195 males was selected, and the total population of females
(168 after exclusions) was included.
The comparison samples of 129 males and 131 female; were selected
from the combined populations of the continuing Orange, Riverside, and
San Bernardino County programs. All persons selected were enrolled in
their respective programs as of September 30, 1978. The comparison
samples were matched for age and race, but otherwise were randomly
drawn from the combined Orange, Riverside, and San Bernardino
County programs.
Effects of Treatment Entry
The pre- to post- treatment increase in desirable outcomes previously
shown for the early admissions to the Southern California methadone
maintenance programs is duplicated by these four samples and specific
results can be obtained from the original reports (McGlothlin and
Anglin 1981a; Anglin et al. 1983). These replications, for samples
drawn from other geographical regions and programs and representing
different populations of addicts, provide strong confirmatory evidence
for the general effectiveness of methadone maintenance in the
treatment of chronic addiction.
Effects of Treatment Termination
The more important information from the Bakersfield and Tulare
samples, and the San Diego and its comparison sample, partially
answers the corollary question concerning the effects of program
termination. To assess these effects, the date of discharge from the
Bakersfield and San Diego programs just prior to their closing
(September 1976, and December 1978, respectively) was used as the
reference point. Dummy discharge dates of August 31, 1976, and
October 1, 1978, were chosen for the respective comparison samples.
Table 2 compares the status and behavior of the Bakersfield and
Tulare samples for the period from closure to interview. The data are
displayed in terms of the percent of the sample involved in the status
or behavior at some time during the interval. In addition, the mean
percent time of the interval that behavior is involved is given for all
measures except for mean number of arrests. The latter is the mean
of the individual percentages, including those with zero time involved.
Except for the incarceration item, percentages are based on the
individual’s nonincarcerated time during the interval. Arrest data were
obtained from the California Criminal Investigation and Identification
Record. Overall, the percentage of Bakersfield respondents arrested,
incarcerated, or on parole or probation, is about twice that for Tulare.
With respect to arrests, most of the difference is accounted for by
drug and minor offenses (warrants for failure to appear in court, drunk
in public, traffic violations resulting in arrest, and miscellaneous
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misdemeanors). Since the Bakersfield police had an especially active
narcotics task force in operation at the time, it is possible this was
partially responsible for the high percentage arrested in the Bakersfield
sample.
TABLE 2
Status on Behavior from Methadone
Program Closure to Interview (a)
Probably the most relevant variables in table 2 are the number of
Bakersfield clients who became readdicted to heroin, and the percent
of time addicted. Slightly over one-half reported addiction at some
time after termination. Of the eight Bakersfield respondents who
transferred directly to another methadone program after the clinic
closing, only one became readdicted to illicit narcotics. If these eight
transfers are excluded, nearly 60% of the sample became readdicted
subsequent to discharge. Overall, the mean nonincarcerated time
addicted was 26%. Of the Tulare sample, only 26 (31%) reported
readdiction, and the mean nonincarcerated time addicted was 12%. Of
these 26, 22 were discharged from the methadone program prior to
interview, and, for 13, all daily use was subsequent to discharge.
122
Alcohol abuse and drug dealing were substantially higher for the
Bakersfield sample than for the Tulare samples. The percentage of
those interviewed who reported engaging in property crime was similar
in both groups. This is consistent with the arrest rates for property
crime. Of the 19 Tulare clients reporting property crime, 14 had been
discharged prior to interview. Seven reported that all property crime
was subsequent to discharge.
Table 3 presents similar information for the San Diego and comparison
sample. The results here must be interpreted with the knowledge that
private methadone programs were made available in San Diego
immediately after the closure of the County program. Some 40% of
the County program clients transferred immediately to these programs.
The cost to these clients was $100 per month at this time. Table 3
shows the status, or behavior, for the period from program closure (or
pseudo-closure for the comparison groups) up to the interview.
Regarding the differences in the male samples, it is significant that
the proportion of San Diego males arrested (60%) is 12% higher than
the comparison group, a reversal of the criminal justice system
involvement evident prior to methadone treatment entry (Anglin et al.
1983). This rise in arrest rates is primarily due to drug offenses.
Increased criminal justice system contact is also indicated by the
greater proportion (and percent time) of the San Diego sample under
legal supervision.
The proportion of subjects using heroin daily and the percent time
involved in daily use are similar for the San Diego and comparison
samples. The greater involvement in dealing apparent in the
pretreatment entry data is also evident in this period for San Diego
males. The property crime data do not indicate any significant
differences, but the reduced involvement for San Diego noted in the
premethadone period continues to be apparent. Other than for percent
time on methadone maintenance, the female samples do not differ for
the postclosure period.
Generally, because of the higher percentage of clients who arranged
fro private methadone maintenance treatment, the clients terminated
from the San Diego program appear not to be substantially different in
behavior for the period from closure to interview from the comparison
group, except in those areas where pretreatment differences existed.
The exception to this is in the level of legal supervision, which is
significantly higher for the San Diego males.
However, one of the most interesting items overall is the percent not
incarcerated, not in treatment, and not “using” daily at the time of
interview. If this is used as a measure of success, the San Diego
clients tend to show poorer outcomes. When the male and female
samples are combined, 47% of the comparison samples meet this
criterion, while 37% of the San Diego sample do so. This difference
achieves statistical significance (p < .05) and is notable, given the
overall better pretreatment characteristics of the San Diego samples.
In addition, the disruption of the treatment process produced by the
program’s closure resulted in an increased personal cost of treatment
which was beyond the means of some addicts. Further, it may have
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TABLE 3
Status on Behavior from Methadone
Program Closure to Interview (b)
prolonged the addiction status for some who would otherwise have
reduced their drug use and involvement in an addict lifestyle at a
faster rate. For the 60% of the San Diego sample who did not
transfer immediately to private programs, outcomes were much poorer
than for the sample overall (Anglin et al. 1983).
It must be emphasized that the San Diego data represent the effects
of program termination on enrolled clients who had had sufficient
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exposure to methadone maintenance to determine its importance in
their lives. At closure, they had some experiential basis to choose, if
financially possible, to continue receiving treatment on a fee-for-
service basis, unlike the Bakersfield terminated clients, who had no
opportunity to do so. The private clinics thus had a pool of
methadone-sophisticated individuals who either made a commitment to
continue treatment (those who transferred without an interruption in
treatment), or who subsequently chose to re-enter a treatment with
which they were already familiar (the 76 who entered private
methadone treatment after an interruption). An important question
which cannot be answered by these data concerns the extent to which
treatment entry by methadone-naive addicts is rejected or delayed
because of the cost of private treatment. The San Diego and
comparison samples show, respectively, 40% and 37% decreases in mean
annual costs to society for their addiction after entering MM. The
sharp declines in social costs associated with treatment entry are not
realized, of course, until an addict enters treatment. To the extent
that the payment requirements of private programs prevent or delay
“new” addicts from entering treatment, or “oldf’ addicts from re-
entering, addiction periods are prolonged. Also, methadone-naive
addicts may be less likely to enter private programs or once admitted,
be less likely to stay, given the lower level of ancillary services
private clinics can provide for the fee charged. The rehabilitation
process, which may be enhanced by ancillary services, would also be
slowed, and problem behaviors in clients expressed for a longer period
of time. While it is by no means clear that counseling or other
ancillary services are particularly effective in the rehabilitation of
narcotic addicts (especially in light of the expense of these services).
these issues must be given consideration. Consequently, the degree to
which rejection or delay of treatment increases property crime and
criminal justice system costs, which might have been reduced had no-
cost treatment been available, is unanswerable at present. Presumably,
the social and individual pressures which motivate entry to methadone
maintenance treatment would have to be higher when treatment is $100-
$150 per month than when it is at a nominal level. This is
particularly true if an addict couple (where costs are doubled) seeks
treatment.
CONCLUSIONS AND DISCUSSION
The results of our evaluations indicate that both civil commitment (as
represented by the California Civil Addict Program) and methadone
maintenance effectively reduce drug use, dealing, income-generating
crime, and arrests, and, to a lesser extent, increase employment and
family responsibility. While civil commitment can be applied to any
identified addict, methadone maintenance seems to appeal to a portion
of the addict population that has not been amenable to other social
intervention strategies. Although the majority of the socially
beneficial improvements in behavior occur during treatment for both
types of programs, there is evidence of some retention of improvement
after treatment. Furthermore, the strength of the effect is probably
related positively to time in treatment.
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Program policy also seems to be an important element. The policies of
the California Civil Addict Program seemed to produce better outcomes
than did those employed by either the New York Civil Commitment
Program, or the Federal Narcotic Addict Rehabilitation Act. The
policies of the Los Angeles and San Bernardino methadone
maintenance programs produced better outcomes than did those of
Orange County. The higher dosage level and flexible policies regarding
dose changes of the former programs produced more desirable outcomes
than did the relatively low dose level and inflexible policies toward
dose changes of the latter program. Further, termination of treatment,
by program closure prior to a discharge point chosen by the client,
generally produces a “bounce back” effect on behavior toward
pretreatment levels.
Clearly, civil commitment was, and methadone maintenance is now, an
important component of the treatment network for heroin addiction.
Neither has produced the results anticipated by early researchers and
policy planners, but disappointed expectations should not detract from
their real and beneficial contribution to reducing the social and
individual costs associated with addiciton.
It is apparent that overall results are determined, in part, by program
administration and policy, including dosage policies in the case of
methadone maintenance, and that some improvement in the proportion
of desirable outcomes would result from relatively simple administrative
changes. High-dose, relatively flexible MM programs were more
effective than low-dose, inflexible ones.
The elements of the Civil Addict Program which were most effective
were the behavioral ones. First, the behavioral goal was clear and
unambiguous: abstinence. (This goal may have been modified at the
application level [parole officer supervision] to the more practical one
of non-addicted use). Second, behavior was monitored by parole
officers and urine testing. This relatively strict supervision typically
revealed relapse to an addicted state soon after it had occurred
(McGlothlin and Anglin 1977). Finally, if readdiction or other failure
to meet parole requirements occurred, a return for a period of
incarceration was imnmediate. Although this model of monitored
behavior and punishment is not the best behavioral one for modifying
undesirable behavior, it is effective when the period of monitoring is
sufficiently long (three years at a minimum). It must also be noted
that the program included elements of the better behavioral
modification model of substituting more appropriate behaviors for
undesirable ones, and reinforcing the substitutions. During the
incarceration period, educational and vocational training were available
and inpatients were encouraged to utilize them. During the outpatient
phase, parole officers referred addicts under their supervision for
further educational and vocational assistance, and also provided
assistance with other social service agencies, such as medical care or
public assistance.
Methadone maintenance can also be described as a behavioral
modification model, but one with a basically different approach from
civil commitment. Methadone maintenance provides addicts with a
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substitute source of meeting their addiction needs, and negates the
otherwise necessary involvement in income-generating activities (crime,
dealing, and the sexual black market) and with other aspects of the
addict lifestyle. Continued involvement in these activities often
occurs, typically at a much reduced level, as addicts continue to
generate a subsistence level of income or maintain a social involvement
with active addicts. Some elements of the behavioral monitoring and
punishment model exist in methadone maintenance programs, such as
urine testing and disciplinary actions for inappropriate behavior.
Simultaneously, more appropriate social behavior is encouraged via
counseling and referral to vocational training, or to other social
service resources.
Since the etiology of addiction has multiple components, and the
population of heroin abusers is heterogeneous, a number of issues
remain to be resolved. It is not yet clear what percentage of the
total addict population would be amenable to these modalities or which
treatment would be most beneficial at different points in the addiction
process. Civil commitment may be more effective in reducing the
frequency and duration of addicted periods and may promote an earlier
“maturing out” for addicts with shorter addiction histories. Methadone
maintenance may be the treatment of choice for long-term addicts who
have not responded to other attempts at intervention. Additionally, it
has not been established what the characteristics are of those most
responsive to each, and if these characteristics change over time.
Finally, the questions of the effective duration of treatment and what
the ancillary rehabilitation components should be for each are still
unanswered. While the treatments described are generally effective
for substantial numbers of chronic addicts, it is unlikely that any major
improvement in their outcomes, above those already demonstrated, can
be achieved without answers to these questions.
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Psychotherapeutic Approaches in
the Treatment of Drug Abuse
Charles P. O’Brien, M.D., Ph.D., George E. Woody, M.D.,
and A. Thomas McLellan, Ph.D.
ADVANCES IN PSYCHOTHERAPY RESEARCH
The effectiveness of talk therapy has been debated for decades.
Some authors have contended that patients treated by psychotherapy
are no better off than waiting list controls and that experienced
therapists are no more effective than inexperienced ones. While
there have been substantial numbers of studies which have found
psychotherapy to be effective, there is agreement that the process
of therapy has been difficult to control and the outcome has been
exceedingly difficult to characterize and quantltate.
In recent years, however, the science of psychotherapy research has
advanced considerably. Controlled studies now include better
patient selection, use reliable diagnostic instruments, specify and
identify therapies using manuals, and include valid, comprehensive
outcome measures. These techniques have permitted a more precise
analysis of the effects of psychotherapy and are leading to clearer
concepts of the benefits and liabilities of psychotherapy.
Perhaps the most important development which has advanced
psychotherapy research has been the improved classification of
patients. The standard use of structured diagnostic interviews as
well as standardized diagnostic criteria (e.g., RDC or DSM III) has
permitted greater homogeneity in subject populations selected for
study.
This in turn has allowed more fine-grained analysis of therapy
effects by enabling patients with similar prognosis to be randomly
assigned to control groups and competing treatments. Of course,
current diagnostic instruments have not been in use long enough to
have satisfactory validity testing by showing that they predict
natural history or course of illness. Also, the diagnoses have not
always shown stability over time. However, the instruments have
shown excellent reliability in that multiple clinicians
independently rating the same patient in the same time period have
obtained similar results.
There have also been improvements in techniques used to investigate
the process of psychotherapy through analysis of taped therapy
sessions. Rating instruments have been developed to measure such
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complex phenomena as patient-therapist interaction and the degree of
direction versus support provided by the therapist. Although
measurement of these phenomena is not easy, results have shown
significant reliability when independent raters review the same
sessions. Taped sessions have also permitted the verification of
the specific type of therapy that is actually being administered.
All of these techniques lead to greater objectivity and precision in
controlled comparisons of types of psychotherapy.
Psychotherapy in Addiction
Clinicians have noted the high degree of psychopathology displayed
by opiate addicts, and that the use of illicit substances frequently
occurs in response to psychiatric symptoms (Khantzian et al. 1974).
In this context, addiction itself has been viewed as self-medication
in an attempt to avoid depression, anxiety, and other psychiatric
symptoms (Wurmser 1979). Recent studies indicate that the types of
psychiatric problems observed in addicts are similar to illnesses
which are often treated with psychotherapy when they occur in
nonaddict populations (Rounsaville et al. 1982). Yet many workers
both within and outside the addiction field have been pessimistic
that professional psychotherapy could make a meaningful contribution
to the treatment of the addicted patient (Bourne 1975; Karkus
1973). This opinion may originate from two lines of experience.
First, there have been numerous attempts to do psychotherapy with
addicts in private practice settings. Here, the patient's need for
drugs and the acting out behaviors that develop around this need
have commonly undermined the chance for a therapeutic relationship.
Second, there has been the perception that all addicts are simply
sociopaths, and that psychotherapy would not work for sociopathy.
Part of this perception appears to have its roots in studies
originating from the Addiction Research Center in Lexington, which
may have involved particularly high levels of sociopathic behavior
because the treatment setting was a Federal penitentiary.
However, there is some evidence to suggest that psychotherapy may be
both practical and helpful with addicts if given under certain
conditions. For example, the development of methadone maintenance
treatment programs has provided a means to reduce much of the
addict's intense, impulsive, and daily search for illicit
substances. Stabilizatlon with methadone has permitted the
development of therapeutic, long-term relationships and thus, in
theory at least, methadone programs might provide a medium in which
psychotherapy could be employed effectively. In addition, the most
recent studies on psychopathology in methadone-maintained patients
showed that depression and not sociopathy is the most commonly
diagnosed psychiatric disorder, though sociopathy is certainly well
represented (Rounsaville et al. 1983). Further, about half of those
patients with a diagnosis of sociopathy also have other psychiatric
problems. Thus, there is reason to believe that psychotherapy may
be capable of providing benefits to addicts, especially if it is
delivered in a methadone treatment program.
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Review of Controlled Studies
No published studies on the effectiveness of psychotherapy with this
population appear to have been done prior to 1970. The one
exception was the work done by Nyswander et al. (1958) which was
completed before the development of methadone treatment. In this
study, professional psychotherapy was advertised as available and
offered to any interested addicts in New York City. Only seventy
people responded by contacting the clinic and only 13 of these
became regularly engaged in therapy. These engaged patients had an
average of 35 appointments with psychotherapists over a period of
approximately 1 year. They were compared with a control group of 22
minimally treated patients who kept an average of 8 appointments.
Although the treated patients showed more benefits than the
minimally treated patients, the investigators decided that the role
of psychotherapy in treating opiate addiction was minimal because so
few patients applied for therapy and because only a small proportion
of those who applied actually became engaged.
Since 1970 there have been other studies of psychotherapy with
addicts, and most of these were done with methadone-treated
patients. In eight of these studies, opiate-dependent patients were
randomly assigned to psychotherapy or to a treatment control
condition, usually drug counseling. Six of the studies (75%) showed
a better outcome in the psychotherapy condition than in the control
condition (table 1). The overall conclusion reached from a review
of these few studies is that there is evidence to indicate that
psychotherapy can be helpful for opiate-dependent patients. This
type of review and conclusion is similar to that reached by Luborsky
et al. and others in their overviews of many diverse psychotherapy
studies of treatment efficacy for psychiatric patients in general
(Luborsky et al. 1975; Smith et al. 1980; Andrews and Harvey 1981).
TABLE 1
Controlled Studies of Psychotherapy with Addicts
No
Authors Psychotherapy Better Difference
Willett 1973 X
LaRosa et al. 1974 X
Abrahms 1979 X
Connett 1980 X
Resnick et al. 1981 X
Stanton et al. 1982 X
Rounsaville et al. 1983 X
Woody et al. 1983 X
SUGGESTIONS FOR FUTURE RESEARCH
Practical Issues
Although the overall conclusions from both past studies and recent
research indicate the benefits of psychotherapy, recent experience
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with conducting controlled comparisons of different types of
psychotherapy has highlighted several practical issues which must be
considered in any future research. First, the research program
should be considered a central part of the treatment program.
Research studies encounter great difficulties when they are
structured as add-ons to a busy treatment program. There is a
natural tension between clinical and research staff which tends to
be exploited in such situations. Ideally there should be an overlap
between clinical and research staff and the principal investigator
or one of the central figures in the research should also be the
clinical director of the treatment program.
Another important issue in conducting psychotherapy outcome research
in a substance abuse population is that the therapists themselves
should be at least part-time members of the treatment staff.
Therapists who are paid by the hour and who give patients
appointments in the private practice model at-e at a distinct
disadvantage to those who are in the clinic for large blocks of
time. The latter staff member/therapists are able to see patients
who drop in at unscheduled hours. Substance abuse patients tend not
to lead orderly, structured lives and thus they have a poor record
of keeping appointments. While improved life organization may be an
important goal of therapy, it is unrealistic to expect patients to
have such independent and organized behavior and to keep
appointments at the beginning of treatment.
Data Collection Instruments
In 1975 the National Institute on Drug Abuse held a drug treatment
efficacy conference in Reston, Virginia. One of the facts which
became obvious during this conference was the need for a generally
agreed-upon measure of the severity of the addiction syndrome. It
was clear that addiction was a multi-dimensional condition which
could not be accurately described by measures taken in only one
domain. The Addiction Severity Index (ASI) was developed by a group
of clinical researchers to fill this need (McLellan et al. 1980).
The ASI is a structured clinical interview which may be administered
by a technician in 30-40 minutes, producing 10-point problem
severity ratings in each of six areas commonly affected by
addiction. The ASI has been found to be useful not only as a
clinical tool for evaluating patients but also as a research
instrument for categorizing patients and for measuring change in the
six outcome areas following treatment. Future research comparing
treatment outcomes should include a comprehensive evaluation
instrument such as the ASI in order to adequately describe the
patient population, to study the relationships between various areas
of disability, and to provide a standardized and comprehensive
assessment of treatment effects.
Another issue that is potentially important in designing and
conducting research in this area is the presence of a psychiatric
diagnosis and the measure of its severity. Patients all tend to
have serious substance abuse problems at the time of admission to
treatment, but there is great variability In the severity of their
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psychiatric problems. Consequently, future research should focus on
the severity of different types of psychopathology found among
addicts. The Schedule for Affective Disorders and Schizophrenia-
Lifetime (SADS-L) has been found to have a high degree of
reliability in psychiatric populations including drug-abusing
populations. Recently, however, it has been shown that even SADS-L
diagnoses change significantly over time. Thus Rounsaville and
colleagues (1981) found 6-month and l-year repeat SADS-L diagnostic
interviews to show marked changes from the lifetime diagnoses made
at the initial evaluation. Future research, therefore, should be
directed at a closer examination of this phenomenon. Perhaps it is
the severity of psychiatric problems rather than the type of
psychiatric problems which is the best predictor of treatment
outcome.
Finally, psychotherapy outcome studies in substance abuse patients
should utilize all of the sophisticated techniques of psychotherapy
research which have been developed over the years. These include
the use of treatment manuals, the use of regular supervision of
therapists, the audio-taping of sessions, and the independent rating
of sessions by external observers. Such techniques insure quality
control and enable a more precise analysis of the factors leading to
the observed results.
Natural History
An area of treatment research which has been neglected because of
the great difficulties in doing such studies is that of the natural
history of untreated addiction. Available data on the consequences
of addiction are obtained from those individuals who apply for
treatment. In the best studies, treatment dropouts are followed as
well as those patients who remain in treatment. However, this does
not provide us with information on those individuals who never apply
for treatment. We do not know whether users who do not seek help
are qualitatively different, or whether they are just in a
preliminary stage which will eventually lead them to reach a stage
requiring treatment.
Treatment Outcome Studies
There have now been three large-scale national studies of the
treatment of drug abuse during the past 10 years. These are the
Veterans Administration study (Lorei et al. 1978), the DARP study
(see chapter in the volume), and the TOPS study (see chapter in this
volume). All of these had a basically similar design in that they
collected demographic data on patients at the time of admission to
treatment, using a variety of social and psychological measures.
They also included a series of intreatment measures and
posttreatment measures. These large studies all provided useful
information, and they were unanimous in showing substantial changes
in those patients who remained in treatment, with longer treament
generally being correlated with better outcome. Individuals who
dropped out of treatment early generally showed much less
improvement over time. It is now appropriate to move from such
large studies to more focused studies of particular patient types
and particular treatments.
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SPECIFIC THERAPIES
TABLE 2
MAJOR MODALITIES
Meth. Therapuetic
Maint. Detox. Antagon. Community
Psychotherapy
Cognitive
Supportive-Expressive
Behavioral
Group
Family
Vocational Counseling
Psychoactive Medication
Anti-Depressant
Anti-Manic
Neuroleptlc
Anti-Anxiety
A typical patient may receive more than one major
modality (columns), in any sequence, although usually
only one at a time, and several specific therapies (rows)
in any order and in different columns.
Future treatment outcome studies should include random assignment of
homogeneous groups of patients to different treatment modalities. On
the basis of past attempts, it seems apparent that random assignment
between major treatment modalities such as therapeutic community and
methadone maintenance is not feasible (Bale et al. 1980). In a
well-designed, energetic attempt to accomplish such a random
assignment, Bale and colleagues found that the majority of patients
went to the modality which they desired rather than the one to which
they had been randomly assigned. However, it is possible to
accomplish random assignment within a major modality (table 2). Good
examples of this are found in the two NIDA-sponsored psychotherapy
outcome studies (Woody et al. 1983; Rounsaville et al. 1983) in which
all patients received methadone maintenance, but patients were
randomly assigned to different types of control or psychotherapy
modalities.
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Genetic Studies
Another area for future data collection should include family
history. Future studies of treatment efficacy should all include a
standard assessment of family history, not only of substance abuse
problems but also of other illnesses, particularly psychiatric
illnesses. The important findings on genetic aspects of alcoholism
make such studies in other areas of substance abuse imperative.
Biological Factors
At the present time it is not feasible to collect biological
measures in most treatment outcome studies. Longitudinal measures
of endorphins in patients undergoing treatment, however, are
currently being conducted in one center (O'Brien et al. 1982).
Eventually, such biological measures may become an important
component of diagnostic assessment and assignment to appropriate
treatment.
CONCLUSIONS
Drug abuse treatment has been extensively evaluated. It has been
the subject of three large-scale studies and several focused,
controlled studies. All of the large-scale followup studies and
most of the controlled studies have found the treatment of drug
abuse to produce substantial positive results, though no treatment
has been developed that offers a high probability of cure. Future
research should involve greater specificity. Patients should be
categorized in more detail and randomly assigned to comparison
groups within a large treatment modality. Recent work indicates
that severity of psychopathology may be a reliably measured variable
which is highly predictive of outcome.
The following specific recommendations should be considered by NIDA:
1. There should be an attempt to obtain some degree of consensus as
to the appropriate battery of testing devices to be included in
treatment outcome studies. Improved diagnosis has been very helpful
in other areas of medicine and psychiatry, such as that of affective
disorders. All treatment outcome studies should include a minimum
battery of tests which should have at least one multi-dimensional
measure such as the Addiction Severity Index. In addition, studies
should include other more focused measures such as the SADS-L or a
social functioning scale, depending on what questions are being
asked in the study. Having a minimum battery for each study,
however, would help to standardize treatment outcome studies in the
field of substance abuse.
2. Future studies should be designed not so much to compare one
treatment with another but rather to determine which patient best
responds to which type of treatment. Although sequential treatments
involving multiple interventions are difficult to study
experimentally, clinical evidence indicates that such complex
studies may be necessary. For example, some patients respond to the
sequence of methadone maintenance, detoxification, and naltrexone,
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with ongoing psychotherapy throughout (O'Brien et al. 1983). A
diagram of the ways in which major treatment modalities interact
with specific therapies is shown in table 2. Psychotherapy or
chemotherapy may cut across major modalities.
Random assignment between major modalities may be impractical, but
random assignment between specific therapies has been effective and
informative. Thus future studies could utilize specific types of
patients (e.g., high severity on ASI) in a specific major modality
(e.g., methadone maintenance).
3. Many of the clinicians providing excellent treatment in the
field of substance abuse are inexperienced in the methodology of
treatment outcome studies. NIDA could provide a service to the
field by making technical information available concerning minimal
requirements of controlled treatment studies. This would include
recommendations regarding the battery of tests to be used in
describing the patient population and the scales to be used in
measuring changes in response to treatment. It would also include
the recommendation of publications describing treatment outcome
methodology, such as that published by the National Academy of
Sciences, Committee on Substance Abuse and Habitual Behavior
(Guidelines for Studies in Substance Abuse Treatment, NAS, 1981).
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Clinical Implications of Drug
Abuse Treatment Outcome
Research
Edward C. Senay, M.D.
The most important fact established by the scores of outcome
studies conducted in the past 15 years is that drug abuse treatment
works (NIDA 1982; Bray et al. 1982; Craddock et al. 1982; Simpson
and Sells 1982; De Leon et al. 1982). The number and quality of
studies carried out demonstrate, as well as can be realistically
expected from any set of studies, that positive changes in client
functioning occur during and after drug treatment. While there
have been programs that have been poorly run and have encountered
serious credibility problems, there can be little question that,
from a public health and national point of view, many people have
been helped by drug treatment.
There are numerous issues relating to treatment outcome, structure,
process, and the changing nature of the drug abuse field and its
treatment populations. I will limit the range of issues to be
considered in this paper to a few of these, based on my impressions
of existing treatment evaluation research and my experience as a
clinician and program director involved in the treatment of drug
dependency. The clinical implications presented here have largely
to do with how and by whom treatment is delivered, and in what
context; how do they affect treatment outcome, and what aspects
should we study in future evaluations? Specifically, I wish to
address the following areas: (1) the structure of treatment
programming and treatment process as they presently exist; (2) the
changing structure of treatment systems, and ways in which change
should be guided; (3) qualifications, training, credentialing,
licensing, and role definition for counselors in an emerging drug
treatment system; (4) the need for special training for those
outside the drug abuse field who are involved in service
delivery/referral of drug abusers; (5) the need for both
professionals and clients to better understand the nature of drug
dependency and the variety of factors which have a bearing on
outcomes; (6) the need for new strategies to improve retention;
(7) improving clinic organization and operation; (8) the need to
better disseminate research findings to the field; and (9) the need
for special studies to better understand emerging drug use
patterns, special needs of treatment populations, and promising
interventions.
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There are two distinct drug abuse treatment issues that have not
been adequately addressed in evaluation efforts but are of crucial
importance to the future success of drug treatment. One is
structural; that is, how drug abuse treatment can be coordinated
with existing service systems. For example, attention must be
given to the relation between drug treatment and standard health
care systems such as mental health and medical health care
institutions and agencies. Drug abuse programs are supposed to
have links wlth hospitals and other community-based service
systems, but these links are generally honored more on paper than
in practice. Drug clients are often too poor for the private care
system and too well off for the public care system. This factor,
combined with negative attitudes toward the problems of substance
abuse, perpetuates parallel systems of care which, in effect,
create second class care for many of the substance abusers'
problems, especially thelr medical and psychiatric problems.
Agencies charged with the future course of drug abuse treatment
must closely examine the feasibility of linking drug treatment with
hospitals in a meaningful way. In such experiments, hospital
administrators will need training in administration of drug clinics
located near or on hospital grounds. Hopefully, the establishment
of Employee Assistance Programs in hospitals will help pave the way
for acceptance of substance abuse treatment in hospital outpatient
facilities. The possible benefits to patients far outweigh the
costs (which are largely attributable to negative attitudes) of
such programs.
The second issue of importance to the future success of treatment
concerns process--how different treatment components or phases of
treatment contribute to client outcome. What are the best modes of
therapeutic interaction in individual or in small group
situations? There are many process questions to be explored; how
should we prioritize this research in relation to research on
structural questions? My bias is that structural experiments are
much more likely to pay off than process experlments. This
judgment is based partially on a conclusion that resources are
limited for either kind of exploration. Even a brief reading of
process therapy research (Smith and Glass 1980; Garfield and Bergin
1978) should convince anyone that process research is extremely
complicated and requires an extensive investment of time and
resources. The report of patients' satisfaction with treatment
summarized in the TOPS data (e.g., Bray et al. 1982) indicates that
programs are doing well clinically. I believe that much more can
be gained from structural changes in the treatment system.
It is far more important to train the staff of a community mental
health center (CMHC) to accept and to use modern treatment methods
for drug abusers than it is to explore counselor-patient exchanges
in the current drug treatment network. CMHCs constitute a
potentially important but underutilized resource for treating drug
abuse clients. CMHCs treat many drug abusers, perhaps in greater
numbers than are treated ln the drug abuse treatment system,
although most do not have drug treatment programs. Therefore,
there is an urgent need to organize systematically and provide
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training support for staff in CMHCs. Given current training and
attitudes in psychiatry, social work, psychology, and nursing, it
would be an error simply to charge the CMHCs with offering drug
abuse treatment without offering training support. Research is
needed to assess the capability of different CMHCs to deliver
treatment to specific kinds of drug abusers, to identify the
knowledge and skills required, and to determine the usefulness of
different training methods and tools. The results of this research
will help prepare the CMHCs for this role.
While the competition for third-party funds is inducing some CMHCs
to add drug abuse services to those routinely provided, preliminary
and fragmentary evidence suggests that this is far from common in
CMHCs (Burke et al. unpublished). Moreover, the incentive of
third-party payment may lead hospitals and CMHCs to be more
selective. Thus, they are more likely to treat patients who have
better social resources (e.g., the employed drug abuser) suggesting
a better prognosis, while shifting the more problematic and needy
client onto the free-standing drug abuse treatment programs. Yet
these clients are likely to be in need of the range of services
which are more readily available in CMHCs and hospitals. For
example, the pregnant addict is in need of both drug treatment and
prenatal health care, as well as other services, but she is far
more likely to receive these services if they are provided in the
same facility. In an integrated setting, she has the benefit of
coordinated care and is spared unnecessary travel.
Research in the past decade has established that substance abuse
populations have significant rates of psychiatric problems, i.e.,
personality disorders, depression, and phobic disorders (Bray et
al. 1982; Rounsaville et al. 1983); and it is the exception rather
than the rule that the schizophrenic addict gets appropriate care.
The mental health system rejects the schizophrenic addict because
he or she is an addict, while the drug abuse treatment system
rejects the schizophrenic addict because he or she is schizo-
phrenic. This is part of a larger mosaic which suggests a need to
reevaluate the treatment system and develop policies and
forward-looking leadership to bring about a better integration of
services. The ideal model treatment system to explore would be one
in which drug treatment facilities (therapeutic communities,
methadone maintenance, and outpatient drug-free programs) are
linked clinically and administratively to community-based service
systems that provide job skills training, mental health and general
health care, etc.
The outcome research of the past 15 years provides a solid basis
for legitimizing and standardizing substance abuse treatment. An
important next step is for single State agencies to take the lead
in the licensing, credentialing, and accreditation of workers in
the field. Hopefully, there would be coordination between the drug
and alcohol fields in this regard. There is, of course, a need for
a systematic training program through which substance abuse
clinicians would receive training in different modalities. For
example, clinicians might work in a therapeutic community for a
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year, the following year in a methadone maintenance program, and
the following year in a drug-free outpatient program. The purpose
of this type of training would be to broaden the horizons and,
consequently, the expertise of workers in the field. Such a
cooperative program could also include clinical experiences which
would span alcoholic and mental health treatment modalities as well
as drug abuse treatment modalities. The training program might be
modeled on the Career Teacher program, with the single State
agencies providing the necessary administrative support. "Lead
clinicians" could be attached to single State agencies to provide a
much-needed link between clinical and administrative functions.
Third-party payers would welcome such a training program. Once
licensing standards and mechanisms for accreditation and creden-
tialing are established, the drug treatment system will be in a
better position to develop formal linkages with the general health
care delivery system. If licensing and credentialing are
established by State/government agencies with the cooperation of
groups such as the Association of Labor and Management
Administrators and Consultants on Alcoholism (ALMACA) and the
National Association of Alcohol and Drug Abuse Directors (NASADAD),
programs can become eligible for third-party payment and, as a
result, have much-needed financial stability.
The multipurpose counselor who works with substance abusers should
have a wide range of skills and should be experienced in particular
clinical methods and techniques, i.e., conducting self-help groups
like Alcoholics Anonymous (AA) and Narcotics Anonymous (NA). By
being exposed to a variety of treatment modalities, drug clinicians
will be seen as having particular skills and knowledge to offer
rather than being identified with a particular service modality. A
concerted effort should also be made to bring mainstream health and
mental health professionals into this program for cross-training
and certification, to improve their ability to provide appropriate
treatment or referral, and to enhance the quality of services
provided to drug abuse clients.
In addition to the need to legitimatize the field by licensing,
there is a need to upgrade the training of professionals and
nonprofessionals in other fields who come into contact with drug
abusers, including physicians and nurses. Prior to being permitted
to work in a drug abuse program, all clinicians should undergo
basic introductory training in addition to their residency.
Counselors, social workers, psychologists, and others involved in
substance abuse programs need similar training to get them out of
the one-channel treatment mode and to realize that there are many
more similarities than differences between treatment methods. It
should be clear from the foregoing that the old division between
alcohol and drugs no longer has much meaning clinically. As
suggested above, efforts should be made to create a broad treatment
role such as substance abuse counselor, chemical dependence
specialist, or whatever term is most appropriate. The name is not
as important as the ability to deliver a range of services for all
problems that people create for themselves with intoxicants.
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The treatment outcome research conducted in the past two decades
has other important implications for clinical practice in the drug
field. Evidence has been produced that just as substance abuse
tends to become a career, so does substance abuse treatment;
studies show that drug abusers tend to have multiple treatment
episodes (Simpson and Sells 1982). There is some disjunction
between this apparent reality and the perception of many, both
inside and outside the treatment community. Many researchers,
practitioners, and clinicians have assumed that treatment should
occur once and should result in cure if it is to be termed
effective. Substance abuse does not appear to be the kind of
problem that makes this orientation pragmatic. When the community
in which people live is so strongly pro-intoxication, it is not
surprising that treated persons are recruited back into the drug
lifestyle. Steps should be taken to orient people to the fact
that, while treatment does not need to be applied forever, repeated
episodes of treatment are probably necessary for most who develop
serious problems with intoxicants. It should be accepted that
repeated episodes are necessary for some and do not indicate
failure on anyone's part, but merely reflect the nature of the
problem and the culture in which we live.
If clinicians in the field are confused about such matters, imagine
the plight of the patients or clients. They come to the treatment
experience with the notion that they are seeking a cure, and they
receive reinforcement for this unrealistic expectation. It makes
better sense to acknowledge that some clients will experience
repeated treatment episodes unless cultural and community
conditions change dramatically. Treatment may be more or less
intensive. For the more fortunate, it may only require one or a
few episodes. But it is reasonable to expect that treatment of
substance abuse is likely to require a sustained commitment, as is
found in other treatment approaches. People in Alcoholics
Anonymous are forever "recovering," not recovered. This concept
applies to the treatment of most intoxicant-related problems.
Outcome research findings suggest that the longer we can retain
people in treatment, the less pathologic the substance abuse career
(National Institute on Drug Abuse 1981). Therefore, both access to
treatment and reentry into treatment should be easy. To accomplish
this objective, we should provide for keeping people in the
treatment system when they are excluded from a particular element
of that system. Outcome research indicates that administrative
discharge is a frequent end to treatment episodes. Those clients
who are administratively discharged from a treatment program but
need further treatment often represent a loss to themselves and to
society. To the extent that we can retain them in some treatment,
albeit under changed circumstances, both the client and society are
likely to benefit. The Illinois Treatment Program had considerable
experience with this problem. Instead of excluding patients who
had to be discharged from regular units because of threats of
violence or misbehavior of some kind, clients were transferred to a
"Losers Unit." As a result, the Illinois program was able to
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maintain well over 50 percent of such patients in the treatment
system. This was both to their advantage and society's (Senay
1981).
Another problem with the organization and delivery of treatment
services in the drug field is scheduling. If programs were
coordinated better, it would be possible to stagger admission times
so that working addicts could obtain treatment in the early morning
or late evening or whenever it would fit their working schedules.
Weekend admissions could be increased by utilizing treatment units
as part of a treatment system. There is a need to have studies
comparing the success rates of communities that utilize isolated
drug treatment units with communities that have implemented
multimodality concepts. To date, most single State agencies have
failed to view treatment units as a system, with the result that
there is much duplication of weekend coverage and no specialization
of treatment units to deal with special problems such as pregnancy
or severe psychiatric problems. Consequently, there is an
unnecessary duplication of services and loss of resources.
In future attempts to evaluate the treatment system, it will be
important to focus more attention on the consumer. Not only can
clients provide data on which aspects of treatment are efficacious,
but they can also provide insight regarding the dynamics of
treatment and the gaps in service.
Studies (McGlothlin 1979; Simpson and Sells 1982; Bray et al. 1982)
show that crime rates of addicts drop substantially during and
after treatment. Further research is needed on the kinds of crimes
that decrease during treatment. The long-term success of the
Treatment Alternatives to Street Crime efforts suggests that
substantial gains can be made through collaborative efforts
involving the criminal justice systems (National Institute of Law
Enforcement and Criminal Justice 1979; Collins et al. 1982). The
fact is that mandatory treatment has benefited both society and the
addicts. So, efforts like those reported by Brill and Lieberman
(1969), which examined the role of rational authority and coercion
In treating addicted probationers, should be applied to addicts
with significant criminal involvement. It would be useful to have
more data on specific changes in criminal behavior to determine
possible correlations with intervention strategies.
FUTURE RESEARCH
To understand the benefits of treatment to clients, researchers
must look beyond the outcome measures that have been used thus
far. Evaluators must consider the value inherent in the ideal
concept of health or total well-being. If the addict survives
heroin addiction to only to die of a carcinoma of the lung, is
that a triumph? Treatment outcome data show that illicit drug use
is reduced by treatment. However, while people in treatment may
have decreased their use of illicit substances such as heroin or
other non medically prescribed drugs, their use of legal
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intoxicants sometimes increases substantially. Researchers at
the University of Chicago (Senay et al. 1983) have just completed a
3-year study evaluating the effectiveness of comprehensive health
programming. More specifically, the study was designed to assess
the benefits of health-oriented counseling in which clients made a
conscientious effort to improve their overall health through
exercise and good eating habits and to confront their cigarette
and/or marijuana smoking as well as their heroin addiction. New
knowledge was gained through this study which can be applied to
future attempts to create rational treatment. It was learned that
many addicts share the general population's concerns about the
health consequences of intoxicants such as alcohol and nicotine and
can be persuaded to do something about them. Once again, the goals
of treatment and, consequently, of outcome research need to be
examined.
Studies are needed on the relative success or failure of programs
as a function of program size. In the early days of building a
treatment system in Illinois, large clinics were built on the basis
of clinical experience (some had a census of 150 patients or
more). It was felt that therapeutic communities should have no
more than 50-75 clients in any one unit. It would be important to
know from a therapeutic effectiveness point of view whether large
clinics with 100 or more clients are as effective in rehabilitating
drug clients as are smaller clinics. Because of implications for
resource management, these research questions should be of
particular interest to single State agencies.
The idea of a large mother clinic with satellite clinics for
special needs (e.g., advanced patients who are working, have years
of clean urines, and no arrests) also merits exploration. This
kind of arrangement could spread resources more effectively, and
perhaps enable programs to increase treatment slots or add
specialized services.
There is a need for studies comparing public with private programs
because clinical experience indicates final outcomes are
different--probably because public and private populations are
different. Ideally, of course, we should have a system in which
private treatment efforts function in concert with public
programming.
Old research questions regarding the usefulness of urinalysis have
not been adequately answered. Many clinicians feel that urinalysis
only confirms signs that are otherwise communicated. It is usually
obvious to a clinician that a person is not doing well, and routine
urines are not needed to confirm this. Havassy and Hall (1982)
found no difference in outcome as a function of using clinical
urinalysis. Such assays are expensive, and their exact role for
clinical purposes should be studied. The role of urinalysis in
treatment outcome studies is extremely important, but the focus on
clinical use can be kept separate from the focus on evaluation
use.
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Researchers should also consider evaluating outreach, in
conjunction with a multiservice system that includes services
provided by drug, mental health, and health agencies in a
coordinated, community-based effort. A variety of outreach
strategies are available and it would be useful to know which are
most (and least) effective for different treatment populations and
service configurations.
Another aspect of the treatment process which needs study is the
initial phase when the client makes the decision to seek
treatment. Both Beck Depression Index and Hamilton Depression
Scale scores have been found to be elevated at the point when a
client comes into treatment and seem to recede whether people stay
in treatment or leave. These scores also recede whether or not
they receive treatment for depression (Dorus and Senay 1980).
After decreasing, the scores are still elevated in comparison to
norms. There is a need to understand these phenomena much better
than we do. It would also be useful to study patients with high
scores on the Beck or Hamilton Scales who are treated with standard
psychiatric techniques. This is the kind of study which could be
carried out more easily in the comprehensive treatment model
previously suggested in this paper.
There are indications that both drug clients and drug treatment
programs have been changing. Drug abuse patterns of 1983 are not
the same as those of 1973, and the changes are significant for
treatment. The drug abuser of 1983 is much more involved with
multiple drugs, some of them relatively new (insofar as treatment
is concerned), such as phencyclidine, cocaine, and marijuana. This
produces serious clinical problems, with implications for
management that are still unclear. The drug abuser of today is
much younger, is more often female, and is more geographically
mobile than the drug abuser of 1973. Retention in treatment is not
as long as it was in the 1970s. In many communities, methadone
treatment is not as acceptable as it once was, and consequently
success rates are not as good as they once were. One can always
expect a lag between institutional arrangements and the appearance
of new social problems; this appears to be what has happened in the
drug field. The problems are changing faster than the treatment
approaches, so we need continued macro studies like DARP and TOPS
as part of a coordinated strategy which employs a mix of macro
studies and micro studies. The kinds of micro studies which would
be an appropriate part of such a strategy are exemplified by that
of Newman and Whitehill (1979) in their clinical study of methadone
maintenance in Hong Kong.
People who work on line in the field need new knowledge. How
should they respond to the new problems with cocaine free-basing or
with young people who say that they are dependent upon marijuana
but that this (drug use) is not a problem? Therapeutic communities
and methadone maintenance, as well as AA, are having trouble
responding to some of the contemporary substance abuse problems.
People in the front lines need to know what others are learning
about these problems.
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The morale of workers in the field is obviously important to their
clinical effectiveness; unfortunately the message that treatment--
at least some of the classical forms of treatment such as thera-
peutic communities and methadone maintenance--has proven to be
effective has not been adequately communicated to those in the
field. Instead, they are exposed to many negative stories about
methadone in the media. For example, a newspaper account which
concluded that methadone led to reduced motivation in people was
actually based on experimental animal studies. One would get the
impression that methadone treatment did not work and that the drug
is harmful to patients. This kind of false extrapolation from
animal data to humans neglects the massive amount of data gathered
in scores of evaluation studies involving humans. Counselors read
these accounts in newspapers and ask questions about them, as do
patients, and both are sometimes confused and concerned as a
result.
We need to continue disseminating information to the field and to
get across the message that: (1) we have built a treatment system
that works for many people, and (2) we have to continue to build
upon our knowledge and skill because clinical problems are
changing. These messages, presented in the right way, could be an
extremely important unifying agent, and hopefully would reduce
factionalism in the field.
A growing number of studies (Willett 1973; Longwell et al. 1978;
LaRosa et al. 1974) indicate that formal psychotherapy may have
something to offer addicts. With the increasing recognition that
many clients are multiply impaired, that treatment of addicts is
frequently complicated by major depressive illness, alcoholism, and
other disorders, it behooves those charged with treating addicts
(and other drug abusers) to delineate and provide appropriate
interventions. McLellan and his colleagues (1979) have had some
degree of success in Philadelphia in improving outcomes for the
severely disturbed client, and have specified some conditions under
which the psychotherapeutic intervention is more effective. The
use of talking therapies and pharmacological agents (e.g., anti-
depressants) to improve outcomes and increase client retention
(which may itself improve outcomes) should be further explored,
systematically tested, and elaborated.
Findings from such studies as the DARP research (Simpson and Sells
1982) might lead some to suggest less emphasis on detoxification
strategies and more emphasis on those treatment approaches that
have proven to be effective and economical (e.g., methadone
maintenance, residential). Detoxification programs have been less
effective in achieving subtantial lasting positive gains. But
again, there is a tendency to regard separate treatments as
unrelated one to the other. From a clinical point of view, we need
detoxification programs to treat episodes, reduce the length and
severity of "runs," and to attract addicts into the treatment
system. Thus, it is important that the field appreciate the place
of detoxification in a system of treatment service delivery.
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Studies should be designed to evaiuate the unique contributions
that detoxification programs make rather than comparing
detoxification results with the results of other treatment
modalities.
Further studies en treatment outcomes for females are also in order
for the future (Beschner et al. 1932). Micro studies of this type
should be high on the evaluation agenda. Micro studies should also
focus on issues such as take-home policy. Do restrictive policies
have an impact on diversion beneficial enough to offset the
decrease in acceptability of treatment? In a similar vein, a focus
of other micro studies should be the question of what duration of
poor performance programs will tolerate. For example, staff at the
University of Chicago Clinic will not really "crack down" until a
client has about a 6-month record of poor performance. At that
point, improvements are expected or the patient is threatened and,
in fact, discharged if performance does not change. Micro studies
are also needed to determine whether clients who have a high
frequency of past criminal behavior require special programmlng.
Studies such as the DARP (Simpson and Sells 1982) have shown
criminal background to be a a powerful predictor of outcome.
Another area in which the drug abuse treatment system can benefit
is from outpatient self-help groups. Unfortunately, AA and NA tend
to be ideological about methadone. There is a need to develop and
evaluate the effectiveness of self-help groups which do not
discriminate against those taking medically prescribed drugs.
To summarize, future evaluation policy should continue macro
studies such as DARP and TOPS with the provision that new clinical
problems be included in the assessment, e.g., cocaine free-basers
and marijuana-dependent patients. A supplementary set of micro
studies would complement macro level studies. Studies at both
levels should focus on a range of issues which the research of the
past decade has indicated are important in treatment outcome, e.g.,
criminal history, pyschlatrlc status, and the length of time poor
progress in treatment should be tolerated. Policymakers should
rank issues and then articulate a coherent policy of evaluation.
As was the case with the TOPS research, the consumer should
continue to be included in evaluatlon studies. Finally, a decision
should be made vis-a-vis structural studies vs. process studies.
Perhaps a balance could be achieved, depending on resources. As I
have indicated above, my bias is for a major allocation of
treatment resources to structural studies.
Such an evaluation strategy should seek to resolve the many open
questions I have described above, with specific attention given to
improving treatment and increasing retention. As the activist
orientation to treatment improvement research suggests, there is a
need to make changes in the organization of drug abuse treatment,
bringing it more into the mainstream of the health establishment,
and to provide a better integration of services for our clients.
Finally, we should redouble our efforts almed at spreading the good
news about drug abuse treatment effectiveness and the findings of
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our considerable investment in treatment research to the drug abuse
field, the medical and allied health professions, and to those
decision makers who will determine the future shape of drug abuse
treatment programming.
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The State Perspective
Douglas S. Lipton, Ph.D., and Philip Appel, Ph.D.
The meeting upon which this monograph is based presented a rare
opportunity to convey the State's interests in a forum specifically
designed to review treatment research efforts supported by the
National Institute on Drug Abuse (NIDA). In part, NIDA's focal
concerns overlap the State's concerns. NIDA is basically
interested in utility, productivity, knowledge, and future
directions; and so are the States. This paper has been written to
review and consider the concerns and recommendations that States
have regarding drug abuse treatment evaluation: dissemination,
utilization, and research directions.
DISSEMINATION
To understand the special interests of States regarding NIDA's
treatment evaluation efforts, it was felt that it would be useful
to solicit opinions and suggestions from a sample of States. This
brief survey had two purposes: (1) to get a sense of how exten-
sively NIDA treatment evaluation materials are used by States; and
(2) to get suggestions for new materials and the best means of
disseminating them.
Nine single State agencies, responsible for coordinating drug
activities in their respective States, were contacted by
telephone. The persons contacted were involved in planning,
research, and evaluation for their State drug abuse agencies. By
virtue of their work performed for a State agency, all of the
respondents were aware of how the National Institute's evaluation
materials were used in their respective States. Respondents were
from the States of California, Colorado, Florida, Illinois,
Louisiana, Massachusetts, Minnesota, New Jersey, and Washington.
The following six questions were asked of all respondents: (1)
What materials from NIDA have you used to evaluate and assess
treatment? (2) Specifically, have you used DARP and TOPS
material? (3) How did NIDA disseminate these materials to you?
(4) If used, which were the most useful? (5) What guidance might
you give NIDA on the mater-ials it develops for treatment
evaluation? and, (6) As far as your State is concerned, should
there be a narrow focus on modality?
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Data were obtained from all nine States, and responses were
tabulated to derive their range and their general thrust. The
results are summarized below, question by question.
R E S U L T S
Question #1. What materials from NIDA have you used to evaluate
and assess treatment?
Responses ranged from reading and use of NIDA-sponsored outcome
studies to no use of NIDA materials for evaluation or assessment of
drug treatment. Two points emerged from the replies with
particular force: (1) Many NIDA materials are used in monitoring,
forming policy, treatment planning, and in treatment evaluation.
DAWN, CODAP, surveys of high school students and household
populations, monographs and technical reports, manuals, etc.. are
used extensively. (2) State agencies' responsibility for managing
and maintaining drug agency budgets needed to support drug programs
has grown significantly in the past 1 to 2 years, to the extent
that keeping abreast of treatment evaluation and related findings
is no longer as salient as that activity had been.
Question #2. Specifically, have you used treatment evaluation
reports?
Responses ranged from little use of treatment evaluation reports
and materials to thorough familiarity and extensive use. Some
extensive use of DARP materials and a number of contacts with the
principal investigators were reported. There was greater
familiarity with DARP and its associated reports and materials than
with other large-scale evaluation study reports.
Question #3. How did NIDA disseminate these materials to you?
This question was broadly interpreted by the respondents. As a
result it is not evident precisely how those respondents who
reported using evaluation reports and materials got them from
NIDA. Some respondents suggested that a regular, personal contact
within NIDA was helpful in getting various kinds of materials.
Virtually all respondents are on NIDA mailing lists. Some
respondents said that, except for Clearinghouse materials, they
have to call and shop around within NIDA to get specific items.
Two of the respondents explicitly suggested that the dissemination
system needed improvement.
Question #4. If used, which were most useful?
Those NIDA publications described as most useful were monographs
involving outcome studies, such as the following:
Robins' study of post-Vietnam drug use by veterans of that
war (1973);
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Studies from the DARP followup research published by NIDA,
such as the first-year posttreatment outcome monograph
(Simpson et al. 1978); and
Nurco's study of heroin addiction over a 25-year period in
Baltimore (1980).
Thus, NIDA treatment evaluation materials, including selected DARP
items produced by NIDA, were considered by a majority of the
respondents to be among the most useful NIDA materials. It is not
clear from the replies, however, which DARP materials/reports were
most useful, except for the mention of the first-year followup
study.
Question #5. What guidance might you give NIDA on the materials it
develops for treatment evaluation?
All of the respondents were able to offer suggestions about
treatment evaluation materials that would be useful to them.
Responses to this question were diverse. For example:
One respondent who is familiar with the various other
followup studies felt that while, cumulatively, they
clearly establish the efficacy of drug treatment, what is
needed in the current fiscal climate are studies of the
cost effectiveness of treatment.
A few of the respondents felt "how-to" manuals for
conducting treatment evaluations would be useful, if they
were geared to treatment administrators. In the same
vein, it was suggested that a detailed set of case
histories of "good" evaluations would provide models that
could be adapted locally.
Another recommended resource was an edited bibliography of
treatment studies which would be sent to program
administrators.
Another class of suggestion concerned processing and
packaging existing treatment evaluation data so that it
could be more useful for program administrators and
clinicians.
Some respondents felt that treatment evaluation data were
not "accessible" and were somewhat difficult to
interpret. Data presentations were seen to be sometimes
directed to researchers rather than at a level useful to
policymakers.
More studies of nonopiate abusers, especially cocaine
abusers, were suggested, as were more studies of programs
outside large metropolitan areas.
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Question #6. As far as your State is concerned, should there be a
narrow focus on modality?
A majority felt that the conventional focus on evaluating
treatment modalities was acceptable and should be
continued, but that there was little to be gained from
cross-modality comparisons.
Some expressed a desire, however, for greater
differentiation within modalities to capture the
considerable variations in services, procedures,
philosophy, etc., between programs of the same type.
There was, in addition, a strong minority view which held
that modality-based data were only useful for
administrative or regulatory purposes.
An alternative model asserts that NIDA and other
researchers should work toward developing typologles of
drug users, the stages in their careers, and under what
circumstances specific interventions were effective (or
ineffective) in favorably modifying those careers.
With respect to dissemination of treatment evaluation written
reports, it was suggested that NIDA produce and routinely
disseminate:
A listing of all treatment evaluation research projects
funded by NIDA. and reports and articles generated by them;
and
A digest or summary of the clinical, cost effectiveness,
and methodological implications derived from the research
NIDA supports.
A dissemination mechanism that NIDA might consider establishing
would be twice- or three-times-a-year l-day multiple city
teleconferences with video. The presentations to be made would
consist of summaries or digests of the results and implications of
clinical and treatment evaluation projects. The audience in each
city, perhaps 30 to 50 people, could comment on the research and
question the presenter. Regional centers could be used, such as San
Francisco, Los Angeles, Chicago, Dallas, Atlanta, Washington, D.C.,
and New York. Travel costs and time spent for the participants
would be reduced and evaluation research results would be more
accessible and more usable (in light of the digesting and short
presentation format). Video tapes of the proceedings could also be
made available for reshowing to selected State audiences, viz:
policymakers, program administrators, and service providers.
Another feature might be an overlay as the presenter speaks, showing
where and to whom to write to obtain a full report.
A compendium of clinical experiences based on successful and
unsuccessful management of common clinical problems that treatment
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personnel encounter was recommended. Case studies written so as to
show other clinicians how and how not to deal with a patient's
avoidance of responsibility, resistance to group therapy, and
refusal to get a job, as some examples, would be useful. Such
compendia could be disseminated as clinical case manuals, each
focused on a related set of clinical problems such as unemployment,
alcohol use, etc. Dissemination by teleconferencing is also
possible for this kind of information.
UTILIZATION
Clearly related to the issue of dissemination is the usefulness of
the evaluation materials that are disseminated to the States. As
seen from the survey, a majority of the respondents wanted NIDA to
know that its evaluation products were frequently difficult to
interpret and to utilize directly. Recently, Davis and Salasin
(1979), Deutschner and Gold (1979), Ianni and Orr (1979), Rossi
(1979), Lawrence and Cook (1982), and Schneider (1982) have all
noted the shift in emphasis away from the rigorous methodology in
evaluation research to making evaluation findings useful to
policymakers and program administrators. NIDA should, to the
extent possible, move in this direction.
There has been a constant call to make evaluation products more
utilizable, beginning with Weiss (1972), through Love (1982), and
Strasser et al. (1983). Evaluation researchers as well as
policymakers (Koretz 1982) and Congressmen (Doty 1982) recognize
this. Unfortunately, historically there has been poor
communication between evaluators and the consumers of evaluation.
Havelock (1981) refers to it as a "dialogue among the hearing and
speaking impaired." This lack of communication is based on several
things: different kinds of training, different world views,
different expectations and frames of reference, different
constituencies, and different languages. The drug abuse research
agency in New York has learned to bridge these differences over the
past 15 years, but not without some pain and frustration. One key
to achieving successful utilization of evaluation results lies in
understanding the perceptions of policymakers. The following
general statements (drawn loosely from Brandl 1980 and others)
typify the policymaker's perceptions and frame of reference
regarding evaluation, its uses, and its limitations.
Policymakers know that evaluations do not always yield
"truth" (Rutman 1977); they sense there is some
arbitrariness to all scientific work, especially
evaluations. Policymakers are aware of holes in
methodology, and they know that much of the logic in
evaluation research rests on unverifiable assumptions.
They believe that evaluations mix objective analysis with
political judgments which politicians are better equipped
to make on their own. For example, the evaluation
research-produced contention that some methadone patients
are not suited for abstinence is rejected by those
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policymakers who believe methadone treatment simply
substitutes one evil narcotic for another.
2. Policymakers note that evaluation almost always answers a
somewhat different question than the policymakers are
asking (Scanlon et al. 1977). For example, it may be true
that methadone maintenance treatment reduces crime and
improves social functioning, but how many addicts are
really "cured"?
3. Policymakers have neither the time nor inclination to
assess the quality of an evaluation (Carlson 1979; Messina
1982). If the basic finding is in agreement with their
existing views, they will include the report in their
armamentarium and wave it high in support of their
argument. If the basic finding is antithetical to their
views, they will reject it as biased, serving the
opposition's cause, and/or shelve it. The quality,
methodology, and skill used are irrelevant.
4. Partly in response to criticisms that evaluators did not
come to grips with the "black box" of treatment, and that
evaluators were too detached from real world problems,
formative evaluation has emerged to occupy increasing
numbers of evaluation researchers in recent years. This
kind of evaluation determines what the program administra-
tion and staff want their program to do, observes the
process of treatment, and assists the staff in modifying
the program during the course of the evaluation as
necessary. This often yields an insightful understandlng
of the treatment program as well as a mutually respectful
partnership between evaluator and program. As the
evaluator becomes directly involved in policymaking,
however, he trades his independence for influence (Weiss
and Bucuvalas 1980). Thus, the policymaker suspects the
evaluator of advocacy, and is convinced that truth is no
longer the evaluator's sole objective.
5. Policymakers believe that "truth" does not determine what
is "right and proper." It may be true that drug abuse
treatment clients receive better care and that more recover
faster in smaller clinical caseloads, but that does not
imply that small caseloads should be mandated, or paid for,
by the State. Also, it may be true that substantial
numbers of persons seeking drug abuse treatment have
serious alcohol or psychological problems, but this does
not mean that State or Federal agencies responsible for
those problem areas should help pay for treatment.
6. Policymakers believe their job is to carry out their
constituents' wishes, regardless of what evaluations show.
If a methadone clinic is stirring up a neighborhood because
of loitering, and the neighborhood brings their legislator
in as a contingent ally, no positive evaluation of the
156
program, or of methadone in general, will be sufficient to
overcome the larger "political" judgment. Likewise, the
findings of evaluation research cannot reverse well-
established, popular convictions which are usually upheld
by policymakers. For example, methadone maintenance is
still controversial in many communities, and this
controversy finds expression through elected officials and
the press, a fact which cannot be lost on policymakers and
which evaluation itself cannot change.
7. Policymakers face myriad desiderata with any decision. An
evaluation is only one contending judgment. The more
complex the evaluation, the more jargon in the language,
the more hidden or equivocated the conclusion, the more
caveats in the preamble, the thicker the report, the more
obscure the evaluator, the more sensitive the issue--the
more apt the policymaker is to discard, ignore, or attack
the evaluation. If he attacks it, the evaluator at least
has a fighting chance to defend it, but usually the
policymaker ignores the report, which is the worst possible
outcome for the researcher.
8. Evaluators other than ourselves have recognized these
perception problems and have suggested various solutions,
such as the Evaluability Assessment (Kay 1978; Rutman 1980;
Wholey, 1977, 1979, 1981), the Stakeholder Survey (Lawrence
and Cook 1982), and the Developmental Evaluation Sequence
(Love 1982).
Our experience in this regard comes from having served
simultaneously in policymaking and evaluation roles. We
have evolved seven rules for maximizing the utilization of
evaluation research.
Establish a dialogue with the primary potential
user--the policymaker (Cox 1977 and Kennedy 1978).
Identify the critical questions and the critical
audiences the user has. From the critical questions,
develop a mission statement for the evaluation with
which the policymaker can agree. With knowledge of
the critical user's audiences, one can tailor the
presentation of the findings appropriately. Remember
that the policy implications of evaluation reports are
singularly paramount, and forget the research paper
style learned in graduate school--that style turns off
policymakers immediately. Provide a clear-cut policy
rationale for the document; researchers without a
policy rationale are viewed by policymakers as
self-aggrandizing. That is, the report will be
perceived as serving no other purpose than to enhance
the evaluator's resume.
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2. Move swiftly to produce; only a researcher is patient
enough to wait 2 or 3 years for an answer to a
question. Long-term evaluation projects are
tolerable only when short-term products are
available. In addressing important questions, even
partial answers are useful, and they create momentum
for more support.
3. Accept incremental improvement; the search for
perfection in evaluation is always fruitless. If one
follows these rules and is patient, incremental
improvement can be expected in data quality, data
systems, definitions, levels of cooperation, and
quality and quantity of staff.
4. Move with progressive refinement. This means that,
initially, researchers must be willing to make crude
or rough estimates. In order to respond swiftly to
information requests, general questions must be
divided into specific ones that can be answered
rapidly by available data systems and staff.
5. Produce reports in four parts.
The executive summary and recommendations must
come first. They should be no longer than two
pages (remember that policymakers receive 40 or
more reports a day). They should cite the main
points clearly in English, not jargon. These
main points should respond to the user's critical
questions and audience;, not necessarily the
evaluator's. Avoid at all costs burying a
critical point (i.e., the answer to a critical
question) in the middle or the end of the
document.
The body of the report should be presented like a
table of contents with summarizing headlines. If
you include tables, they should be clearly
understood by lay persons, and the numbers from
table to table should never contradict each
other. There is always someone who checks these
numbers, and if the numbers do not agree, he or
she will call to question the credibility of the
entire document. If the data permit, include an
analysis of the cost effectiveness of the program
and include a cost effectiveness or cost benefit
statement in the conclusions. Provide legis-
lators with conclusions, not with recommendations
unless they are asked for. Making recommen-
dations and policies is the legislature's job.
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Agency directors and senior administrators or
advisors, on the other hand, may appreciate
recommendations as well as conclusions.
Write conclusions in short paragraphs,
preferably in "bullet" form. This saves wading
through ponderous rhetoric to find the
conclusions, and they can then be used
immediately by decisionmakers as announcements
for press purposes. Recommendations should also
be "bulleted" and incorporated into the
Executive Summary. Prepare the bullets with the
"stand-alone principle," using oversimplified
statements which can be quoted in legislative or
cabinet-level debates, or in interviews with the
public media. They should be written for
multimedia impact.
Put all technical material in the appendix.
This includes all technical and complex tables,
technical caveats, statistical procedures,
cost-benefit calculations, and methodological
details. Such material is useful to other
researchers, but disconcerting and annoying to
policymakers.
6. Organize the results by political jurisdiction before
presenting them by census tract. Policymakers cannot
relate to problem estimates for areas that have no
political reality. This implies that the evaluator
has an obligation to understand something about the
political dynamics of the questions he or she
investigates. In the same light, NIDA evaluation or
epidemiological products that cannot be related to a
single State have very limited use (if any) for the
State. And, if the potential audience includes
legislators, the evaluator should try to present data
by assembly and senatorial districts. Remember that
politicians always have the needs of their
constituents uppermost in their minds.
7. The purpose of evaluation and social science research
in government can easily be remembered as three "P"s
and three "A"s:
It should be PRACTICAL--that is, it should
ANSWER the critical questions.
It should be PECUNIARY--that is, it should
provide ACCOUNTABILITY for critical dollars.
It should be POLITICAL--that is, it should
recommend ACTION for critical audiences.
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RESEARCH DIRECTIONS
The section that follows is a potpourri of treatment evaluation
ideas. They are viewed as guidelines and seeds for thought and
possible future directions. The ideas are the fruit of brain-
storming among evaluation researchers and, as such, vary in levels
of development.
1. Numerous studies have shown that time in treatment is
correlated with outcome. Yet, there has been very little
research on factors that might lead to higher retention
rates among programs. If the specific factors leading to
higher retention rates could be identified, this might
lead to relatively inexpensive methods of retaining
clients in treatment and significantly improving treatment
outcomes. Conversely, cases of those persons who leave
programs prematurely as a result of external pressures
could be studied; then researchers could identify the
pressures and other problems patients are likely to
encounter and develop program elements to counteract
them.
2. We also need to study ways of recruiting detoxified and
untreated drug users. Research has shown that there are
many such people who are not motivated to enter
treatment. Using ethnographic techniques, factors that
breed resistance to treatment and those that foster entry
can be identified. Then, in turn, specific methods can be
tested to overcome the source of resistance and augment
those factors that boost entry.
3. Usually treatment is thought of as restricted to within
the program; external influences on treatment outcome are
rarely considered in any type of treatment planning,
though some attention recently has been given to family
therapy. There is a need for more studies of how external
influences have an impact on treatment outcomes. In
particular, studies of external economic influences are
needed. The illicit drug business is very large and
profitable. Thus part of the difficulty in getting
clients to stop using illicit drugs is undoubtedly due to
the economic forces involved in the illicit drug business,
but the exact nature and impact of these forces have never
been studied. Our ability to counter these external
limitations on treatment effectiveness will remain limited
if we do not increase our understanding of them. We also
need to explore what external factors encourage or result
in patient amenability and cooperation during treatment,
and then develop techniques to enhance them.
4. Examining the drug abuse treatment evaluation literature,
one is struck by the emphasis on fine tuning of existing
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5.
6.
7.
modalities. With the exception (in recent years) of
antagonist therapy, no new methods for the treatment of
drug abusers have been explored. In the late seventies,
efforts were made to investigate techniques such as
acupuncture (for detoxification), hypnosis, biofeedback,
transcendental meditation, nutrition therapy,
transactional analysis, and other "therapies" in vogue at
that time. These studies should be reviewed
systematically and findings communicated, together with
limitations on their use, to evaluation audiences.
There is a need for studies on the effectiveness of
short-term early intervention treatment for young drug
users. In particular, holistic approaches dealing with a
broad range of services to reach a broad range of problems
among such youth need investigation. These methods, if
effective, would add low-cost treatment altenatives to
dealing with the bulk of the youthful drug users in the
country. Similarly, studies are needed of the effective-
ness of employee assistance programs. These programs have
been initiated and are being advocated all over the
country, but remain unevaluated.
Studies of treatment failure using case study techniques
could inform the process of treatment. And, in this vein,
case studies of persons who ceased drug use without
treatment, such as those conducted by Waldorf (1983), could
be equally informative. Recent studies of weight loss and
smoking cessation show that self-treatment efforts may be
much more effective than previously thought. But the
research on self-treatment for illicit drug use is
relatively scarce, and mostly confined to heroin use. Much
can potentially be learned from studies of how people stop
using a variety of illicit drugs without formal treatment.
Such studies should also examine why some self-treatment
efforts fail, and whether the factors that lead
self-treatment to fail are repeated in formal treatment
programs.
Formal drug treatment programs almost exclusively proclaim
abstinence as the only suitable goal for treatment of
illicit drug abuse. This goal is rarely achieved in any
single episode of treatment, which suggests two lines of
treatment evaluation research. First, the effects of
multiple episodes of treatment need to be coherently
explicated. Second, the utility of less-than-total
abstinence goals should be explored. It is quite likely
that many clients and staff actually share such treatment
goals, but there is almost no information on how frequently
this occurs and what effect it has on treatment processes
and outcomes.
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8. One concern expressed repeatedly has been that treatment is
largely a "black box." The people, events, and
interactions subsumed by labels such as "therapy,"
"counseling," "referral for services," and "remediatlon"
remain largely undescribed in drug programs. As a result,
variations in delivery and efficacy, which are crucial to
treatment evaluation, are also unspecified. NIDA should
support research on these processes as they occur in
programs--call it applied microsociology or preevaluatlve
research. To us, knowledge of these processes appears
essential for understandng and improving treatment.
9. The current treatment paradigms were originally designed
for the treatment of opiate abusers. The patients we often
encounter now, however, consist of cocaine, marijuana, and
polydrug abusers. These persons are not necessarily suited
to opiate treatment, and much of the "fine tuned" research
done on opiate users needs to be repeated for them.
10. NIDA should consider competitive awards for new treatment
approaches. For such an award, NIDA would issue a problem
analysis focusing on a specific problem such as the cocaine
user, the psychotic self-meditator, the young heavy
marijuana/alcohol user, or prescription drug misusers, and
request treatment evaluators to submit proposals of new
techniques tailored to the specific population.
11. In the same vein, NIDA could encourage grants assessing the
effectiveness of acupuncture in treatment of heroin
addiction, for example, and receive highly focused
evaluation proposals for specific methods.
12. A serious problem affecting all treatment effectiveness is
the social stigma which current drug users and former drug
users bear. Studies into stigma management and methods for
changing the public's and employers' attitudes are needed.
Just as important, if more general, are studies of how to
build community support for treatment. Antagonistic
communities prevent treatment programs from opening and
inhibit their operation. Supportive communities, on the
other hand, can facilitate job placement and social
reintegration, while encouraging treatment recruitment and
cooperation.
13. NIDA should consider studies of systematic shifts in
service delivery, such as private physician/pharmacy
dispensation of methadone, and short-term intensive
residential treatment for marijuana or cocaine abusers.
14. NIDA should consider an evaluation of a vocational program
designed for the drug abusers who have never worked. This
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15.
16.
SUMMARY
program could provide for testing, guidance, training,
guaranteed placement, and followup support during
employment, plus pay a profit based on success as an
incentive to the training company, which would also provide
followup support.
NIDA should fund a meta-evaluation of all treatment
evaluation research performed over the last 25 years.
This compendium of treatment effectiveness should be
classified by treatment method and outcome. It would be
the state-of-the-art document for all treatment.
NIDA should fund studies of treatment effectiveness for
the following special populations:
The multiply handicapped, e.g., deaf drug abusers
Violent drug abusers
New immigrant groups, e.g., Southeast Asians, Cubans,
Haitians
Abuser families
Alcoholic drug abusers
Athletes, musicians, entertainers and other
professional groups
Our survey showed that State agencies make use of NIDA materials of
all sorts, including NIDA treatment evaluation materials. A
majority of the respondents indicated that NIDA treatment
evaluation materials were among the most useful of its products;
most frequently mentioned was DARP, then Nurco's and Robins' work,
and TOPS. That DARP was most frequently mentioned is not a
contradiction, since the responses were stated in a general sense,
not in terms of a specific report or material.
In the past 1 to 2 years, many State drug abuse agency budgets have
been substantially reduced due to declines in Federal funding. As
a result, treatment evaluation reports and related materials are
viewed somewhat differently than they were in the past. The fiscal
climate in various States may thus be another factor contributing
to the greater familiarity and reported use of reports such as
DAWN, CODAP, and case management and monitoring manuals published
by NIDA.
A number of suggestions were made about the kinds of evaluation
materials needed by States. It was generally agreed that attempts
should be made to produce treatment evaluation findings/new
knowledge in a format where it would be more accessible to
administrators (e.g., "how-to" manuals, evaluation case studies,
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dissemination of treatment evaluation bibliographies) and should
assist in making existing treatment evaluation results more
accessible (divide results for modalities into subtypes, provide
data on the effectiveness of specific interventions with specific
conditions, diversify the settings of programs in which evaluations
are done, etc.). The theme of these various suggestions is to make
evaluations more available, usable, and specific, especially now in
view of the reduced ability of many States to carry on their own
evaluation activities.
The general sense of the respondents regarding dissemination was
that right now, in view of other problems such as the financial
crunch, NIDA's system of distribution cannot be a salient concern.
Nevertheless, from a State perspective, NIDA's dissemination of
treatment evaluation materials is particularly important in the
light of the paucity of resources States have to conduct their own
research. Thus, having access to NIDA's usable evaluation data is
all the more crucial to improving service delivery and its cost
effectiveness. Another factor to bear in mind at the present time
is the absence of opportunities to share evaluation results at
national conferences which formerly were, of course, major
mechanisms for formal dissemination.
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A Treatment Evaluation Agenda:
Discussion and Recommendations
Frank M. Tims, Ph.D., and Sherry Holland, M.S.
INTRODUCTION
This review, as stated in the Introduction to this volume, had two
purposes: (1) to assess critically the state of the art of
treatment evaluation--i.e., where we are in our knowledge regarding
treatment evaluation and treatment effectiveness, and (2) to assess
the most important needs of the field, both in terms of research
areas or questions and methodological issues which should be
resolved. A panel of nationally recognized experts was convened to
review the state of the art and to develop a body of
recommendations for future research.
In response to these questions, a number of themes emerged.
Prominent among these were (1) the need for a synthesis of prior
research. (2) the opportunities afforded by existing data bases for
secondary analysis, and (3) development of an agenda for new
research, Including continuing examination of drug abuse treatment
systems and populations, studies of treatment process, assessment
of treatment for nonopioid abuse, continued study of drug abuse
careers, and studies of untreated drug abuse populations. Also of
concern was the need to disseminate treatment research findings
widely, both to researchers in drug and alcoholism treatment, and
to treatment providers.
DISCUSSION
To return to the first question of this review, "What do we know
today about the effectiveness of drug abuse treatment?", today's
state of knowledge represents a stage of an evolutionary sequence,
as we confirm treatment effectiveness in general terms, and turn to
the task of being more specific about how and for whom what aspects
of treatment are effective. Our answers have tended to raise many
more questions. The field has now developed a knowledge base from
which to apply increasingly sophisticated methodologies to
treatment studies. Because the drug abuse evaluation field may be
characterized as evolving, both in terms of knowledge advancement
and methodological aspects, and involving a multiplicity of
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disciplines, our present knowledge contains not only gaps but also
inconsistencies. Resolving the apparent conflicts in research
findings represents a major task for treatment evaluation at this
point. Two principal approaches which make use of existing data
are suggested: A synthesis of existing studies, and secondary
analysis of available treatment research data.
Synthesis of Existing Studies
Although the evidence for the effectiveness of drug abuse treatment
is impressive, there are questions, problems and issues of
interpretation that remain to be clarified. A systematic review
and synthesis of treatment outcome studies which has as its major
objective the clarification and, where possible, resolution of
treatment issues could be of great benefit to the field. Such a
synthesis should provide an estimate of the magnitude of treatment
effects across studies. In addition, a cross-study summary of
observed relationships among client, treatment, and outcome
variables might usefully distinguish among client variables
associated with positive outcomes irrespective of type/setting of
services, treatment variables associated with positive outcomes
irrespective of client variables, and client-treatment
interactions. The research synthesis should include a critical
examination of methodologies used, with a view to identifying the
strongest studies and sources of inconsistency in findings.
Secondary Analysis and Modification of Existing Studies
Other possible sources of new knowledge and clarification of
research findings may be found in existing data bases and ongoing
studies. During the past decade, a large and rich body of data has
been developed in a variety of drug treatment studies. With regard
to resolving or clarifying apparently conflicting results of
different studies, consideration should be given to reexamining the
analytic approaches and, where possible, reanalyzing study data
itself. Several issues meriting reanalysis were identified,
including the interdependence of outcome behaviors; the ability of
psychopathology to predict outcomes; the nature of the relationship
between time in program and changes in criterion behaviors; and the
relationship between severity of drug and alcohol dependence and
posttreatment outcomes.
Some investigators have found relatively low correlations among
posttreatment outcome behaviors (e.g., drug use, employment,
criminality). This finding suggests that treatment procedures may
cause positive changes in some behaviors and not others. Thus the
question of client-treatment matching--"What procedures work best
for what types of clients"--needs more thorough consideration of
the nature and degree of the anticipated changes.
Pretreatment severity of psychopathology is associated with poorer
posttreatment outcomes in some studies but not in others. Some
programs screen out psychiatrically disturbed clients. This
restriction on within-program variance may place a ceiling on the
correlation between psychopathology and outcome. A "state-trait"
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problem may also exist. Clients with long-term psychiatric
disorders may have outcomes which differ from those whose
symptomatology is a transient condition associated with the
circumstances of their treatment admission. Data for these two
subgroups should be examined separately.
Several major drug treatment evaluations have found that time in
program predicts posttreatment outcomes. This has provided
critical support for the treatment hypothesis in studies without
controlled assignment. However, in the TOPS data time in program
and posttreatment outcomes are weakly related. Such an apparent
conflict with previous research findings suggests that the data be
carefully examined and reanalyzed to explain or resolve the lack of
a significant time-in-treatment effect. Possible explanation of no
such finding would include differences in the populations being
studied, and measurement artifacts which tended to obscure
differences in response to treatment between subgroups.
Unpublished analyses of TOPS data conducted since this review have
controlled for selected covariates and found what appears to be a
time-in-treatment effect, but the meaning of the effect is not yet
clear. The time-in-treatment effect, which is among the most
significant findings in treatment evaluation, needs to be further
explored, clarified, and tested.
Gaps in knowledge may also be at least partially filled by
secondary analysis of existing data, and adding or reorienting
questions in ongoing research to capture variables not previously
identified, to address questions which have emerged as our state of
knowledge has evolved. For example, new insights into the
importance of the role of psychopathology in determining treatment
outcome suggest that prospective studies should have more detailed
information in this area on clients entering treatment, to enable
appropriate classification into subgroups for which outcomes may be
differentiated. The TOPS has obtained some limited depression
indicators for clients at admission, as well as alcohol use and
pretreatment criminal involvement. It may be possible retro-
spectively to develop life history data in future followup
interviews which could be used to develop subgroups of clients who
had been violent, frequently depressed, or who may have been
dysfunctional in particular areas of life with problems in
childhood, adolescence, and/or adulthood. Family health history
could also provide valuable data.
Future Treatment Assessment Research
Turning to the shape of future studies, it is clear that some
periodic large-scale or medium-scale followup studies will be
needed at intervals, (1) to assess the changing nature of
treatment populations and services, (2) to provide sufficiently
large data bases on contemporary client samples for multivariate
analysis, and (3) to provide replications where needed to confirm
or clarify previous research findings. Such prospective studies
probably should not reasonably be expected to involve the large
numbers of clients tracked in DARP and TOPS, although the
169
information available on the client population base should be
sufficient to permit appropriate sampling. These studies should be
effectively coordinated with smaller, program-based studies. The
program-based studies, in which investigators affiliated with
treatment programs or larger treatment organizations are involved,
could address highly focused questions related to treatment process
and outcome issues.
Large-scale studies have made a point of comparing outcomes across
modalities. The general pattern of findings suggests that few
meaningful differences are likely to be found in outcomes among
opioid addicts in methadone maintenance, residential drug-free, and
outpatient drug-free treatment that are not either a function of
client differences or of time in treatment. Future studies can
more appropriately examine how given treatments work for
well-defined subgroups of clients within a particular modality or
program. When we better understand the dynamics of treatment
services or therapies for such well-defined client types, the
assignment of those clients to a particular regimen can be made
more meaningful. A convincing case has been made for the
usefulness of controlled studies to test hypotheses regarding
client-treatment matchings. While attempts to randomly assign
well-defined, homogeneous client pools to modalities have been
frustrated by clients crossing over to their treatment of choice,
random assignment within modalities to service configurations and
to more satisfactory control groups has proved feasible.
Whether we speak of medium-scale prospective studies or
program-based studies, naturalistic or controlled, such studies
must include better client data at admission. In particular, a set
of core variables and measures whose validity and reliability are
reasonably well established should be developed and used in all
future treatment evaluation studies which involve clients entering
treatment. Such "minimum research criteria" would provide the
well-defined subgroups of clients for better analysis and would
enable comparability across studies, which has been problematic in
the past. The minimum research criteria would include specified
Information on drug and alcohol use over specific pretreatment
intervals, employment, criminal history, and treatment history, as
well as measures of psychopathology and social functioning.
Consideration should also be given to including family history
data, with particular reference to health and genetic variables.
There are, of course, a number of existing instruments which could
be used. These would have to be carefully evaluated and a set
chosen which would be methodologically satisfactory, appropriate to
key research issues, and which would not pose insurmountable
obstacles to acceptance by clinicians who would, In many cases, be
asked to use them. The practical issues of acceptance of the
be considered. Greater
in co-principal investigator
ingness to use the prescribed
measures at the clinical level must
involvement of clinicians, perhaps
roles, may result in increased will
instruments.
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Treatment process studies are clearly needed. While the DARP,
TOPS, and other studies have recognized the eventual questions of
process, research priorities have focused largely on outcome
studies, with process very much the junior partner. As suggested
above, program-based studies offer the best opportunitles for
testing specific variations in services or therapies, although it
Is also possible that larger scale, externally based research
efforts could make contributions in this area, given appropriate
program involvement and an imaginative design. One much-needed
process study would test approaches for increasing retention by
modifying program content in the critical early weeks of
treatment. For therapeutic communities, especially, where
attrition is high In the first 4 - 6 weeks, it is suggested that
while some clients are not suited to a high-intensity treatment
involving confrontation, others who drop out of treatment could
benefit, given proper support and clarification of treatment
content. Such a program of treatment improvement research is
activist In orientation, and may provide an important contribution
to our understanding of the role retention plays in improving
outcomes.
Research on treatment effectiveness for those clients who are
primarily involved with nonoploid drugs has been largely
neglected. Because the community-based treatment system was
developed to deal primarily with opioid addiction, and because so
many researchers and clinicians have had a primary interest in
oploid addiction, this area has received most attention. Attempts
to deal with nonopioid abusers in the DARP and TOPS have been
problematic, owing largely to difficulties in conceptualization and
having insufficient numbers of clients involved primarily with
particular nonopioid abuse patterns. The lack of treatment
evaluation research focused on clear subtypes in well-defined
treatments suggests a need for special efforts to develop such
studies.
In treatment evaluation studies which have attempted to impose
quasi-experimental research designs on treatment systems, controls
or comparison groups have always been a problem. The usual
compromise is to take some group which is presumably similar to the
treated groups but which has not itself received treatment, and
consider them a "no treatment comparison group." The argument
against using these "no treatment" comparison groups is that they
usually turn out to be something else. They drop out of treatment
but many of them re-enter treatment. Analysis of the DARP data
suggests that, while as a group they have less satisfactory
outcomes, substantial numbers of these comparison group subjects
are doing well at followup.
It is also widely recognized that substantial numbers of addicts
carry on long addiction careers, remaining outside the treatment
system. We do not know how similar or different these untreated
addicts are from those who make their way into treatment, but
existing natural history studies are hampered by the fact they have
only involved addicts captured by the treatment system or the
criminal justice system. Natural history studies should, of
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course, include studies of clients from treatment populations such
as DARP and TOPS over the longer term, but there should also be
efforts to ascertain what happens to people who leave treatment
after only minimal contact, and those who are never treated. The
"minimal treatment" and "never treated" groups could be explored
from the standpoint of what the natural history is in the absence
of treatment, as well as what the potential is for bringing these
individuals into treatment by various strategies.
In any event, this expanded version of the natural history of drug
abuse/addiction would be useful in enabling us to understand
important aspects of drug abuse careers. It is also important to
note that our concern with natural history over the longer term has
understandably been with opioid addiction, since these are the
client populations which have been around long enough to mature
sufficiently for such studies. The large client populations never
addicted to opioids, but involved primarily in the various
nonopioid abuse patterns, should be similarly followed up over
time. An important first step in this regard is to examine closely
the data already available from such studies as DARP and TOPS.
This provides the opportunity to begin accumulating a knowledge
base with regard to defining the different subgroups,
characterizing them in terms of client background characteristics,
their treatment and/or criminal histories, and exploring outcome
patterns over whatever time period is available in the data.
Subsequent long-term followups could be initiated once the nature
and availability of suitable samples are assessed.
Dissemination
A variety of research consumers have a need for current information
on treatment research findings, including researchers, clinicians,
administrators, and others who are charged with the responsibility
for decisions affecting treatment programming. NIDA's treatment
research dissemination strategy has included publication of
scientific reports and monographs, as well as short summaries of
research findings, both in Clinical Research Notes and as
individual publications. These have been directed to clinicians.
researchers, and a more general audience. Dissemination of these
publications has been through the National Clearinghouse for Drug
Abuse Information (NCDAI) and through other distribution channels.
Several of the participants in this review suggested that, in
addition to continuing to provide such timely summaries, NIDA
explore alternative strategies for using research findings to
stimulate appropriate programmatic change.
RECOMMENDATIONS
The following recommendations resulted from the review. While
consensus was evident on most of these points, the order of
presentation does not imply priority. Specifically, it was
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recommended that research be supported and encouraged in the
following areas:
A comprehensive review and synthesis of findings from
existing studies. This should include comparison across
studies and, where appropriate, reanalysis of data bases,
to resolve apparent inconsistencies in the overall pattern
of findings in the literature.
Continued large- to medium-scale studies such as DARP and
TOPS, coordinated with smaller scale studies to extend and
clarify findings.
Program-based studies to investigate treatment process,
clarify program differences, and foster utilization of
findings by treatment programs.
Controlled studies designed to produce reliable data on
outcomes for specific treatment interventions, e.g.,
long-term vs. short-term programs, brief therapy vs.
routine treatment, aftercare initiatives vs. no such
services.
Studies evaluating treatment for nonopioid clients.
Natural history studies to better characterize and
understand the complex of events and influences
experienced by drug abusers before, during, and after
their periods of abuse, including those for primarily
nonopioid abusers.
Studies evaluating psychodiagnostic and other strategies
for subclassifying clients and exploring more appropriate
client-treatment matching. The question of "what
treatment works best for what type of client" has not been
adequately addressed. Studies should focus on better data
for classifying clients (e.g., biologic, psychiatric, and
pyschosocial, as well as drug use patterns) to permit
studies of matching.
Studies of the feasibility of using standardized
instrumentation in treatment evaluation. NIDA should
support and encourage the use of standardized research
criteria in order to identify client subpopulations and
develop useful measures of client change during
treatment.
Systematic studies of interventions (outreach strategies)
with untreated drug abusers and of interventions with
early dropouts from treatment to determine the most
appropriate forms of treatment for these populations.
In addition, it was recommended that NIDA continue its
efforts to provide up-to-date summaries of research
findings (such as the DARP summary and review papers
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published by the Institute) and disseminate these to the
field in a timely manner. Study should be made of
different strategies for using research findings to guide
programmatic change.
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